In Vitro and In Vivo Comparison of the Pathogenicity of Four Influenza Virus Strains by Hurst, Brett L.
Utah State University 
DigitalCommons@USU 
All Graduate Theses and Dissertations Graduate Studies 
5-2012 
In Vitro and In Vivo Comparison of the Pathogenicity of Four 
Influenza Virus Strains 
Brett L. Hurst 
Utah State University 
Follow this and additional works at: https://digitalcommons.usu.edu/etd 
 Part of the Dairy Science Commons 
Recommended Citation 
Hurst, Brett L., "In Vitro and In Vivo Comparison of the Pathogenicity of Four Influenza Virus Strains" 
(2012). All Graduate Theses and Dissertations. 1220. 
https://digitalcommons.usu.edu/etd/1220 
This Thesis is brought to you for free and open access by 
the Graduate Studies at DigitalCommons@USU. It has 
been accepted for inclusion in All Graduate Theses and 
Dissertations by an authorized administrator of 
DigitalCommons@USU. For more information, please 
contact digitalcommons@usu.edu. 
 IN VITRO AND IN VIVO COMPARISON OF THE PATHOGENICITY OF  
 
FOUR INFLUENZA VIRUS STRAINS  
 
 
 
by 
 
 
 
Brett L. Hurst 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree 
 
of  
 
MASTER OF SCIENCE 
 
in 
 
Bioveterinary Science 
 
 
 
 
 
Approved: 
 
 
_____________________                                         _____________________   
E. Bart Tarbet                                                                     Donald F. Smee 
Major Professor                                                             Committee Member 
 
 
_____________________             _____________________ 
Kerry Rood       Ken White 
Committee Member      Head of Animal, Dairy and  
                                                                                            Veterinary Science Department           
                                                                                        
 
 
_____________________ 
Mark R. McClellan 
Vice President for Research and 
Dean of the School of Graduate Studies 
 
 
 
 
 
UTAH STATE UNIVERSITY 
Logan, Utah 
 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Brett L. Hurst 2012 
 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
ABSTRACT 
 
 
 
In Vitro And In Vivo Comparison of The Pathogenicity of  
 
Four Influenza Virus Strains  
 
 
by 
 
 
Brett L. Hurst, Master of Science 
 
Utah State University, 2012 
 
 
Major Professor: Dr. E. Bart Tarbet 
Department: Animal, Dairy, and Veterinary Science 
 
 
 Influenza viruses cause between 3 and 5 million cases of respiratory infection each year 
and are responsible for between 250 and 500 thousand deaths.  There are principally two 
avenues for the treatment and prevention of influenza. They are vaccination and antiviral 
regimens.  Prevention of infection is largely accomplished through vaccination.  While vaccines 
remain the preferred method for controlling the spread of influenza, treatment with antiviral drugs 
is important for treatment of severe infections that are caused by viruses that are different from 
the vaccination strains.  The two major classes of antiviral drugs for influenza treatment are the 
adamantanes and the neuraminidase inhibitors.  While most viruses have become resistant to the 
adamantanes, the neuraminidase inhibitors remain the primary choice for treatment of infections.  
Oseltamivir is the most important of the neuraminidase inhibitors.  Data from an experiment run at 
Utah State University displayed a characteristic that is reflected in other published data.  
Oseltamivir, which has been shown to be effective against influenza virus strains in vitro, is 
unable to sufficiently protect mice from lethal infections.  The focus of the present research was to 
identify viral differences that might explain for this discrepancy.  Four viral strains were chosen 
that display differing susceptibilities to oseltamivir in mice.  The viruses used were Influenza 
A/Duck/MN/1525/81 (H5N1), A/Victoria/3/75 (H3N2), A/NWS/33 (H1N1) and A/California/04/2009 
(Pandemic H1N1).  Oseltamivir was unable to protect mice that were infected with the 
 iv 
A/Duck/MN/1525/81 and A/Victoria/3/75 viruses.  These two viruses, along with the A/NWS/33 
and the A/California/04/2009 viruses, were compared in vitro using virus replication kinetics, 
neuraminidase inhibition assays, and antiviral assays in cell culture.  The viruses were studied in 
vivo by comparing survival, weight loss, lung scores and weights, lung virus titers, complete blood 
counts, cytokine assays, and histopathology.  A second in vivo experiment was run to determine 
the effects of oseltamivir on survival, weight loss, lung scores and weights, lung virus titers, and 
histopathology.  The two in vivo experiments summarized in this study confirmed previous data 
since oseltamivir was unable to protect mice infected with the influenza A/Duck and A/Victoria 
viruses.  Overall, the virus infections behaved remarkably similar.  The most interesting difference 
was that the A/Duck/MN/1525/81 and A/Victoria/3/75 viruses were able to induce more severe 
histopathological damage in mouse lungs earlier in the infection.  The ability to cause severe 
disease more quickly might explain why the A/Duck/MN/1525/81 and A/Victoria/3/75 viruses 
remain lethal, despite oseltamivir treatment.   
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 Influenza viruses cause between 3 and 5 million cases of respiratory infection each year 
and are responsible for between 250 and 500 thousand deaths.  Two avenues for the treatment 
and prevention of influenza virus infections are vaccination and antiviral chemotherapy.  
Prevention is largely accomplished through vaccination.  While vaccines remain the preferred 
method for controlling the spread of influenza, antiviral treatment is important for severe infections 
caused by new and emerging virus strains.  Occasionally new viruses emerge to which the 
population has no previous immunity.  Such was the case when the pandemic H1N1 influenza 
virus appeared in 2009.  When new viruses such as this emerge, it can take months to formulate 
a vaccine to protect individuals from infection.  In this case, antiviral drugs are used to treat 
influenza infections and thus decrease the spread of the disease.   
One drug currently approved by the Food and Drug Administration (FDA) is Tamiflu® 
(oseltamivir).  Treatment with in mice has shown that some viruses have a unique response to 
oseltamivir.  A study performed at Utah State University showed that oseltamivir is unable to 
protect mice from a lethal infection even though the viruses remain sensitive to oseltamivir in 
vitro.  In the previous study, oseltamivir was unable to protect mice from a lethal infection with two 
oseltamivir-sensitive influenza strains: A/Duck/MN/1525/81 (H5N1) and A/Victoria/3/75 (H3N2).  
This research was performed to verify differences in mortality observed in the Utah State study 
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and to determine if there are significant differences between the viruses that allow them to 
overcome treatment with oseltamivir.   
We used the A/Duck/MN/1525/81 (H5N1) virus, the A/Victoria/3/75 (H3N2) virus, and the 
A/NWS/33 (H1N1) virus.  All three were used in the study completed at Utah State.  We added 
the 2009 pandemic influenza virus, A/California/04/2009 (H1N1), for a more recent comparison.  
For each virus, we observed viral replication in cell culture, measured performance in a cell 
culture antiviral assay, and tested for oseltamivir resistance with a neuraminidase inhibition 
assay.   
Groups of mice were infected with each virus to determine effects of virus strain on 
survival, mean body weight, mean lung virus titers, lung weights, and discoloration of the lungs 
due to hemorrhage.  Lungs were also sent for histopathology.  A complete blood count (CBC) 
was run on infected mice and 16 pro-inflammatory cytokines were measured to determine the 
host response to infection. 
We then completed an animal experiment to observe the effects of oseltamivir treatment 
at 5 mg/kg/day and 40 mg/kg/day on mortality, mean body weight, lung virus titers, lung weights, 
and discoloration of the lungs.  Following oseltamivir treatment, lungs were sent for 
histopathology as well.   
We confirmed that the A/Duck/1525/81 (H5N1) and A/Victoria/3/75 (H3N2) viruses 
caused significantly higher mortality in mice than the A/NWS/33 (H1N1) and A/California/04/2009 
(H1N1) viruses when treated with oseltamivir.  We also discovered that the A/Duck/MN/1525/81 
(H5N1) virus causes mortality more quickly in mice than the other viruses.  This would make 
infection with that virus more difficult to treat with oseltamivir.  The A/Victoria/3/75 (H3N2) virus 
did not cause early mortality but was still less susceptible to treatment with oseltamivir than the 
A/NWS/33 (H1N1) and the A/California/04/2009 (H1N1) virus.     
Treatment with oseltamivir at either dose did not significantly lower the lung virus titers in 
mice infected with the A/Duck/MN/1525/81 (H5N1) and A/Vicotria/3/75 (H3N2) viruses.  Both 
doses of oseltamivir were able to moderately reduce the lung virus titers in mice infected with the 
A/California/04/2009 (H1N1) virus.  Treatment with either dose of oseltamivir was able to reduce 
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the lung virus titers in mice infected with the A/NWS/33 (H1N1) virus significantly more than 
any of the other infected mice.  This indicates that the A/NWS/33 (H1N1) virus is uniquely 
sensitive to oseltamivir treatment compared to the other three viruses.   
Lung weights, discoloration of the lungs, and histopathology results all pointed to a more 
rapid onset of disease in mice infected with the A/Duck/MN/1525/81 (H5N1) and A/Victoria/3/75 
(H3N2) viruses.  Lung weights were the most solid evidence of a more severe infection with those 
two viruses.  Lung weights increased more dramatically earlier in the infection with these two 
viruses.  The infection progresses more rapidly in mice infected with the A/Duck/MN/1525/81 
(H5N1) and A/Victoria/3/75 (H3N2) viruses.   
  Since oseltamivir is one of the primary drugs that would be used with an emerging 
pandemic, more research concerning its effectiveness should be done.  This study showed that 
despite remaining sensitive to oseltamivir in vitro, some viruses are able to cause mortality in 
mice despite treatment with oseltamivir.  Further studies can be done to optimize oseltamivir 
treatment by increasing concentration or lengthening the duration of treatment.  If oseltamivir will 
be used in a future pandemic, knowledge of its strengths and weaknesses will maximize its 
effectiveness. 
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 1 
CHAPTER I 
INTRODUCTION 
 
Epidemiology of Influenza Viruses 
 
Influenza is the name given to the respiratory disease caused by one of three influenza 
virus subtypes (58).  Each year worldwide annual epidemics result in three to five million cases of 
severe illness with anywhere from 250 to 500 thousand deaths attributed to influenza and 
influenza related illnesses (10).  Most deaths occur in people who are over the age of sixty-five or 
are in other high-risk groups such as the chronically ill or very young (10).  Influenza viruses are 
classified into three main types named Influenza A, B, and C (81).  Influenza A is the most 
prevalent for humans and has been the cause of the major pandemic influenza outbreaks 
including the 1918 pandemic that killed an estimated fifty million people.  Influenza A also infects 
avian species causing further concern for possible future pandemics (80).  Influenza A virus is the 
most prone to antigenic drift while influenza B is slightly less susceptible.  Influenza B causes 
regional outbreaks every two to four years but does not seem to become pandemic (81).  
Influenza C was discovered in 1950 and doesn’t pose significant risk to humans (81).  It appears 
that the type C influenza is relatively genetically stable and perhaps an indication as to why it is 
not as prevalent at causing disease (7).  Birds appear to be the natural hosts with all of the 
currently known strains having been isolated in birds and only a select few that are capable of 
infecting other animals.  Birds are capable of producing high titers of viral particles while 
remaining largely free of any disease symptoms (7).  Production of high viral titers while 
remaining asymptomatic makes birds a natural reservoir for influenza viruses.  The introduction of 
a novel pandemic influenza A H1N1 virus in 2009 dramatically increased the rates of confirmed 
laboratory testing of influenza and hospital visits for influenza like illness (ILI) throughout the 
United States (11).  The number of laboratory-confirmed positive tests for influenza was four 
times higher than the average for the previous four years from 2005 to 2008 (11).  This accounts 
for a substantial cost for the health care field and also loss of productivity and labor days due to 
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flu-related symptoms.  While the new H1N1 virus has not proved to be more pathogenic than 
currently circulating seasonal strains, the impact it had on the healthcare system was fairly 
dramatic. 
 
Molecular Biology of Influenza Viruses 
 
Influenza virus has a single-stranded, negative-sense RNA genome divided into eight 
segments (77). The eight segments of the influenza A genome are numbered according to 
decreasing length (6).  These segments allow the recombination of multiple genomes if one host 
cell is infected with two different strains of influenza, an event known as antigenic shift (6). The 
combination of multiple genomes within a single cell can produce novel antigenic proteins to 
which the population will have no immunity (6).  Such was the case with the 2009 H1N1 swine flu 
where a normal human influenza combined with an influenza virus that typically infects pigs.  The 
2009 H1N1 pandemic influenza killed 3,900 people between April and November of 2009 (11).  
The influenza A and B viruses are nearly identical in morphology when viewed under an 
electron microscope.  They appear as either spherical or filamentous shapes with the spherical 
shapes averaging 100 nM in diameter and the filamentous shapes 300 nM in length (6).  The 
influenza A virus is coated with glycoprotein spikes of hemagglutin (HA) and neuraminidase (NA) 
with the HA glycoprotein outnumbering the NA four to one (60).  The glycoproteins originate from 
a host cell-derived lipid membrane and a smaller number of M2 ion channels dot the exterior of 
the virion (6).  The M2 ion channels and the NA glycoproteins have both been used as targets for 
anti-viral chemotherapeutic agents (81).  There are at least sixteen different HA proteins 
numbered 1-16 with types H1, H2, and H3 capable of producing human epidemics (6). 
Hemagglutin allows the virus to bind to the host cell surface receptor to gain entry to the host cell. 
The HA protein is largely the target for the binding of antibodies to the influenza virus (7).  The 
neuraminidase protein comes into play at the end of the viral replication cycle by assisting viral 
budding from the infected host cell membrane (77).  Nine different types of NA proteins have 
been identified with N1 and N2 being significant in causing human disease.   
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The two surface antigens, hemagglutinin and neuraminidase, undergo antigenic 
variation frequently and are two of the major factors that contribute to susceptibility and 
pathogenicity of influenza viruses (6).  When a minor change occurs it is termed antigenic drift 
while antigenic shift indicates a more substantial change (7). Antigenic shift introduces a novel 
HA glycoprotein formed from the genetic reassortment of two or more influenza viruses.  Since 
binding of the HA by host antibodies will neutralize the infectivity of the virus, influenza viruses 
constantly evolve different amino acids at the antigenic sites of HA (6).  This is the hallmark of 
antigenic drift.  These small amino acids changes create a hemagglutin receptor that is no longer 
recognized by the host immune system (6).  The antigenic shift is more likely to result in an 
epidemic since antibodies that recognized previous influenza virus would not likely recognize the 
new strain.  Changes in the HA protein drive the continual evolution of the flu virus. 
 Influenza virus infects host cells by attaching to the cell surface receptor of the host cell 
and stimulating receptor-mediated endocytosis.  The virus recognizes N-acetylneuraminic (sialic) 
acid residues to stimulate viral binding (6).  The specificity of the receptor to influenza virus 
infection is determined by one of the carbons of the nine-carbon sugar.  The bond formed by the 
carbon-2 of the nine-carbon monosaccharide defines the specificity of the influenza virus for host 
cells.  Carbon-2 is capable of binding either the carbon-3 or carbon-6 forming α-2,3 or α-2,6 
linkages respectively (6).    The HA glycoprotein of the virus recognizes the different steric 
configurations formed by these bonds.  The α-2,3 linkages are more common in avian gut 
epithelium but are still found in the deeper respiratory tract of humans such as the bronchioles 
and alveoli.  The upper respiratory tract of humans utilizes more α-2,6 linkages than the α-2,3 
linkages.  Since the α-2,6 linkages are more common in the upper respiratory tract of humans, 
influenza viruses are more likely to cause an infection in the upper respiratory tract.  Avian 
influenza viruses prefer the α-2,3 linkages to the α-2,6 linkages.  The α-2,3 linkages are found in 
the lower respiratory tract of humans and are less physically accessible to viruses, thus, direct 
infection of avian influenza strains in humans is not very common but produces severe infections 
due to the infection deeper into the respiratory tract (6).   
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Low pH in the endosome formed during viral entry into the cell stimulates the entry of 
ions into the viral particle from the endosome (7).  The ions cause a conformation change in the 
HA protein allowing viral nucleocapsids to be released into the host cytoplasm (77).  Hydrogen 
ions are then pumped into the virus particle using the M2 transmembrane ion channel found only 
on influenza A viruses (6).  Entry of ions into the particle allows the virus to uncoat and release 
the viral ribonecleoproteins (RNPs) into the host cytoplasm (6).  The viral genome is transported 
to the nucleus by host proteins that utilize nuclear localization signals (NLSs) found on the viral 
proteins (17).  The NLSs are usually a short stretch of basic lysine residues separated by spacers 
of varying lengths (17).  The negative-sense viral RNA (vRNA) is utilized as a template by the 
vRNA-dependent RNA polymerase to create two positive-sense RNA strands (6).  One template 
is the mRNA template for viral protein synthesis while the other is a complementary RNA (cRNA) 
that the RNA polymerase uses to duplicate more negative-sense, genomic RNA copies (77).  
Synthesis of the envelope proteins (HA, NA and M2) is accomplished using mRNA of viral origin 
and the membrane-bound ribosomes of the host cell endoplasmic reticulum (6).  After 
posttranslational modification, the envelope proteins are guided to the cell membrane to await 
final virion assembly (6).  Specific coding regions on each of the eight viral genomic segments 
increase the chances that each virion receives a full complement of the viral genome (22). 
Influenza virus begins budding at the cell membrane.  Sialidase activity of the NA releases the 
virions from the host cell membrane (6).  Finally the neuraminidase “removes terminal sialic acids 
from cellular and viral surface glycoproteins, facilitating the release of virus particles from the cell 
and preventing their aggregation” (7).  Removing the terminal sialic acids from the glycoproteins 
also enhances infectivity of the influenza virus (59).  Recent data suggests that neuraminidase 
may play a role by aiding viral infection of the epithelial airways (66).  Neuraminidase may also 
help break down mucin allowing the virus physical access to the epithelial cells (66). Viral NA 
affects the viscosity of the mucous film in the respiratory tract thus increasing viral spread deeper 
into the lungs (7). 
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Clinical and Diagnostic Signs of Influenza Virus Infections 
 
Patients with influenza may present with a variety of symptoms. These usually include 
chills, headache, and a dry cough.  There is usually a high fever (>102°F), fatigue and anorexia.  
The fever and systemic symptoms usually last for three to five days (7).  The severe respiratory 
symptoms can last for another four days but cough and weakness may last up to a month after 
the initial symptoms.  The major problem with influenza is that it weakens the host to a variety of 
secondary diseases, usually pneumonia.  A virus, bacteria, or possible combination of the two 
can cause the bronchopneumonia that often leads to deaths attributed to the influenza virus (7).  
The most common occurrence is the initial infection of the influenza virus that leaves the host 
susceptible to a secondary bacterial infection that becomes pneumonia.  There is a possible 
synergistic effect obtained by the viral-bacterial infection.  It has been suggested that 
Staphylococcus aureus is capable of producing a protease that cleaves the influenza hemagglutin 
protein allowing the production of higher viral titers (7).  When the influenza virus itself causes the 
pneumonia, it is labeled a primary viral pneumonia.  When a bacteria or other virus induces the 
pneumonia, it becomes a complicated influenza.  Most of the patients that died from the 2009 
H1N1 died from secondary bacterial infections and not from the primary viral infection.  The 
Centers for Disease Control and Prevention indicate that the best way to prevent the spread of 
influenza is to be vaccinated (24).  Vaccination has been the key tool that has aided in controlling 
influenza outbreaks; the additional benefit of antiviral compounds should not be overlooked.  This 
is especially true since there are since specific concerns surrounding vaccination such as 
suboptimal immunogenicity and efficacy among the elderly and the very young, the very groups 
most likely to suffer a severe influenza infection.  Antiviral drugs provide a last line of defense in 
cases of severe or highly pathogenic influenza virus infections (24). 
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Antiviral Therapy for Influenza 
 
 Knowledge of the life cycle of the influenza virus has led to the development of antiviral 
chemotherapeutic agents that target three different aspects of viral production.  The first class of 
antivirals that was generated was the adamantanes.  These drugs consist of amantadine and 
rimantadine.  The adamantanes block the M2 protein ion channel and prevent viral uncoating 
after endocytosis into the host cell (66).  However, influenza viruses, most particularly those of 
the H3N2 and H5N1 types develop quick resistance to this class of drugs, and 1895 (99.8%) of 
the 1899 isolates of the pandemic H1N1 flu virus from the 2009-2010 flu season were resistant to 
adamantanes (11).  None of the H3N2 viruses isolated from the same flu season were sensitive 
to the adamantanes (11).   
The second class of drugs is the neuraminidase inhibitors (NAIs) that include oseltamivir, 
zanamivir, and peramivir with several others currently under development (66).  The 
neuraminidase inhibitors hinder the cleavage of sialic acid residues from cell surface receptors.  
Without the cleavage of the sialic acid residues, the virus is prevented from detaching from the 
host cell surface (63).  It is easier for viruses to generate resistance to the adamantanes than the 
NAIs (49).  Within the NAI class, each of the three compounds display a different resistance 
profile depending on the similarity of the chemical structure to the natural substrate for NA (63).  
The closer the drug comes to resembling the natural substrate, the lower the resistance profile 
will be.  The fact that they retain different resistance profiles means that a virus that has been 
isolated and is resistant to oseltamivir may yet remain sensitive to zanamivir.  It also opens the 
possibility of developing specific neuraminidase inhibitors in response to certain mutations in the 
influenza neuraminidase (79).  This would effectively allow drug development to be custom-
tailored to meet the increasing resistance of the influenza viruses.   
A third promising class of antiviral agents for influenza inhibits viral RNA polymerase.  
This class notably includes ribavirin, T-705 (favipiravir), T-1105, and T-1106.  These compounds 
work by selectively inhibiting viral RNA polymerase (24).   The FDA has not approved ribavirin for 
use in treatment of influenza infections due to concerns over toxicity, efficacy and a lack of 
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specificity (52).  Favipiravir is interesting because it seems to remain effective by inhibiting viral 
RNA polymerase but does not affect host RNA or DNA synthesis (23).  RNA polymerase 
inhibitors remain an interesting area of focus with most viruses already being resistant to the 
adamantanes, and neuraminidase resistance a concern for the future of influenza antiviral 
therapy.  Antiviral therapy will continue to be necessary since production of vaccines takes time 
and vaccinations need to be given prior to a viral infection (4).  Antiviral therapy will help to 
reduce the impact of a possible pandemic influenza infection (4, 54, 56).  Antiviral drugs will need 
to be used in combination with vaccination strategies to combat the continuing influenza threat. 
 
Host Response to Influenza Virus Infections 
 
One factor that affects pathogenicity of the influenza viruses is the host response to 
infection.  The body’s response to an influenza virus infection is characterized by several different 
methods for clearing the body of the infection.  Influenza viruses, similar to other respiratory 
infections, generally produce an acute infection usually limited to the upper respiratory tract (41).  
The respiratory tract is constantly monitored by epithelial cells, macrophages, and dendritic cells 
(DC) that are responsible for identifying potential pathogens and alerting the body to invasion 
(41).  Recognition of a pathogen by these immune surveillance cells leads to an acute response 
that stimulates a number of cytokines and chemokines creating a local antiviral state (41).  
Production of these cytokines leads to a variety of effects for circulating immune cells.  
Neutrophils are mobilized by cytokines and chemokines to enter sites of infection to phagocytose 
invading pathogens (61).  Despite appearing in high numbers near the sites of infection, 
neutrophils have not been shown to be necessary in viral clearance (41).  Infection by influenza 
virus was shown to produce a rapid and distinct increase in the number of monocytes in the blood 
(27).  Monocytes are leukocytes found circulating in the blood and can become sedentary tissue 
macrophages when they mature (61).  Once they have become macrophages, they are well 
equipped to be phagocytic cells.  They have an large cytoplasmic area with a number of 
vacuoules and are responsible for phagocytosing and disposing of dead cells and debris (61).  
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With influenza infection it is common to see an increase in the number of monocytes, 
macrophages, and neutrophils at the site of infection and in the serum. 
Cytokines are small molecules that function to regulate inflammation and the immune 
system (57).  An influenza virus infection leads to a rise in production of both pro-inflammatory 
and anti-inflammatory cytokines and chemokines.  The pro-inflammatory and anti-inflammatory 
cytokines and chemokines are divided into four general classes of small molecules.  These four 
classes of small molecules are important in modulation of the immune system and are labeled as 
interleukins, interferons, colony stimulating factors, and chemokines.  Interleukins are involved in 
directing immune function by guiding the proliferation and differentiation of the different immune 
cells.  Interferons are cytokines that associated with the inhibition of viral replication in infected 
cells.  Colony stimulating factors are important for conducting hematopoiesis and stimulation of 
the mobilization of precursor immune cells from bone marrow (48).  Chemokines are composed 
of a group of chemoattractant molecules that affect cell adhesion, activation and trafficking. Many 
of these groups are affected during an influenza infection.  A series of patients with extensive viral 
replication showed high levels of several cytokines and chemokines such as IP-10, MCP-1, IL-8, 
IL-6 and IL-10 (18).  Induction of a large cytokine response has been suggested as a rationale for 
the difference in pathogenicity of influenza viruses (14).  It has been noted that some strains of 
influenza viruses are able to induce higher levels of cytokines responses than other, less virulent 
strains (3, 15).  Induction of a more pronounced cytokine response has been termed the “cytokine 
storm” (15).  In particular, H5N1 strains of influenza virus have often had an increased virulence 
possibly associated with a strong induction of pro-inflammatory cytokines (18, 82).  However, 
other recent studies note that similar cytokine profiles were induced using high challenge doses 
of viruses that led to a loss of viral containment early on in the infection (33).  At this point, it is 
unclear whether there is a true difference between cytokine profiles induced by each influenza 
virus or whether virus kinetics or other factors may be responsible for these apparent differences.   
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The Role of Cytokines During Infection 
 
There are a number of pro-inflammatory and anti-inflammatory cytokines that increase 
during an influenza infection.  Each of these cytokines has many diverse physiological effects on 
the body.  In mice, influenza virus has been shown to induce increased levels of active 
Transforming Growth Factor-β (TGF-β) which has an immunosuppressive role in the body (5).  It 
has been suggested that stimulation of an immunosuppressive cytokine might give the virus a 
pathogenic advantage during infection.  However, cytokines display a large amount of 
redundancy and pleiotropy depending on the cells triggered by each cytokine, so the exact role of 
TGF-β is difficult to ascertain (5).    Each cytokine has a unique private receptor but may also 
share a common public receptor with many other cytokines which may explain the redundant and 
pleiotropic nature of cytokines (5).  A closer look at some of the different cytokines that are 
affected during an influenza infection may shed light on the pathogenicity displayed by different 
strains of influenza. 
Interleukin-1 (IL-1) is a pro-inflammatory cytokine produced by monocytes, macrophages, 
B cells, dendritic cells, and also by endothelial cells such as those found on the interior surface of 
the lungs (76).  IL-1 along with Tumor Necrosis Factor-α aid in the entry of neutrophils, natural 
killer (NK) cells into areas affected by inflammation and swelling (61).  There are two structurally 
distinct forms of IL-1; the acidic form is known as IL-1α, while the neutral form is labeled IL-1β 
(76).  One systemic effect of inflammatory cytokines such as IL-1 is to cause a febrile response in 
the host (61).  A second systemic effect of these cytokines is to change to array of soluble plasma 
proteins secreted by the liver, causing what is termed the “acute-phase response.”  Two of these 
proteins, C-reactive protein and mannose-binding lectin, increase binding of complement to 
pathogen surfaces (61).  IL-1α also displays a unique feature of being a “dual-function” cytokine.  
IL-1α is able to bind to the cell surface receptor to develop an inflammatory reaction and also 
forms an intracellular precursor that increases the transcription of pro-inflammatory genes (21).  
IL-1 has also been shown to have effects as an adjuvant and aids in the polarization towards a 
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Th17 response (21).  While the above mentioned effects can be considered beneficial to the 
host, overproduction of inflammatory cytokines such as IL-1 can lead to pathological destruction 
beyond the effects of the actual viral infection (40). 
Interleukin-2 (IL-2) a lymphokine produced by T cells that aids in regulation of immune 
function (76).  Once produced, IL-2 is responsible for the control and differentiation of cells in the 
immune response (61).  In addition to the ability to stimulate growth and differentiation of immune 
cells, IL-2 also triggers T cells to produce other cytokine such as Interferon-γ and Interleukin-4 
(IL-4) (73).  IL-2 is also capable of acting as a chemoattractant for T cells (5).  It is interesting to 
note that IL-2 is also selectively produced by influenza virus-specific CD8+ T-cells and likely plays 
an important role in the clearance of the virus-infected cells (47). 
Interleukin-3 is produced by effector CD4 T cells and stimulates the production of 
macrophages and granulocytes from the bone marrow (61).  IL-3 acts on numerous target cells 
within the hemapoietic system and may cause in increase in platelet levels though it has not been 
shown to have any role in steady state hemopoiesis (73).  IL-3 essentially provides a link between 
the surveillance cells of the immune system and the hemopoietic system which generates the 
cellular elements that make up the defense and repair responses (73).  IL-3 is also known to be a 
survival factor that is necessary for the maintenance of dendritic cells that have descended from 
lymphatic origins (8).  It has been shown that IL-3 plays a critical role in the development of 
monocytes into dendritic cells (8). 
Interleukin-4 (IL-4) is an anti-inflammatory cytokine produced by T cells, mast cells and 
NK-cells that acts upon B-cells and may modify viral replication (76).  When high levels of IL-4 are 
present in the environment, a Th2 response is favored (61).  Addition of IL-4 to a patient suffering 
from an inflammatory disease from excessive Th1 activity may re-equilibrate the balance between 
Th1 and Th2 cells (73).  Specifically, in mice infected with influenza, dosing with IL-4 led to an 
increased Th2 response that also delayed viral clearance from the animals (55).  Increased 
production of IL-4 may indicate an attempt to ameliorate an excessive inflammatory response.  IL-
4 has a critical role in determining the size and quality of a pathogen-specific immune response 
(34). 
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Interleukin-5 (IL-5) is a cytokine largely noted for its involvement with both helminth 
infections and allergic reactions (5).  IL-5 is produced by T-cells and mast cells but has a specific 
chemotactic activity for eosinophils (73).  IL-5 is also capable of stimulating naïve B-cells to 
differentiate into plasma cells secreting IgM.  IgM will be the first antibody to show up in an 
infection where there are no thymus-independent antigens (61).  In human patients with 
pandemic influenza virus infections, IL-5 was shown to be present at higher levels in patients that 
had developed pneumonia versus those who had not (70). 
Interleukin-6 (IL-6) is manufactured by monocytes, macrophages, T-cells and bone-
marrow stromal cells and has three major functions.  These functions are to stimulate 
differentiation of B-cells into plasma cells, stimulate antibody secretion, and to induce the 
synthesis of acute-phase proteins (76).  IL-6 production was shown to be up-regulated in patients 
suffering from influenza induced pneumonia (46).  In addition, excessive lung inflammation in 
influenza A viral infections is often attributed to deleterious effects of IL-6 and TNF-α (48).  
Certain levels of IL-6 may be necessary since IL-6 has been shown to be necessary for 
developing a local IgA immune response (45).  IL-6 may be important since it is one of the only 
cytokines that seems to correlate with disease severity (33). 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has down-regulatory effects on 
many of the pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6 and IL-8 (5).  It has also beens 
shown to have inhibitory effects on the responses of T-cells (1).  IL-10 is produced by T-cells, B-
cells monocytes, macrophages, and eosinophils with a major function to suppress the 
inflammatory response (76).  B-cells are the primary producers of IL-10 in mice (73).  Additionally, 
IL-10 upregulates IL-1R antagonist and haemoxygenase1, both of which have anti-inflammatory, 
antiapoptotic and antiproliferative actions (78).  IL-10 has many pleiotropic effects so it is not clear 
exactly which mechanism is responsible for limiting the inflammatory response.  Other effects of 
increased IL-10 include the production of Treg cells, which diminish Th1 and Th2 responses, as 
well as destabilization of cytokine mRNA (78).  In a recent study of human infections caused by 
the Influenza H1N1 2009 pandemic virus, IL-10 production was actually shown to be decreased 
(46).  Decreased production of IL-10 may allow the pro-inflammatory cytokines to cause 
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excessive damage due to lessened anti-inflammatory regulation.  One of the central roles of IL-
10 appears to be limiting immunopathology associated with strong immune responses but this 
can also be detrimental as it can decrease the effectiveness of an efficient Th1 response (50).  
The same authors also noted that production of IL-10 might actually decrease protection from 
influenza viruses when an extremely high challenge dose is used. 
Interleukin-12 (IL-12) is an immunomodulatory cytokine that affects T-cells, NK cells, and 
hematopoietic stem cells and causes the induction and release of IFN-γ and other cytokines (1).  
In effect, IL-12 acts as a bridge between nonspecific innate immunity and the later antigen-
specific adaptive immunity (32).  Apoptosis of T cells and dendritic cells has been shown to be 
inhibited by IL-12 (31).  Production of IL-12 tends to polarize the immune system towards a Th1 
cell response (73).  A Th2 response is generally obtained when IL-10 levels are increased since 
IL-10 inhibits the production of IL-12 and thus prevents the induction of a Th1 response (61).  
Production of IL-12 is controlled by both positive and negative feedback mechanisms by IFN-γ, 
IL-10 and by type 1 IFN (32).  The development of a Th1 immune response towards an antigenic 
challenge augments the cellular immunity against viral, bacterial and protozoan infections by 
reducing the pathogen load, hastening the clearance of lesions, and has also been shown to 
prolong survival of severe combined immune deficiency (SCID) animals with viral infections (73).  
Induction of IL-12, and by association, a Th1 immune response also suppresses the development 
of Th2 cell types (73).  In fact, with mice lacking the capacity to produce IL-12, Th1 immunity can 
still occur by is significantly depressed (73).  Although IL-12 plays a significant role as one of the 
body’s first lines of defense against infection, it is also responsible for some of the negative side 
effects of inflammation such as hematological alterations and tissue damage (5).  IL-12 has been 
studied in patients with mild and severe Influenza H1N1 2009 infections and was present at 
significantly higher levels than control groups (31).  This data seems to conflict with other recent 
reports that IL-12 is not important for protection against Influenza A infection (74).   
IL-17 is a proinflammatory cytokine and was the first cytokine to be sequenced without 
prior knowledge as to its function (5).  It is believed that IL-17 is a cytokine inducing cytokine that 
exhibits indirect pro-inflammatory and hematopoietic activities (73).  Its main function seems to be 
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an upstream inducer of pro-inflammatory responses, although it is not known whether it has a 
unique function or whether it is simply one of many cytokines that might be responsible for 
commencing pro-inflammatory interactions (5). 
Monocyte chemoattractant protein-1 (MCP-1) is produced by a variety of cells such as 
monocytes, macrophages, neutrophils, lymphocytes, endothelial cells and epithelial cells, among 
others (1).  As its name suggests, the primary function is to attract monocytes to sites of 
inflammation and infection and may play a critical role in the development of an inflammatory 
response.  MCP-1 is one of many cytokines produced by epithelial cells, monocytes, and other 
cell types in response to an influenza virus infection (37).  Specifically, the effects of MCP-1 have 
been shown to limit viral growth and decrease weight loss associated with influenza virus 
infection (19). 
Interferon-γ (IFN-γ) is one of the primary cytokines of both innate and adaptive immunity 
and is responsible for producing a Th1 cellular immune response (61).  It is responsible for 
activating macrophages, stimulating differentiation of Th1 from T cells, inhibiting the Th17 
pathway and controlling intracellular pathogens (31).  IFN-γ is secreted by CD8 T cells and has 
been shown to inhibit replication of viruses in infected cells while increasing presentation of viral 
antigens (61).  IFN-γ can also activate macrophages that clear infected cells to allow damaged 
tissue more space to heal (61).  NK cells are a primary producer of IFN-γ in early stages of 
infection and inflammation (73).  Production of IFN-γ is typically regulated by other cytokines and 
determines whether an activated CD4+ T cell is a low or a high IFN-γ producer (5).  IL-2 is the 
prototypical up-regulator while IL-10 is the down-regulator.  In the murine model, activated CD4+ 
T cells are thus classified as being high IFN-γ/low IL-4 producers (Th1 clones) or they can be low 
IFN-γ/high IL-4 producers (Th2 clones) or intermediate production of both (Th0 clones) and this is 
a largely a result of the cytokine environment in which the cells matured (5).  IFN-γ is interesting 
in that it exhibits both pro- and anti-inflammatory activities.  The underlying cellular mechanisms 
surrounding its pro- and anti-inflammatory activity are encompassed by 1) generation of reactive 
oxygen and nitrogen, 2) augmentation of endothelial adhesiveness, 3) induction or suppression of 
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chemokine production, and 4) synergy with other cytokines (5).  When exposed to IFN-γ, 
mononuclear phagocytes mount a respiratory burst response that is generates reactive oxygen.  
The reactive oxygen generated is necessary for microbicidal activity but can also cause 
undesirable tissue damage (5).  Nitrogen oxide is similar to reactive oxygen and is produced by a 
variety of cell types upon stimulation of IFN-γ.  One of the most important elements in 
inflammation is the role of vascular endothelial cells since they create the barrier that leukocytes 
must traverse to infiltrate the site of inflammation (5).  IFN-γ increases the adhesion molecule 
ICAM-1 and E-selectin expression on endothelial cells.  E-selectin is likely responsible for loose 
adhesion and ICAM-1 would be the cause of stronger adhesion to allow entry into the 
inflammatory site (5).  Once these leukocytes have entered the sites of infection, interactions with 
chemokines stimulate the release of granular contents and proteases that can further damage the 
tissue.  IFN-γ generally up-regulates the production of CC-chemokines, which attract monocytes, 
and down-regulates the production of CXC-chemokines, which attract neutrophils.  The net result 
is the promotion of monocyte attraction and a decrease in neutrophil attraction (5).  Increased 
IFN-γ production has been seen, particularly with the pandemic H1N1 influenza virus, which was 
also correlated with increased pathology when compared to the seasonal influenza strains . 
Tumor necrosis factor-α (TNF-α) is a membrane bound cytokine that acts locally in the 
area of the bound T-cell (61).  TNF-α is produced by macrophages and NK cells and activates 
polymorphonuclear cells, monocytes, and endothelial cells.  Its main role lies in inducing 
inflammation and the febrile response (78).  TNF-α activates endothelial cells, activates 
neutrophils, aids in the synthesis of acute phase proteins, and induces apoptosis of many 
different cell types (31).  Originally identified for its role in the regulation of antitumor growth 
activity, it is now recognized for its effect on the growth, differentiation and metabolism of many 
cell types (73).  Even though it is often seen in cases of tissue injury, studies show that TNF can 
be important for repair and regeneration of tissue as well.  One theory regarding TNF is that low 
levels are beneficial while higher levels can lead to excessive tissue damage (73).  Another 
primary effect of TNF is on the endothelial cells of the blood vessels.  Activation of the endothelial 
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cells aids in the migration of leukocytes to sites of inflammation.  TNF also causes the release 
of chemokines that further aid the migration of inflammatory cells (5).  With direct ties to influenza, 
TNF-α has demonstrated the ability to increase production of cytokines that are stimulated by 
influenza infections (75).  TNF also becomes important for its utilization in tissue remodeling.  
TNF stimulates the influx and proliferation of many cells that aid in the repair and reconstruction 
of damaged tissue (5).  TNF-α has been suggested as a key cytokine that if induced to very high 
levels is an indicator of more pathogenic viruses, specifically with H5N1 strains.  A recent study 
indicated that this is more likely strain specific and other influenza viruses are capable of being 
highly pathogenic without inducing high levels of TNF-α (53). 
 Macrophage inflammatory protein-1α (MIP-1α) is a chemokine produced by monocytes, 
T-cells, mast cells, and fibroblasts and aids in the attraction monocytes, NK cells, T-cells, 
basophils and dendritic cells.  It is also known for the ability to stimulate production of other pro-
inflammatory cytokines such as IL-1, IL-6, and TNF-α (61).  A recent study demonstrated that 
MIP-1α levels increase dramatically in more severe cases of influenza compared to more mild 
infections (25). 
 T lymphocytes, macrophages, endothelial cells, and a few other cell types are the key 
producers of granulocyte macrophage colony-stimulating factor (GM-CSF) in vivo (73).  Levels of 
GM-CSF, along with the other colony-stimulating factors are not constitutive and significant levels 
cannot be detected in the blood.  However, when induced by other cytokines or physiologic 
conditions, increased levels can be detected readily (5).  The action of GM-CSF depends on the 
cell type upon which it is acting.  With neutrophils, GM-CSF enhances antimicrobial activity 
through a variety of methods such as increasing phagocytosis, release of lysozyme and 
chemotactic factors (73).  GM-CSF enhances differentiation of monocytes to macrophage-like 
cells and also increases production of TNF, IL-1α, IL-1β, IL-6, IL-8, IL-12, M-CSF and IL-1Ra 
(73).  It has also been shown that GM-CSF has chemotactic properties for the accumulation of 
neutrophils and mononuclear cells (73). 
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 Regulated on Activation, Normal T Express and Secreted (RANTES) is a protein that is 
a member of the IL-8 superfamily of cytokines.  RANTES aids the immune system by directing 
the trafficking of leukocytes to sites of infection or injury (1).  RANTES a particular feature of a 
inflammation and has a significant role in the immune response to viruses since it is produced by 
activated virus-specific T cells (2).  It has been shown to play a role in the attraction and 
activation of eosinophils, T-cells and basophils.  These cell types are most often associated with 
chronic inflammatory diseases or autoimmune processes such as asthma and allergy (1).  It is 
now recognized that in addition to chemotactic activities, it might also be responsible for the 
activation of leukocytes once they have entered the sites of inflammation (2).  It has been shown 
that RANTES is more strongly induced by highly pathogenic H5N1 strains of virus than by less 
pathogenic H1N1 strains, though this does not seem to be necessary for highly pathogenic 
viruses (13). 
 
Pathology Associated with Influenza Virus Infections 
 
Macroscopically, an autopsy performed on a patient who died of an influenza infection 
will show inflammation of the upper respiratory tract.  The trachea, bronchial tree, and even 
alveolar ducts can show a large degree of inflammation.  Sometimes bleeding in the respiratory 
tract is visible (20).  There may also be a mucopurulent material covering the trachea and 
bronchi.  These changes lead to increased difficulty in breathing and sometimes cyanosis visible 
in the tips of the fingers.  In mice, the lungs often undergo consolidation and change from a bright 
pink to a dark red color.  The lungs will lose their spongy texture and become less elastic and 
more rigid.  The epithelium may be filled with thin blood stained fluid.  As the infection progresses 
the epithelium may become necrotic.  Influenza virus-induced pneumonias also show other 
pathologic signs such as “capillary and small vessel thromboses, interstitial edema and 
inflammatory infiltrates, the formation of hyaline membranes in alveoli and alveolar ducts, varying 
degrees of acute intraalveolar edema and/or hemorrhage, and diffuse alveolar damage in 
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addition to necrotizing bronchitis and bronchiolitis” (71).  As the disease progresses evidence 
of fibrosis, epithelial regeneration and squamous metaplasia are visible.   
 Upon closer examination, influenza virus infection produces “multifocal destruction and 
desquamation of the pseudostratified columnar epithelium of the trachea and bronchi.  Edema 
and congestion of the submucosa are often marked” (71).  The virus causes cytonecrosis that 
may be phagocytosed by macrophages.  There may be pathologic regions directly bordering 
regions that appear histologically normal.  Neutrophils are markedly absent in the initial stages of 
infection but may show up as necrosis of the epithelium continues to occur.  The epithelial layer 
may be completely lost in the later stages of infection indicative of the formation of hyaline 
membranes at the site of necrosis (71).  Other changes that may be visible include generalized 
vascular congestion around the upper airways.  Hyperemia, edema and inflammatory cell 
infiltration of the tunica propria and submucosa are often seen in the areas of viral replication.  
Neutrophils may be seen without a secondary bacterial infection but only in small numbers.  A 
large number of neutrophils is a good indicator of a secondary bacterial infection in the area.  
Morphologically, it may be difficult to distinguish a primary influenza viral pneumonia from 
pneumonia caused by bacteria.  The patterns are generally the same and are referred to as 
atypical pneumonias.  Atypical refers to the fact that only moderate amounts of sputum are 
produced, lack of consolidation in the lungs, only a moderate amount of white cell elevation, and 
absence of exudates from alveolar cells (44).  The septa of the lungs are usually widened and 
edematous with evidence of mononuclear lymphocytes, histiocytes and sometimes plasma cells 
(44).  Alveolar epithelial cells may display pyknotic nuclei stemming from viral replication in these 
cells (71).  Chronic inflammation of the lungs and alveolar cells can lead to the formation of 
hyaline membranes and thrombi in the alveolar capillary bed.  The capillary thrombosis may lead 
to necrosis of the alveolar wall.  Necrotic sites in the lungs are often diffuse and vary due to the 
progression of the disease.  A massive secondary infection may lead to difficulty in identifying 
some signs of the primary viral infection.  During the pandemics in both 1889 and 1918, the 
pathologists concluded that it was nearly impossible to separate lesions caused by the bacteria 
from those caused by the virus (71).  Comparisons were made between the pandemic fatalities 
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and those caused by the inter-pandemic flu strains.  No visible difference was seen in the 
pathology between the pandemics that killed millions and the other strains that kill thousands.  
This indicates that there is not likely a large difference in the pathology caused by different strains 
of the influenza virus.  The lethality of each virus strain is due to differences in transmissibility and 
the ability of the virus to weaken the body for a secondary infection.     
The pathology caused by influenza is similar to that of other atypical pneumonias, but is 
often characterized by a lower increase in white cells and only a moderate amount of sputum 
production (43).  Influenza viruses are responsible for the majority of viral pneumonias in 
otherwise healthy individuals (39).  Although the pneumonia associated with influenza virus 
infections is usually mild, it can be fatal within 24 h.  Histologically, the airways are congested and 
radiographs often show patchy areas of air-space consolidation with pneumonias induced 
influenza virus infections (39).  The primary pathology caused by the initial influenza infection 
weakens the body enough to allow a secondary bacterial infection that worsens the viral 
pneumonia (26, 38).  The viral pneumonia is not distinguishable from the secondary bacterial 
pneumonia so the cause of death is usually linked to the bacterial pneumonia rather than the viral 
pneumonia (65). 
 
Effects of Infection on Complete Blood Counts 
 
Many different cell types and reactions to infections can be monitored with a complete 
blood count (CBC) to ascertain the approximate levels of each cell type found in the bloodstream 
as well as give an overall indicator of host health.  Usually, a CBC will give information regarding 
three cell types.  The first cell type is white blood cells (WBCs), the second is red blood cells 
(RBCs) and the third is platelets (PLT).  WBCs are further categorized into lymphocytes, 
monocytes, and granulocytes.  Red blood cells include information on mean corpuscular volume 
(MCV), hematocrit (Hct), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red blood cell distribution width (RDW), and hemoglobin (Hgb).  Platelet 
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data includes mean platelet volume (MPV), plateletcrit (Pct), and platelet distribution width to 
indicate any platelet abnormalities. 
Changes in the number of WBCs are often indicative of the type of disease and is also 
specific depending on the changes of each cell type.  An increase in lymphocytes is often seen in 
both viral and bacterial infections.  Neutrophils, also classified as a type of granulocyte, are often 
elevated during infectious diseases but may decrease in viral infections in children (9).  
Depending on when the sample is collected, neutrophils may be elevated or decreased in viral 
infections.  Initially, the percentage may increase as neutrophils migrate to inflamed tissue, but 
later on in the infection the percentage of neutrophils in the blood will decrease as neutrophils 
extravasate and remain localized in sites of infection (16).  Monocytes may be involved in an 
influenza infection but are more likely to be seen in chronic infections or long-term disease states 
(16). 
Factors that might influence the number of circulating RBCs might be impaired 
production, excessive destruction, blood loss or in chronic inflammatory diseases (9).  Hematocrit 
is usually tied directly to the RBC count.  Determination of hemoglobin concentration is useful 
because the oxygen-carrying capacity of the blood is linked to the amount of Hgb and not to the 
number of circulating erythrocytes (9).  To be useful, the Hgb concentration must be used in 
conjunction with the Hct.  The Hct should be three times the Hgb for a healthy individual.  The 
mean corpuscular volume is an indicator of the size of the RBCs.  Changes in size in either 
direction can indicate diseases such as iron deficiency anemia or other factors such as recent 
alcohol intake (16).  MCH and MCHC are related to the amount of hemoglobin present in one cell.  
The MCHC is the MCH multiplied by 100.  They are both ways to determine whether the 
erythrocytes are normal color (normochromic), less than normal color (hypochromic) or more than 
normal color (hyperchromic) (16).  The RBC distribution width is calculated from the MCV and the 
RBC.  Only an increase is important and can be used for diagnosing different types of anemia 
(16).  
Platelets are involved in the formation of blood clots and the maintenance of normal 
hematopoietic function.  Decreased levels of platelet production can often occur during viral 
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infections and changes in the platelet size (mean platelet volume, MPV) occur during various 
diseases (9).  MPV is similar to the aforementioned MCV and indicates size of the platelets.  The 
platelet hematocrit is the percentage of whole blood composed of solely platelets.  Platelet 
distribution width is based on the platelet count and the MPV (16). 
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CHAPTER II 
 
STATEMENT OF THE PROBLEM 
 
With the recent emergence of the swine influenza H1N1 infections and the looming threat 
of a lethal avian influenza virus on the horizon, understanding factors that contribute to the 
pathogenicity of influenza viruses is more important now than ever before.  Pathogenicity refers to 
the ability of the organism to harm the host and is sometimes used interchangeably with 
virulence, which refers to the amount of pathology caused by the organism (72).  Studies have 
shown that different viral strains may vary greatly in virulence when used in vitro and in vivo (28-
30, 36).  A full explanation of the diversity of virulence seen by infection with different influenza 
strains still cannot be made.  Humans infected with avian influenza viruses, especially the H5N1 
strain, differ from typical influenza infections in viral load kinetics, viral spread beyond the 
respiratory tract, and induction of unusual amounts of inflammatory cytokines (62).  Differences 
observed between the virulence of each strain along with host responses to the virus can account 
for part of the lethality of the viruses and the effectiveness of antiviral therapy.  Determining which 
factors contribute to virulence in the mouse model may increase our ability to better treat the 
infection in humans.     
A study that combined the novel RNA polymerase inhibitor T-705  with the neuraminidase 
inhibitor oseltamivir, found that oseltamivir was able to protect nearly every mouse from the 
A/NWS/33 (H1N1) virus at a concentration of 1 mg/kg/day (69).  However, the efficacy of the 
treatment with oseltamivir against the A/Victoria/3/75 (H3N2) and H5N1/MN/1525/81 (H5N1) was 
not as pronounced (69).  Treatment by oseltamivir at 50 mg/kg/day was only able to protect 6 out 
of 10 mice from A/Victoria/3/75 and was only successful after extending the course of treatment 
from 5 to 7 days.  This is reflected in similar results where oseltamivir treatment had to be used at 
higher does for longer treatment schedules to promote survival (28).  Oseltamivir at 40, 20 and 10 
mg/kg/day was not effective at increasing survival but did significantly increase the mean day of 
death with any of the treatment doses.  A similar trend was seen with T-705 indicating that H5N1 
was less susceptible to treatment with T-705 than either of the other viruses (69).   
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There are several possible factors that might contribute to variability in treatment 
benefit with influenza virus strains.  One explanation might be a difference in replication time 
between virus strains.  A more rapid replication time might allow the virus to overcome antiviral 
treatment and replicate to a lethal infectious dose.  The rate of influenza virus replication cycle 
was shown to be more important for determination of the amounts of virus than the infectivity of 
the virus (51).  The same study also indicated that the rate of replication influenced the peak viral 
titers that the virus was able to produce.  A faster replication cycle might influence the mean day 
of death of infected animals.  Differences in viral burst size could also affect the effectiveness of 
drugs. If one virus was capable of producing higher titers of virus in the host than another virus, it 
would give the first virus an advantage in replication in spite of antiviral therapy.  A study that 
documented the increasing neuraminidase resistance among influenza viruses noted that there 
was also an increase in virulence seen with H5N1 avian influenza viruses.  It was suggested that 
this might be the result of cytokine storm, systemic viral dissemination or alveolar flooding (63).  
Another study noted an increased duration of oseltamivir treatment was required when using a 
more virulent influenza strain (28). 
Another possibility for explaining variability in drug treatment efficacy is the host response 
to the viral infection.  Different virus strains can produce varying effects on the host and thus have 
an effect on disease progression.  This can be evaluated based upon cytokine analysis, complete 
blood counts, and blood chemistry that may be run at varying stages of infection to determine 
host response to the viruses. To our knowledge, this type of analysis has never been performed 
before and would represent novel information regarding the host response to viral infection in the 
mouse model.  Lung tissue can also be evaluated for identification of disease symptoms and 
possible histopathological following infection with different strains.   
Genetic variations in viral neuraminidase might also explain why certain viruses are more 
resistant to oseltamivir treatment in vivo but would not explain the increased resistance to T-705.  
Also, previous studies have indicated that viral neuraminidase enzymatic activity cannot be 
correlated with outcomes in the mouse model (29). 
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Another possible difference between viral strains might be found in the pathology that 
each strain can cause in infected tissue.  As previously discussed, the ability of each virus to 
cause pathology might be a possible difference between the sensitivity of each virus to treatment 
with oseltamivir.  If one virus is able to cause more severe pathology or cause pathological 
damage more quickly, this might allow the virus to cause lethality in mice before oseltamivir is 
able to offer any protection.   
Understanding differences between viral strains and their impacts on the murine model 
will benefit those who research influenza both in vitro an in vivo.  The main purpose of the present 
research was to elucidate differences between the viruses that might explain why some of the 
viruses are more treatable than others with antiviral compounds.  The two differences observed in 
the initial study were the effectiveness of oseltamivir in protecting the mice and markedly different 
mean days of death for untreated mice infected with different virus strains.  We utilized the three 
viruses from the aforementioned study, A/MN/1525/81 (H5N1), A/Victoria/3/75 (H3N2) and 
A/NWS/33 (H1N1).   Since all three of these viruses are older viruses that have been extensively 
researched, we added the recent pandemic influenza isolate A/California/04/2009 (H1N1) to 
determine how it would compare to the other virus strains. 
Specific aims of this project were: 
1.  To compare different viral strains using in vitro methods to characterize viral replication 
kinetics and susceptibility to oseltamivir. 
A) In vitro replication curves were generated for each virus by infecting Madin-Darby 
Canine Kidney (MDCK) cells in T-25 flasks and titrating the samples by end-point dilution on 
MDCK plates. 
 B) The susceptibility of each virus to oseltamivir was measured by testing each virus in 
an antiviral assay in cell culture.  Concentrations of oseltamivir that were able to effectively 
protect fifty-percent of the cells (EC50) were calculated and compared to each other. 
 C) The ability of oseltamivir to inhibit the neuraminidase produced by each virus was 
compared by a neuraminidase inhibition assay.  Concentrations of oseltamivir that were able to 
inhibit fifty-percent of the viral neuraminidase (EC50) were calculated and compared to each other. 
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2.  To determine differences between viral strains in the mouse model and to identify possible 
indicators for severity of disease.   
A) A primary mouse experiment was set up by sacrificing infected mice at multiple time 
points to compare viral growth.  Homogenized lung samples were titrated by end-point dilution to 
quantify the amount of virus at each time point. 
 B) Blood was collected from each mouse to run a complete blood count at each time 
point to see if there were any potential indicators of disease severity.  
C) Lung samples were sent for histological examination to determine if there were 
differences in pathology between the viral strains.  The Utah Veterinary Diagnostic Laboratory 
performed all histological examinations. 
D) Homogenized lung samples were analyzed for cytokine concentration to determine if a 
potential “cytokine storm” had any impact on the lethality of the viruses.   
3.  To determine differences between viral strains in the mouse model when treated with 
oseltamivir.  All infected groups received identical treatment doses. 
 A) Mice were sacrificed at specific times to determine the disease progression in the 
presence of oseltamivir.  All lung samples were homogenized and titrated by end-point dilution to 
determine the effect of oseltamivir on lung virus titers.    
B) Lung samples were sent for histological analysis to determine the ability of oseltamivir 
to prevent tissue destruction.  
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Antiviral Compounds 
 
Oseltamivir carboxylate, the active form of oseltamivir, was provided by Jack Nguyen 
(Adamas Pharmaceuticals, Emeryville, CA).  Oseltamivir phosphate (Tamiflu) was purchased 
from a local pharmacy.  Hereafter, oseltamivir phosphate will be referred to as oseltamivir.  Since 
the oseltamivir obtained from the local pharmacy contained excipients as well, the entire 75-mg 
capsules minus the shell were added to water to make up the highest mg/kg of body weight/day 
dose of the drug.  Lower doses were made by serial dilutions in water.  Water served as the 
placebo.  The 75 mg of drug specified in the capsule represents oseltamivir carboxylate liberated 
in vivo, since the mg amount of the prodrug (oseltamivir) is actually higher than this. 
 
Viruses 
 
Influenza A/California/04/2009 was previously adapted for BALB/c mice and was 
provided by Elena Govorkova (St. Jude Children’s Research Hospital, Memphis, TN).  The virus 
was passaged once in Madin-Darby Canine Kidney (MDCK) cells to make a larger pool.  
Influenza A/California/04/2009 will be referred to as p-H1N1 since it is the pandemic-H1N1 
influenza virus.  Influenza A/Victoria/3/75 (H3N2) was purchased from the American Type Culture 
Collection (Manassas, VA).  The virus was passaged serially seven times in the lungs of mice to 
make it lethal in the murine model.  The Influenza A/Victoria/3/75 virus will be referred to as H3N2 
from this point on.  Influenza A/NWS/33 (H1N1) was originally obtained from Kenneth Cochran 
(University of Michigan, Ann Arbor, MI).  The virus was passaged three times in mouse lungs.  
From this point forward, Influenza A/NWS/33 will simply be referred to as H1N1. Influenza 
A/Duck/MN/1525/81 (H5N1) virus was provided by Robert Webster (St. Jude Children’s Research 
Hospital, Memphis, TN).  It was passaged three times in mouse lungs to make the virus lethal in 
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mice.  Influenza H5N1/MN/1525/81 will be referred to as H5N1 from this point forward.  Virus 
pools were pre-titrated in mice to determine approximate 90% and 100% lethal doses (LD90 and 
LD100).  Pools for use in cell culture assays were made by diluting the mouse stocks 1:30. 
 
In Vitro Viral Replication Kinetics 
 
Viral replication kinetics were determined by seeding MDCK cells into T-25 flasks 
(Corning Inc., Corning, NY).  MDCK cells were diluted in 5 ml of Eagle’s minimum essential 
medium for a total of 8.0 x 106 cells/flask.  Three flasks were seeded for each virus as replicates.  
Each flask was infected with an MOI of 0.001 for each virus.  Each flask was incubated for 2 h at 
37°C to allow viral attachment.  After 2 h, the flasks were rinsed with clean media to remove any 
unattached virus remaining in the flask.  Samples were harvested every 3 h for 72 h by removing 
500 µl of supernatant from each flask.  After sample collection, 500 µl of clean infection media 
was placed in each flask.  Virus titers from each sample were assayed in 96-well microplates 
infected with approximately 50 CCID50 per 0.1 ml, by quantifying virus yield by the end-point 
dilution method (64, 68).  Medium for replicating viruses was Eagle’s minimal essential medium, 
0.22% sodium bicarbonate, 10 units/ml trypsin, 1 µg/ml EDTA/ and 50 µg/mL gentamicin.  
Replication curves were created for each virus by plotting log10 CCID50 versus time post infection 
using Prism graphing software (GraphPad Software, San Diego, CA). 
 
Viral Neuraminidase Inhibition Assay 
 
Inhibition of viral neuraminidase by oseltamivir was assayed using a commercially 
available kit (NA-Star influenza neuraminidase inhibitor resistance detection kit; Applied 
biosystems, Foster City, CA) in 96-well solid white microplates following manufacturer’s 
instructions and has been previously reported (67).  Oseltamivir carboxylate was diluted in half-
log increments and incubated with each of the four virus strains (as the neuraminidase source).  
Approximately 500 cell culture infectious doses (CCID50) were added to each well.  Plates were 
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preincubated for 10 min at 37°C prior to the addition of chemiluminescent substrate.  Following 
the addition of substrate, plates were incubated for 30 min at 37°C.  The neuraminidase activity 
was evaluated using a Centro LB 960 luminometer (Berthold Technologies, Oak Ridge, TN) for 
0.5 s following addition of the NA-Star accelerator solution.  Fifty-percent inhibitory concentrations 
(IC50) of viral neuraminidase activity were determined by plotting chemiluminescence counts 
versus log10 oseltamivir concentrations. 
 
Antiviral Assay in Cell Culture 
 
Antiviral studies of oseltamivir carboxylate were performed by using confluent cultures of 
MDCK cells in 96-well microplates.  The assays were infected with approximately 50 cell culture 
infectious doses (CCID50) of virus by quantifying virus-induced cytopathic effect (CPE) by neutral 
red dye uptake (68).  Three microwells were infected at each concentration.  Two wells were 
uninfected served as toxicity controls.  Plates were examined under a light microscope three days 
post-infection to determine when the virus had reached 100% CPE.  When virus control wells 
reached 100% CPE, the plates were incubated for two h with neutral red (0.011% final 
concentration) at 37°C.  Excess dye was rinsed from each well with phosphate-buffered saline 
(PBS).  The absorbed dye was extracted using 0.1 ml of 50% Sörensen’s citrate buffer (pH 4.2)—
50% ethanol.  Plates were read for determination of optical density (OD) at 560 nm.  The OD 
readings were converted to a percentage by using a Microsoft Excel® spreadsheet developed for 
that purpose.  Fifty-percent virus-inhibitory concentrations (50% effective concentrations [EC50]) 
were calculated by plotting percent CPE versus log10 concentrations of oseltamivir carboxylate.  
Toxicity was determined using the same method. 
 
Characterization of Influenza Virus Replication and Lethality in Mice 
 
Specific-pathogen-free BALB/c mice weighing approximately 17 to 19 g were purchased 
from Charles River Laboratories (Wilmington, MA).  They were maintained on standard rodent 
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chow and given water ad libitum with water bottles.  The animals were quarantined forty-eight h 
prior to beginning of studies.  Mice were anesthetized with ketamine (100 mg/kg) and then 
infected intranasally with either 90-ul (H1N1, H3N2 and H5N1) or 75-µl (p-H1N1) suspension of 
virus. Dilutions of each virus were 1:150, 1:45, 1:200 and 1:150 for H1N1, H3N2, H5N1 and p-
H1N1 respectively.  While the exact amount of virus varied according to strain, the infecting virus 
titers were approximately 104.5 to 105.0 CCID50 per mouse to achieve 100% lethality.  This 
corresponded to a 50% mouse LD50 (MLD50) of 3, 2, 4, and 3 for the H1N1, H3N2, H5N1, and 
p-H1N1 respectively.  Groups of five mice were sacrificed at 3, 6, 12, 18, 24, 36, and 48 h and 
daily until day 6 for lung scores, lung titers, and lung weights.   Lung scoring was done by gross 
examination of lungs following removal from the mice.  Lung virus titers were determined at each 
day of sacrifice.  Harvested lungs from sacrificed mice were weighed and then frozen at -80°C 
until processed.  Thawed lungs were homogenized in 1 ml of cell culture medium (minimal 
essential medium) and then were refrozen.  Later thawed samples were centrifuged at 2,000 X 
gravity for 10 min and titrated by end-point dilution in 96-well microplates as described in “in vitro 
growth curves assay”.  Virus titers were converted to CCID50/g lung tissue.  The homogenized 
lung samples were also analyzed for cytokine concentrations on days 1-6 using the Q-Plex™ 
Mouse Cytokine – Screen (16-plex) (Quansys Biosciences, Logan, UT).  Samples were diluted 
according to the manufacturer’s instructions and the plates were imaged with Canon EOS 50D 
digital camera and the resulting image was interpreted with with Quansys’ Q-View software.  
Resulting cytokine levels were normalized for lung weights and plotted versus time post-infection.  
One half of each lung sample was preserved in 10% Neutral Buffered Formalin (10% NBF) then 
sent for histopathologic analysis by Dr. Ramona Skirpstunas (Utah Veterinary Diagnostic Lab, 
Utah State University, Logan, UT).  Blood samples from days 1, 2, 3, 4, 5, and 6 were analyzed 
for a complete blood count (CBC) using the Vetscan® HMT hematology analyzer (Abaxis, Union 
City, CA).  Healthy controls (10 uninfected, untreated animals) were weighed in parallel with the 
infected groups. 
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Characterization of Influenza Viruses in Mice Treated with Oseltamivir 
 
Animals were obtained as before and maintained under identical circumstances.  The 
mice were again anesthetized with ketamine (100 mg/kg) and infected intranasally with 90-µl of 
suspension of each virus.  The infectious doses of each virus were adjusted to achieve 100% 
mortality for untreated mice.  The dilution of the H5N1 was identical to the previous study.  The 
dilution of the p-H1N1 virus was adjusted so that the same infectious dose was used but the virus 
was diluted 1:180 and an equal 90-µl suspension was used for infection.  The infectious doses of 
the H1N1 virus and the H3N2 virus were increased to ensure that all untreated mice died.  The 
dilution of H1N1 was a 1:120 and H3N2 was 1:30.  Mice were treated with doses of oseltamivir, 
either 40 mg/kg/day, 5 mg/kg/day or placebo.  Treatments began 1 h post-infection and continued 
twice a day (at 12-h intervals) for 5 days.  Groups of 5 animals were sacrificed at day 1, 2, 4, 6, 8, 
and 10.  The mice at each time point were analyzed for lung viral titers, score, and weight.  One 
half of the lung tissue was again sent to the Utah Veterinary Diagnostic Laboratory for 
histopathology.  Lungs were processed as before.  Mice were weighed every other day 
throughout the infection.  Healthy controls (10 uninfected, untreated animals) were weighed in 
parallel with the infected groups. 
 
Statistical Analyses 
 
The in vitro growth curves were evaluated by two-way ANOVA with Bonferroni post-tests.  
Neuraminidase results and the neutral red for the cell culture antiviral assays, were evaluated by 
a one-way ANOVA and a secondary Tukey’s Multiple Comparison Test.   Increases in total 
survivors were evaluated by a Kaplan-Meier test followed by the Gehan-Breslow-Wilcoxon test.  
The Mann-Whitney U-test was used to evaluate differences in the mean days of death.  
Differences in body weight were compared using a one-way ANOVA.  All data obtained from 
complete blood counts, cytokine concentrations and lung viral titers were compared using a two-
way ANOVA with Bonferroni post-tests.  Lung scores and histological lesion scores were 
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analyzed by nonparametric analysis using the Kruskal-Wallis test with a Dunn’s Multiple 
Comparison post-test.  One analysis was performed for each time point that was measured.  All 
analyses were calculated using Prism 5.0 (GraphPad Software, San Diego, CA).   All figures were 
also created used Prism 5.0 (GraphPad Software, San Diego, CA).  Detailed reports from each 
statistical test performed are included in the appendix. 
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CHAPTER IV 
IN VITRO COMPARISON OF INFLUENZA STRAINS 
 
Viral Replication Kinetics in MDCK Cell Culture 
 
The abilities of influenza viruses to replicate in MDCK cells were evaluated by infections 
of 25 cm2 flasks repeated in triplicate.  When each replication curve was compared to the others, 
the overall curves were not significantly different from each other.  However, there were 
significant differences between the virus strains at individual time points when they were 
compared by two-way ANOVA.   
 
p-H1N1 Compared to H1N1 
Comparison of the p-H1N1 virus to the H1N1 virus revealed that the p-H1N1 virus was 
able to produce significantly higher viral titers in MDCK cells at seven of the time points 
throughout the infection (Figure 1).  Comparison by two-way ANOVA showed significant 
differences at seven different times (Table A.1).  Titers were significantly higher in samples taken 
from the p-H1N1-fected flasks at 9 h, 24 h, 27 h, 63 h, and from 66-72 h.  However, these 
differences do not seem to affect sensitivity to oseltamivir since treatment with oseltamivir 
remains highly effective, even at lower doses, against both of these viruses.  The comparison of 
these two viruses illustrates the fact that virus replication alone, especially determined from in 
vitro studies, does not determine the ability of oseltamivir to protect the mice from a lethal 
infection.  The differences seen with in vitro titers cannot be directly correlated to results following 
infection of mice.  
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Figure 1 In Vitro Replication Curves of p-H1N1 and H1N1 Influenza Viruses on MDCK Cells.  
T-25 flasks of MDCK cells were infected with influenza viruses and samples were taken every 
three h post-infection.  The p-H1N1 virus had significantly higher titers in MDCK cells than the 
H1N1 virus at 9 h (P<0.001), 24 h (P<0.01), 27 h (P<0.001), 63 h (P<0.01), and from 66-72 h 
(P<0.001).   
 
p-H1N1 Compared to H3N2 
The replication curves of the p-H1N1 virus and the H3N2 virus were nearly identical to 
each other (Figure 1).  Analysis by two-way ANOVA illustrated three significant differences 
between replication curves of the two viruses (Table A.1).  Infection with the H3N2 virus produced 
significantly higher titers in MDCK cells at 15 h and 18 h post-infection.  The p-H1N1 virus 
produced higher titers at 72 h post-infection.  While these differences are significant, overall, in 
vitro replication kinetics were very similar, especially starting with 27 h post-infection.  The early 
differences in the replication curves may be beneficial for the H3N2 virus since higher viral titers 
early in the infection would allow the virus to overcome the effects of oseltamivir treatment. With 
replication curves that otherwise are so similar, the differences in susceptibility to oseltamivir 
therapy are hard to explain. 
 
0 12 24 36 48 60 72
0
2
4
6
8
10
p-H1N1
H1N1
***
** *** **
*********
**=P<0.01
***=P<0.001
p-H1N1 vs. H1N1
Hours Post Virus Exposure
Me
an
 Vi
rus
 Ti
ter
 (C
CID
50
/m
L)
 33 
 
Figure 2 In Vitro Replication Curves of p-H1N1 and H3N2 Influenza Viruses on MDCK Cells.  
T-25 flasks of MDCK cells were infected with influenza viruses and samples were taken every 
three h post-infection.  The p-H1N1 and H3N2 viruses had similar replication curves and H3N2 
had significantly higher titers at 15 h (P<0.01) and 18 h (P<0.05) post-infection.  The p-H1N1 
influenza virus had a significantly higher titer at 72 h (P<0.001) post-infection. 
 
p-H1N1 Compared to H5N1 
When the H5N1 virus was compared to the p-H1N1 virus, the replication curves were again 
similar (Figure 3).  Statistical analysis by two-way ANOVA was used to compare differences at 
each time point (Table A.3).  Though H5N1 was able to grow to a higher titer at sixteen of the 
twenty-four time points, including all samples from 27 to 63 h, none of the differences were 
statistically significant.  Though other differences were not statistically different, it is hard to say 
what kind of an impact the small differences in titer have on each virus’ susceptibility to 
oseltamivir.  It does appear from this comparison, that while the replication curves appear very 
similar, the outcomes following oseltamivir treatment are very different.  This data supports the 
idea that the differences between the viruses may be apparent in mice, but are not reflected in 
cell culture studies.  There are not many differences between the two viruses in cell culture and 
we have not previously studied the effects of oseltamivir on mice infected with each of these 
viruses in the same study.  Based solely upon the in vitro replication, we would expect the 
sensitivity to oseltamivir to be approximately the same. 
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Figure 3 In Vitro Replication Curves of p-H1N1 and H5N1 Influenza Viruses on MDCK Cells.  
T-25 flasks of MDCK cells were infected with influenza viruses and samples were taken every 
three h post-infection.  None of the differences in the in vitro replication curves were statistically 
significant.   
 
H1N1 Compared to H3N2 
The two in vitro replication curves that showed the most differences were those created 
by H3N2 and the H1N1 viruses (Figure 4).  Comparison was done be two-way ANOVA (Table 
A.4).  The H3N2 virus displayed higher titers at nearly every time point sampled and was 
significantly higher than H1N1 at 9 h, 15 and 18 h, 27 h, 30 h, and also from 63-69 h.  This 
difference between viral titers, specifically the early times differences that occur in the first 24 h, 
might partially explain differences in susceptibility to oseltamivir.  The H3N2 virus displays a 
replication curve that increases earlier post-infection than the H1N1 virus.  The H3N2 virus has a 
selective advantage due to a faster replication cycle compared to the H1N1 virus.  Higher virus 
titers are also seen in MDCK cells with the H3N2 virus.  It is not certain whether these in vitro 
characteristics will remain significant in mouse studies. 
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Figure 4 In Vitro Growth Curves of H1N1 and H3N2 on MDCK Cells.  T-25 flasks of MDCK 
cells were infected with influenza viruses and samples were taken every three h post-infection.  
The H3N2 virus produced much higher virus titers in MDCK cells throughout the infection and 
was significantly higher at 9 h (P<0.001), 15 and 18 h (P<0.05), 27 h (P<0.001), 30 h (P<0.05), 
and from 63-69 h (P<0.001) post-infection. 
 
H1N1 Compared to H5N1 
Influenza H5N1 was able to produce higher virus titers than the H1N1 virus at twenty-one 
of the twenty-four time points throughout the infection (Figure 6).  The two strains were compared 
using a two-way ANOVA (Table A.6).  All of the differences that were significant show that the 
H5N1 virus produces higher virus titers in MDCK cells.  The H5N1 virus produced significantly 
higher titers at 9 h, 27 and 30 h, 33 and 60 h, 63-69 h and at 72 h following infection as well.  The 
differences at early time points (9 h and 27-33 h) may be important, but it is difficult to say that 
these relatively small differences would account for the dramatic differences in the susceptibility 
to oseltamivir that has been seen in mouse experiments.  The H5N1 virus is able to grow to 
higher titers at 75% of the time points as seen in the graph, but the differences between the 
measurements are not statistically significant.  At least in vitro, it appears that the H5N1 virus has 
an advantage to replicate more quickly and would theoretically spread faster in mice.  Faster viral 
spread in mice means that the virus is capable of causing more tissue damage and would thus be  
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Figure 5 In Vitro Replication Curves of H5N1 and H1N1 Influenza Viruses on MDCK Cells.  
T-25 flasks of MDCK cells were infected with influenza viruses and samples were taken every 
three h post-infection.  The H5N1 virus had a consistently higher titer throughout the infection.  
Virus titers produced by the H5N1 virus were significantly higher at 9 h (P<0.01), 27 and 30 h 
(P<0.001), 33 and 60 h (P<0.01), 63-69 h (P<0.001), and at 72 h (P<0.01) post-infection. 
 
more difficult to treat.  This should be confirmed in mouse studies to determine if this 
characteristic remains consistent in vivo. 
 
H3N2 Compared to H5N1 
When compared against the H5N1 virus, the influenza H3N2 virus displayed a similar 
replication curve (Figure 6).  Comparison was done by two-way ANOVA (Table A.6).  They 
differed significantly at only two time points.  The H3N2 virus was able to produce a significantly 
higher titer at 9 h while the H5N1 virus was able to achieve a higher virus titer at 72 h post-
infection.  These very similar replication curves might be partially responsible for the similar 
outcomes following oseltamivir therapy.  The H3N2 virus seems to have an advantage in the first 
24 h and then the H5N1 virus maintains a higher titer throughout the remainder of the infection, 
with one exception at 66 h post-infection.  Comparison in vivo will help to determine if these 
similar replication curves help each virus overcome oseltamivir therapy.  The fact that these two 
viruses show similar susceptibility to oseltamivir makes sense considering their comparable 
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Figure 6 In Vitro Replication Curves of H5N1 and H3N2 Influenza Viruses on MDCK Cells.  
T-25 flasks of MDCK cells were infected with influenza viruses and samples were taken every 
three h post-infection.  The replication curves were very similar and the only two significant 
differences.  The H3N2 virus produced a higher viral titer at 9 h (P<0.01) and the H5N1 virus had 
a significantly higher titer at 72 h (P<0.05). 
 
 
replication kinetics.  Replication kinetics cannot be responsible for all of the differences because 
the replication kinetics seen with the p-H1N1 and H1N1 virus were not that different from the 
kinetics of the H5N1 and H3N2 virus. 
 
Viral Neuraminidase Inhibition Assays 
 
The four viral strains were evaluated by viral neuraminidase inhibition assay against 
oseltamivir (Figure 7).  Three of the four viruses were very similar in the susceptibility of the 
neuraminidase to ostelamivir.  Effective concentrations able to inhibit 50% of the viral 
neuraminidase (EC50) were calculated for each virus.  When performed in triplicate, the mean 
EC50 for p-H1N1, H1N1 and H3N2 were 1.08 nM, 1.53 nM, and 1.77 nM, respectively.  The  
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Figure 7 Viral Neuraminidase Inhibition of Influenza Viruses by Oseltamivir Carboxylate.  
The inhibition of viral neuraminidase by oseltamivir was measured using the NA-Star 
neuraminidase resistance detection kit.  EC50s were calculated for each viral neuramindase.  The 
H5N1 virus had the only neuraminidase that was significantly different from the other viruses.  
The EC50 for the H5N1 virus was significantly higher than that of the H3N2 and H1N1 viruses 
(P<0.05) as well as the p-H1N1 virus (P<0.01). 
 
only virus that was significantly different by one-way ANOVA (Table A.7) was the H5N1 virus and 
had a mean EC50 of 3.83 nM.  Standard deviations of EC50 values of p-H1N1, H1N1, H3N2 and 
H5N1 were 0.57, 1.0, 0.72, and 0.38 respectively.  The difference between the H5N1 viral 
neuraminidase EC50 was statistically significant from the H3N2 and H1N1 viruses as well as 
significantly different from the p-H1N1 virus.  The fact that the H5N1 viral neuraminidase is less 
sensitive to oseltamivir may explain part of the difference seen in the mouse experiments.  This 
does not fully account for the difference because the H3N2 virus was also more resistant to 
oseltamivir therapy in mice, but had a neuraminidase EC50 that was nearly identical to that of 
H1N1.  The differences in viral neuraminidase susceptibility to oseltamivir carboxylate are likely a 
contributing factor, but not the only reason for decreased susceptibility to oseltamivir.  However, 
the fact that the H5N1 virus has an EC50 value that is approximately three times that of the other 
three viruses would give the H5N1 virus a distinct advantage in mice.  Compared to the other 
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viruses, the H5N1 viral neuraminidase is less inhibited by oseltamivir and would thus be more 
lethal despite oseltamivir treatment. 
 
Cell Culture Antiviral Assays 
 
When compared in a standard antiviral cell culture assay, the ability of oseltamivir to 
prevent cell death was measured.  The effective concentration of oseltamivir carboxylate that was 
able to prevent cell death in 50% of the cells (EC50) was calculated for each viral strain.  The cell 
culture EC50 was calculated based on CPE inhibition by neutral red uptake assay (Figure 8).  The 
mean EC50 for p-H1N1, H1N1, H3N2 and H5N1 were 0.13, 0.034, 0.0076 and 0.039 µM 
respectively.  The standard deviations of the mean EC50 were 0.010, 0.0033, 0.0029, and 0.021 
in the same order. Comparison was done by one-way ANOVA (Table A.8).  The EC50 values 
calculated by the neutral red assay were only statistically significant when compared with the  
 
 
Figure 8 Antiviral EC50 of Oseltamivir Carboxylate in Neutral Red Uptake Assay.  The EC50 
of oseltamivir was calculated for each virus using a standard antiviral assay.  The only EC50 that 
was significantly different was that of the p-H1N1 virus.  The EC50 of oseltamivir against the p-
H1N1 virus was significantly higher than the H3N2 virus (P<0.001), the H1N1 virus (P<0.01) and 
the H5N1 virus (P<0.01). 
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p-H1N1 virus.  The EC50 of the p-H1N1 virus was significantly higher compared to H3N2, H1N1 
and H5N1 viruses.  While there is a slight difference between the in vitro EC50 values, they do not 
correlate well with in vivo data.  By this assay, all of these viruses are considered sensitive to 
oseltamivir.  Also, the differences between the mean EC50 values are relatively small considering 
the half-log dilutions that were used in the antiviral assay.  The fact that in vitro assays do not 
correlate with the in vivo experiments has been discussed previously and has been documented 
in the literature (29).  While the cell culture assays are not always indicative of the ability to 
prevent death in mice, they were performed and have been included for completeness. 
 
Conclusions 
  
Results of the in vitro studies showed a few small differences between the viruses but not 
anything that would explain the differences in oseltamivir sensitivity that have been seen.  
Replication in MDCK cells showed that the replication occurs at the fastest rate with the H3N2 
virus.  The replication rates were very similar for the H5N1 and p-H1N1 viruses.  The H1N1 virus 
displayed the slowest replication rate on MDCK cells as it lagged about three h behind the H3N2 
virus.  Surprisingly, none of the viruses are capable of producing significantly higher titers 
throughout the 72 h following the infection.  Replication rates in MDCK cells do not explain the 
differences seen with each virus’ susceptibility to oseltamivir. 
 The neuraminidase assay does give some insight into the differences in susceptibility to 
oseltamivir therapy seen with the H5N1 and H3N2 viruses.  The only EC50 that was significantly 
different was the one shown by the H5N1 virus, and it was different from the EC50 all three other 
viruses.  Though it is significantly different, the neuraminidase EC50 of the H5N1 virus is not that 
different from the EC50 of the other three viruses.  It is only about three times higher than the 
other EC50s.  While this may seem fairly large, it is only one half-log dilution higher.  Half-log 
dilutions were used in the assays so it is only one dilution different.  All four of the viruses are 
considered sensitive to oseltamivir by the results of the neuraminidase assay.  It may give the 
H5N1 virus a selective advantage in mice, but does not fully explain the differences since the 
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H3N2 virus has a nearly identical neuraminidase EC50 to both of the other viruses that are very 
sensitive to oseltamivir. 
 The in vitro antiviral assay did not shed any additional light on the differences between 
the viruses.  The results of the antiviral test showed that the p-H1N1 virus was the least sensitive 
to oseltamivir while the other three viruses were approximately equal.  In vitro antiviral assays do 
not always correlate well with the in vivo data so it is not surprising that the results are not in line 
with results from mice.   
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CHAPTER V 
CHARACTERIZATION OF VIRAL GROWTH AND LETHALITY IN MICE 
 
Parameters Measured in Mouse Experiments 
 
Survival 
 Survival curves were generated by infecting twenty mice with each virus strain.  Survival 
was plotted versus the day post-infection (Figure 9).  The survival curves were compared using 
the Kaplan-Meier analysis followed by the Gehan-Breslow-Wilcoxon test (Table A.9).  None of the 
survival curves were significantly different from each other with the exception of the H5N1-
infected mice.  The mice infected with the H5N1 virus died much quicker and the curve was 
significantly different (P<0.001) when compared to the three other virus strains.  There is   
 
 
Figure 9 Survival Curves for Influenza-Infected Mice.  Groups of twenty mice were infected 
with the four influenza virus strains.  Percent survival was plotted versus the day post-infection.  
Comparison of the survival curves was done by the Kaplan-Meier analysis followed by the 
Gehan-Breslow-Wilcoxon test.  Mice infected with the H5N1 virus had a significantly different 
survival curve compared to the other three viruses (P<0.001).   
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obviously something different about the way that the H5N1 virus affects the mice.  A 
significantly shorter survival curve would definitely impact the ability of oseltamivir to provide 
protection for themice.  The standard oseltamivir treatment in mice is twice a day for five days 
(28, 29, 69).  There were also differences in the numbers of mice that survived the infection.  
Mice infected with the H1N1 virus and the H3N2 virus had survivors at the dilution of the virus 
that was used.  Influenza H1N1 had two mice that survived while influenza H3N2 had three 
surviving mice.  
There was a noticeable difference between the mean days of death from the initial animal 
experiment (Table 1).  Mean day of death was only calculated using the mice that died from the 
infection since the H3N2 and H1N1 viruses both had surviving mice.  Comparison of the mean 
days of death for influenza-infected mice was evaluated by the Mann-Whitney U-test (Table 
A.10).  The H5N1 virus had a significantly earlier mean day of death when compared to the other 
three viruses.  It was more significant against H1N1 and p-H1N1 (P<0.001) than it was against 
H3N2 (P<0.01) likely due to a higher standard deviation for the H3N2 virus.  The fact that H5N1 is 
able to kill mice more quickly has been noted previously and may be partially responsible for the 
resistance of H5N1 to oseltamivir.  Oseltamivir must control viral titers early since it does not 
actually eliminate viruses but instead prevents them from detaching from cells that they have 
infected.  While the mean day of death may be significant for H5N1, H3N2 had previously shown 
increased resistance to oseltamivir and had the highest mean day of death in this study.  In this 
particular study, three mice infected with the H3N2 virus died rather late in the experiment (two at  
 
Table 1 Mean Day of Death in Influenza-Infected Mice.  The mean day of death was calculated 
for each group of mice following infection with the four influenza viruses.  The H5N1 infected-mice 
died significantly earlier when compared to the p-H1N1 and H1N1 infected-mice (P<0.001) as 
well as the H3N2 infected-mice (P<0.01). 
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day 13 and one at day 16) that contributed to a larger standard deviation.  The mean day of 
death for the H3N2-infected mice may also be different because the infectious-dose that was 
used was not sufficient to kill all the mice.  Whether or not the mean day of will change depending 
on the infectious dose is unknown.  By this standard, the mean day of death for H1N1-infected 
mice is also questionable.  Both of these will need to be re-evaluated with an infectious dose that 
produces equivalent results in mice. 
 
Weight Loss 
 The body weights of infected mice were measured every other day throughout the 
experiment and each weight was calculated as a percentage of weight at day zero (Figure 10).  
For this experiment, the measured body weights were an average of the groups of twenty mice  
that were used for survival as well.  Comparison of the body weight measurements by one-way  
 
 
Figure 10 Percentage of Body Weight in Influenza-Infected Mice.  Body weights of the twenty 
mice infected with four strains of influenza were measured every two days following infection.  
Body weights were converted to percentage of initial body weight.  Changes in the percentage of 
body weight were not significant when compared by one-way ANOVA. 
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ANOVA showed that all viruses were significantly different than uninfected controls, but none 
of the viruses were significantly different from each other (Table A.11).  Interestingly, body 
weights of the H3N2 and H5N1-infected mice dropped more quickly than was seen with the other 
groups.  This seems particularly noteworthy with the H3N2 virus since the infectious dose was 
sub-optimal and mice survived the infection.  Comparison of body weights with more equal 
infectious-doses may help reveal differences between the pathogenicity of each virus.  There 
does seem to be a difference but this should be evaluated with dilutions of each virus that 
achieve the same lethality in mice. 
 
Lung Virus Titers 
Lung samples were titrated by end-point dilution and a lung virus titer was calculated for 
each homogenized lung sample.  There were many significant differences between virus strains 
so graphs were created comparing only two virus strains at a time. 
   
p-H1N1 Compared to H1N1 
Comparison of the p-H1N1 and the H1N1 virus showed significant differences between 
the two viruses throughout the infection (Figure 11).  Comparison of mean lung virus titers was 
done by two-way ANOVA (Table A.12).  Early in the infection, higher lung virus titers were seen in 
the H1N1-infected mice at 6 and 18 h after infection.  Lung virus titers from p-H1N1-infected mice 
surpassed those seen with the H1N1-infected mice from 18 h until day 5 post-infection.  
Differences were significant at 36 h, day 2, day 3, day 4 and day 5 post-infection.  While there are 
differences between virus titers at nearly every time point, these two viruses do not show 
significant differences when comparing the ability of oseltamivir to protect mice.  While the lung 
virus titers were higher earlier in the infection with the H1N1-infected mice, both viruses displayed 
a slower initial replication curve in mice when compared with the H3N2 and H5N1 viruses.  If 
virus titer impacts sensitivity to oseltamivir, the first 36 h must be relevant.  These viruses may be 
similar since the lung virus titers of the H1N1-infected mice were higher in the first 18 h but the 
lung virus titers of the p-H1N1-infected mice were higher from that point until 36 h post-infection. 
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Figure 11 Mean Lung Virus Titers in Mice Infected with p-H1N1 and H1N1 Influenza 
Viruses.  Five mice were sacrificed at each time point.  Lung titers of H1N1-infected mice were 
higher titers at 6 and 18 h post-infection (P<0.001).  The lung titers of p-H1N1-infected mice were 
higher at 36 h (P<0.001), day 2 (P<0.01), day 3 (P<0.001), day 4 (P<0.001) and day 5 (P<0.01) 
post-infection.   
   
p-H1N1 Compared to H3N2 
Lung virus titers of H3N2-infected mice and p-H1N1-infected mice showed higher lung 
virus titer with the H3N2-infected mice at most time points following infection (Figure 12).  
Comparison of the two groups was done by two-way ANOVA (Table A.13).  Higher lung titers 
were seen in the H3N2-infected mice from 3 h through 24 h that were all equally significant.  
Differences were not significant at 36 and 48 h post-infection.  Higher lung titers were visible in 
the p-H1N1-infected mice at day 3 and day 4.  Days 5 and 6 did not show any significant 
differences between the two viruses.  The H3N2 virus was less susceptible to oseltamivir therapy 
and also showed higher virus titers early post-infection.  This has been hypothesized to affect the 
ability of oseltamivir to protect the mice from a lethal infection.  Differences in lung virus titers 
after day 2 do not seem to be important for the susceptibility to oseltamivir.  If oseltamivir is 
unable to prevent viral spread in the first two days, the virus has likely spread throughout the  
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Figure 12 Mean Lung Virus Titers in Mice Infected with p-H1N1 and H3N2 Influenza 
Viruses.  Five mice were sacrificed at each time point.  Higher lung virus titers were seen from 
H3N2-infected mice compared to p-H1N1-infected mice at the early points in the infection.  
Differences were equally significant (P<0.001) at 3, 6, 12, 18, and 24 h post-infection.  The lung 
virus titers of p-H1N1-infected mice were significantly higher at day 3 (P<0.001) and day 4 
(P<0.01) post-infection. 
 
lungs and will still be able to cause significant tissue damage.  Since oseltamivir functions by 
preventing virus from exiting infected cells, if a significant number of lung cells are infected early 
on, the virus will still kill the infected cells and damage the lung tissue enough to remain lethal in 
mice. 
 
p-H1N1 Compared to H5N1 
Comparison of mice infected with the H5N1 and p-H1N1 viruses showed that higher virus 
titers were seen in the lungs from H5N1-infected mice early in the infection but surprisingly the 
virus titers from the p-H1N1-infected mice were higher from 36 h until day 6 (Figure 13).  Two-
way ANOVA was used again to determine significant differences between lung virus titers (Table 
A.14).  Virus titers from the H5N1-infected mice were higher than those seen in the p-H1N1-
infected mice at 6, 12, and 18 h following infection.  No differences were seen at 24 h, but the 
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virus titers from p-H1N1-infected mice were significantly higher at 36 h, day 2, as well as day 3, 
4, and 5 post-infection.  The differences at day 6 were not significant although the virus titers from 
the p-H1N1-infected mice were still higher.  These differences further support the idea that only 
the first two days of lung virus titers are significant for influencing the ability of oseltamivir to 
prevent a lethal infection in the mice.  While virus titers may vary in the later parts of the infection, 
the ability of the virus to produce a lethal infection in mice has likely already been determined by 
the higher virus titers of the first two days.  While lung titers may play a critical role in determining 
pathogenicity, the differences seen here do not fully explain the differences in oseltamivir 
susceptibility observed between these viruses.    
 
 
Figure 13 Mean Lung Virus Titers in Mice Infected with p-H1N1 and H5N1 Influenza 
Viruses.  Five mice were sacrificed at each time point.  Lung virus titers of H5N1-infected mice 
were higher than the titers p-H1N1-infected mice titers at 6, 12 and 18 h post-infection (P<0.001).  
Lung titers of the p-H1N1-infected mice were higher than the lung titers of H5N1-infected mice at 
36 h (P<0.001), day 2 (P<0.05), and day 3, 4, and 5 (P<0.001).   
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H1N1 Compared to H3N2 
The lung virus titers of mice infected with the H1N1 and H3N2 viruses were significantly 
different especially at the early time points following infection (Figure 14).  Comparison was done 
by two-way ANOVA (Table A.15).  Lung virus titers from the H3N2-infected mice were higher than 
the titers from the H1N1-infected mice at every time point following infection and was significantly 
higher at 3, 6, 12, 18, 24, 36, and 48 h.  Lung virus titers from H3N2-infected mice were still 
higher from day 3 to day 6 but the differences were small and not statistically significant.  These 
differences may factor into the differences in susceptibility to oseltamivir shown by these two 
viruses.  The H3N2 virus is able to replicate to a higher titer in the lungs of mice especially early 
in the infection.  This early replication of virus may be difficult for oseltamivir to contain and thus 
the virus is able to spread more rapidly and remains lethal despite treatment.  Early production of 
a high virus titer in mouse lungs could produce an infection that is more difficult to contain using 
oseltamivir.   
 
 
Figure 14 Mean Lung Virus Titers in Mice Infected with H1N1 and H3N2 Influenza Viruses.  
Five mice were sacrificed at each time point.  Lung virus titers from H3N2-infected mice were 
higher than H1N1-infected mice at 3, 6, 12, 18, 24, and 36 h (P<0.001) as well as day 2 post-
infection (P<0.01).  
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H1N1 Compared to H5N1 
When lung virus titers of the mice infected with the H1N1 and H5N1 influenza viruses 
were compared, only a few time points were significantly different (Figure 15).  Comparisons of 
mean lung virus titers were made by two-way ANOVA (Table A.16).  Lung titers of H5N1-infected 
mice were significantly higher than H1N1-infected mice at 6, 12, and 18 h post-infection.  None of 
the other differences were statistically significant.  While this resembles the pattern seen with 
H3N2-infected mice, the differences are less pronounced with mice infected with the H5N1 virus.  
This seems to contradict data shown in previous experiments.  If a higher virus titer in the lungs 
helps to overcome oseltamivir, it would seem logical that mice infected with the H5N1 virus would 
have a higher titer than H3N2-infected mice since it showed increased resistance to oseltamivir.  
While virus titer may contribute to oseltamivir susceptibility, it is not likely the only factor.  The 
findings that the H5N1 and H3N2-infected mice have in common are higher lung virus titers prior 
to day 2.  
  
 
Figure 15 Mean Lung Virus Titers in Mice Infected with H1N1 and H5N1 Influenza Viruses.  
Five mice were sacrificed at each time point.  Lung virus titers of H5N1-infected mice were higher 
than titers seen with the H1N1-infected mice at 6 (P<0.001), 12 (P<0.01), and 18 h post-infection 
(P<0.001).  None of the differences from that point on were statistically significant.  
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H3N2 Compared to H5N1 
Comparison of the lung virus titers of the mice infected with the H3N2 and H5N1 viruses 
showed that higher lung virus titers were seen in mice infected with the H3N2 influenza virus at 
nearly every time point (Figure 16).  Two-way ANOVA was utilized to determine statistically 
significant differences between mean lung virus titers (Table A.17).  Lung virus titers of H3N2-
infected mice were higher at 3, 6, 12, 18, 24, and 36 h.  Lung virus titers of H3N2-infected mice 
were also significantly higher at day 2, day 4, and day 5.  Lung virus titers were not significantly 
different at day 3 or 6.  Lung virus titers from the H3N2-infected mice were significantly higher at 
nearly every time point throughout infection.  If virus titer alone contributed to lethality and 
increased resistance to oseltamivir, the H3N2-infected mice should have a lower mean day of 
death and be less susceptible to oseltamivir than the mice infected with the H5N1 virus.  While 
that discrepancy is not as easy to explain, both of these viruses are able to replicate more quickly 
 
 
Figure 16 Mean Lung Virus Titers in Mice Infected with H3N2 and H5N1 Influenza Viruses.  
Five mice were sacrificed at each time point.  Lung virus titers of the mice infected with the H3N2 
virus were higher than lung titers of H5N1-infected mice at 3, 6, 12, 18, 24, and 36 h (P<0.001) as 
well as day 2 post-infection (P<0.01).  The higher lung virus titers seen with the H3N2-infected 
mice were also significant at day 4 (P<0.01) and day 5 (P<0.001) post-infection. 
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 and produce higher lung virus titers in mice when compared to the H1N1 and p-H1N1 viruses.  
Higher lung virus titers prior to day two may contribute to the inability of oseltamivir to effectively 
protect mice from influenza infections.  This would seem logical since the use of oseltamivir in 
human infections requires treatment very early to be effective. 
 
Lung Score 
 Upon removal from the mice, lungs are scored for the degree of hemorrhage by gross 
examination on a scale of 0 to 4.  A lung score of 0 is equivalent to no signs of consolidation or 
necrosis. A score of 1 is equivalent to 25% of the lungs surface area showing a color change 
indicative of influenza infection.  A score of 2 is 50%, 3 is 75% and 4 is 100%.  Scores are also 
given in half values such as 1.5, 2.5 and so on.  While being fairly subjective, the lungs are 
usually scored by one person during an experiment to minimize variation between technicians.  
Mean lung scores were plotted versus the day post-infection to give an estimation of the severity 
of the influenza infection in the lungs (Figure 17).  A Kruskal-Wallis test with Dunn’s multiple 
comparisons was done at each time point to evaluate significant differences in lung scores (Table 
A.18).  There were some visible differences that, while not statistically significant, might still be 
important.  These differences were not significant since only five mice were used for each group.  
Lung scores are nonparametric data so a two-way ANOVA was not appropriate to evaluate 
differences between the virus strains.  Including more mice for each group might have made 
differences between infected groups easier to visualize using nonparametric analyses.   
Only mice infected with the H3N2 virus had any visible hemorrhage prior to day 2.  At 36 
h post-infection, one of the five mice that was sacrificed had a lung score of 0.5 that is likely not 
important since the other four mice did not show any signs of hemorrhage.  Also, the five mice 
that were infected with the H3N2 virus that were sacrificed at day two did not have any visible 
signs of infection.     
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Figure 17 Mean Lung Scores in Influenza-Infected Mice.  Five mice infected with each strain 
of influenza were sacrificed at each time point.  Lungs were scored for degree of hemorrhage by 
gross examination on a scale of 0 to 4.  The mean lung score was plotted versus the day post-
infection for each virus.  None of the differences were statistically significant.      
 
On day 3, lung scores of the mice infected with the H3N2 and H5N1 viruses were higher 
than the lung scores seen with both of the H1N1-infected groups.   The lung scores of the p-
H1N1-infected mice were higher than those seen in the H1N1-infected group.  To this point, this 
is the most compelling evidence of the differences between the four virus strains.  
At day 4, lung scores of the H5N1 and p-H1N1-infected were higher than the lung scores 
of the groups of mice infected with the H1N1 or the H3N2 viruses.   
On day 5, lung scores of the H3N2-infected mice were increased compared to mice 
infected with either of the H1N1 viruses.  Lung scores of the H3N2-infected mice were even 
slightly higher than those seen in the H5N1-infected groups, but the difference was not as 
dramatic.  
On day 6, lung scores of H5N1-infected mice were higher than the mean lung scores any 
of the other three infected groups.  Lung scores of the p-H1N1-infected mice were slightly lower 
than the lung scores of the H5N1-infected mice.  Mean lung scores of the H1N1-infected mice 
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were lower than those seen in the p-H1N1-infected mice and the lowest mean lung scores 
were seen in the mice infected with the H3N2 virus.  This is interesting because the highest lung 
scores on day 5 were seen in the H3N2-infected mice, while the lowest scores on day 6 were 
seen in the same group.  While these results are not definitive due to a small sample size, the 
differences in mean lung scores seem to change incrementally with the mice infected with each 
influenza virus strain.  Lung scores of the mice infected with the H3N2 virus seem to remain 
constant for two sequential days and then a dramatic increase in the lung score happens 
following the second day.  These differences in gross lung scores seem to support the variations 
in oseltamivir susceptibility.  The lung scores from the H5N1 and H3N2-infected mice are visible 
one day earlier than from the H1N1-infected mice and are more severe than the lung scores of p-
H1N1-infected mice. 
 
Mean Lung Weights 
 Lungs were weighed and the weights were plotted versus the time post-infection (Figure 
18).  Two-way ANOVA was used to analyze differences between lung weights of mice infected 
with each of the virus strains (Table A.19).  Since lung weights are a sign of increased 
consolidation of the lungs and infiltration by inflammatory cells, increased lung weight is a good 
indicator of disease progression, although it has limitations.  Differences in lung weight show up 
later in the infection than other indicators such as lung virus titer and lung score.  Increases in 
virus titer and score both precede the increase in lung weights and changes in lung virus titer and 
lung score are visible earlier in the infection.  Lung weights do have one advantage over lung 
scores in mice.  Since lung scores are nonparametric, the same statistical analyses cannot be 
used for lung scores and weight.  A two-way ANOVA can be used for lung weights since they are 
a measured sign of disease rather than a subjective indicator, such as lung scores.  The two-way 
ANOVA requires a fewer number of mice to determine a significant difference between infected 
groups when compared to parametric measurements.  Nonparametric data requires larger 
differences if there are only a small number of replicates. 
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Figure 18 Mean Lung Weights in Influenza-Infected Mice.  Groups of five mice were sacrificed 
for each time point for each virus strain.  Mean lung weights for each group of mice were plotted 
versus time post-infection.  A. Lung weights of the p-H1N1-infected mice were higher than the 
H1N1-infected mice at 24 h post-infection (P<0.05).  B. Lung weights of the H3N2-infected mice 
were heavier than the lung weights of the p-H1N1-infected mice at day 2 (P<0.05) as well as day 
5 and 6 (P<0.001).  C. Lung weights of the H5N1-infected mice were higher than the lung weights 
of p-H1N1-infected mice at day 3 (P<0.05) and days 4, 5 and 6 (P<0.001).  D. Lung weights of 
the H3N2-infected mice were higher than the lung weights of the H1N1-infected mice at day 2 
(P<0.01) and days 5 and 6 (P<0.001).  E. Lung weights of the H5N1-infected mice were 
significantly heavier than lung weights of H1N1-infected mice at days 4, 5 and 6 (P<0.001).  F. 
Lung weights of H5N1-infected mice were higher than the lung weights of H3N2-infected mice at 
day 4 (P<0.001).   
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Comparison of the lung weights from mice infected with the H1N1 and p-H1N1 viruses 
revealed only two differences and they were earlier than any other differences that were 
observed. (Figure 18.A).  Lung weights from mice infected with p-H1N1 were significantly heavier 
than the lung weights from p-H1N1-infected mice at day one post-infection.  These differences 
were not as statistically significant (P<0.05).  A difference in lung weight at day one is likely due 
to variation between mouse body weight and not actual differences in lung weight.  The average 
body weight from the p-H1N1-infected mice was slightly higher than the average body weight 
from the H1N1-infected mice.   
When lung weights from mice infected with the p-H1N1 and H3N2 viruses were 
compared, some significant differences were seen later in the infection (Figure 18.B).  Lung 
weights from H3N2-infected mice were higher than those from the p-H1N1-infected mice at day 2, 
5 and 6.  These differences show increased hemorrhage and consolidation of the lungs in the 
mice infected with the H3N2 virus.  This supports the idea that the H3N2 virus is able to cause 
more destruction in the lungs than the p-H1N1 virus.  While the differences in lung weights are 
not observed until later in the infection, the differences in lung weights are suggestive of the 
increased pathogenicity of the H3N2 virus compared to the p-H1N1 virus.  This also correlates 
with the increased lung virus titers seen early after infection with the H3N2-infected mice.  The 
increased lung scores for H3N2-infected mice on day 3 are also indicative of the ability of the 
H3N2 virus to cause disease more quickly than the p-H1N1 virus. 
Comparison of the lung weights from H5N1 and p-H1N1-infected mice revealed dramatic 
differences between infected groups (Figure 18.C).  The lung weights of mice infected with the 
H5N1 virus were heavier than the lungs of the mice infected with the p-H1N1 virus at day 3 and 
days 4 through 6.  Since the H5N1-infected mice died nearly two days earlier these higher lung 
weights would likely correlate to lung weights seen at days 7 or 8 with the p-H1N1 infected mice.  
This is indicative of a trend of more severe disease earlier in the mice infected with the H5N1 
virus.  The increased destruction of lung tissue earlier post-infection would lead to an earlier 
mean day of death and would make treatment with oseltamivir more difficult.  The mice die 
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quickly when infected with the H5N1 virus and oseltamivir has less time to provide a beneficial 
impact on the survival curves of the mice. 
Comparison of the lung weights from mice infected with H3N2 and H1N1 influenza 
viruses showed a similar trend that was seen when the lung weights from the H3N2-infected mice 
were compared to those from p-H1N1-infected group (Figure 18.D).  Lungs from H3N2-infected 
mice were heavier at day 2, in addition to days 5 and 6.  Influenza H3N2-infected mice did have 
an earlier mean day of death compared to p-H1N1-infected mice and this may be an indicator of 
a more severe infection.  The lung weights seem to support the idea of more severe infection in 
mice with the H3N2 and H5N1-infected mice when compared to either of the H1N1 strains.   
 When the lung weights from mice infected with the H1N1 and H5N1 viruses were 
compared, heavier lung weights were observed in the H5N1-infected mice (Figure 18.E).  Lung 
weights from H5N1-infected mice were higher than the lung weights of H1N1-infected mice at day 
3, 4, 5, and 6.  Based solely upon changes in lung weights, it is possible to see the increased 
lung damage that occurs with the H5N1-infected mice.  Lung weight seems to be a solid indicator 
of the severity of disease in mice infected with each of the influenza virus strains. 
 The lung weights from the mice infected the H5N1 and H3N2 viruses showed only one 
significant difference at day 4 (Figure 18.F).  The lungs from H5N1-infected mice were 
significantly heavier at day 4 compared to the lungs from H3N2-infected mice.  The lung weights 
are very similar up to day three but the H3N2-infected mice do not show a large change in lung 
weights between day three and four while the H5N1-infected mice had a dramatic increase in 
lung weights at day 4.  Again, this is likely an indicator of the earlier mean day of death seen with 
the H5N1 virus. 
 
Histological Lesion Score 
 Lung samples preserved in 10% Neutral Buffered Formalin sent to the Utah Veterinary 
Diagnostic Lab for histopathological examination.  A report of the findings explained the amount 
of histopathology seen with each sample.  While extremely detailed, it was apparent that 
comparison between virus strains would be difficult and significant differences would be difficult to 
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determine.  Being an initial study to identify useful parameters, a rough conversion table was 
made to approximate the histopathology and create a numerical value that could be graphed and 
compared statistically (Table 2).  The conversion table was not ideal since it weighted all findings 
as equal in severity.  For example, severe necrosis of epithelial cells is weighted the same as 
severe luminal cellular debris when in reality, necrosis is more severe finding than cellular debris.  
While this was not ideal for utilization in this experiment, it did help to improve the parameters for 
the second experiment that examined the effects of oseltamivir on these same factors.  Scoring 
based upon these criteria, led to a scoring scale from 0 to 20 for any histopathology sample.  The 
samples that were sent for analysis were 24 h, 36 h, 48 h and 72 h.  The lung score was plotted 
against the day post-infection, which could then be compared statistically (Figure 19). None of the 
differences were statistically significant based upon a Kruskal-Wallis test with a Dunn’s multiple 
comparison post-test (Table A.20).  At 24 h post-infection, histological lesion scores from H3N2-
infected mice were higher compared to the lesion scores in the mice infected with any of the other 
viruses.  At 36 h post-infection, the lesion scores in H3N2-infected mice were the most elevated.  
Lesion scores in H5N1-infected mice were a close second, followed by the histological lesion 
scores in mice infected with the p-H1N1 virus.  The lowest histological lesion scores were seen in 
mice infected with the H1N1 at 36 h post-infection.  While not statistically significant, it is 
interesting to note that the lesion scores in the groups infected with both the H3N2 and H5N1 
viruses increase dramatically in the first 36 h post-infection.  By 48 h post-infection, the lesion 
scores are similar among all infected groups.  While the histological lesion score was not ideal 
due to equal weighting of all findings, it does appear that the H3N2 and H5N1 viruses are capable  
 
Table 2 Factors Utilized for Approximating Histopathology Score.  The table was created to 
convert the histopathology report to a numerical value so the amount of histopathology could be 
compared between viruses.  The finding was correlated to a numerical score according to 
severity. 
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Figure 19 Histological Lesion Scores in Influenza-Infected Mice.  Five mice infected with 
each strain of influenza were sacrificed and sent to the Utah Veterinary Diagnostic Laboratory for 
analysis.  The histopathology report was converted to a numerical score to aid in visualization 
and analysis.  The histological lesion score was plotted versus the h post-infection.  None of the 
differences were statistically significant.     
 
of more destruction of lung tissue than the H1N1 viruses.  The exact cause for increased 
destruction is not clear, but higher viral titers shown by these two viruses are at least partially 
responsible.  Increased lethality associated with the pandemic 1918 influenza virus has shown 
that it is not usually one particular factor that makes the virus particularly lethal, but rather the 
additive effect of many small differences (3, 26, 38).  After seeing results from this study, we were 
able to refine the parameters for the following experiment.  Histopathology became central to the 
second experiment.  Unfortunately, the statistics from the primary experiment were not run until 
very late in the research process.  Because of that fact, the numbers of mice utilized for the 
histopathology in the second experiment were not increased to a number that would have aided 
in determining statistical significance. 
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Conclusions 
 
 The survival curve of the H5N1-infected mice was significantly different from the survival 
curves of the other infected groups.  The mice infected with the H5N1 virus also died significantly 
earlier than the other groups of infected mice.  There were a few anomalies with this part of the 
study since there were three mice that survived the H3N2 infection and two mice that survived the 
H1N1 infection.  Dilutions of the virus stocks need to be adjusted to cause 100% mortality in mice 
infected with each virus strain and then it will be possible to verify whether differences seen in the 
H5N1-infected mice remain. 
 There were no significant differences in the mean body weight changes between infected 
groups.  Despite the differences seen from the survival curves, the percentage of weight loss 
seen with each infected group was approximately equal.  In the first few days of the infection, the 
H3N2 and H5N1-infected mice appear to lose weight more quickly than the mice infected with 
either of the H1N1 viruses.  This should be confirmed with oseltamivir treatment to see if this 
trend continues. 
 Lung virus titers varied depending on the day post-infection.  The first 36 h post-infection 
showed that the lung virus titers were highest in H3N2-infected mice followed by the H5N1-
infected mice.  The lung virus titers from H1N1-infected mice were higher than the lung virus titers 
from the p-H1N1-infected mice for the first 36 h as well.  Starting at day 3 post-infection, the lung 
titers from the p-H1N1-infected mice are the highest followed by the lung titers from H3N2-
infected mice.  The lung titers from the H1N1-infected mice were only slightly higher than the lung 
titers from H5N1-infected mice for the last four days that were measured.  The lung virus titers 
may partially explain the different susceptibilities to oseltamivir.  The first few days seem to be the 
most important in determining a lethal outcome.  The H3N2 virus seems to have a unique ability 
to replicate more quickly in the lungs of mice compared to the other viruses.  The lung virus titers 
from the H5N1-infected mice are higher for the first 24 h compared to the lung virus titers from 
mice infected with the p-H1N1 and H1N1 viruses. 
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 Lung scores did not show any significant differences due to the overall small 
differences between infected groups.  With only five mice used for lung scores from each infected 
group, differences in lung scores need to be fairly large in order for the differences to be 
statistically significant.  Lung scores from the H3N2 and H5N1-infected mice were higher at day 
3, followed by the lung scores from mice infected with the p-H1N1 virus.  Lung scores from H1N1-
infected mice were not measurable until day 4 post-infection.  This may indicate a slightly more 
rapid and severe infection in the mice infected with the H3N2 and H5N1 viruses but these results 
need to be re-examined following the adjustment of virus dilutions to achieve 100% mortality in 
mice. 
 Differences in lung weights gave the best indication as to the differences in oseltamivir 
susceptibility.  The lung weights from mice infected with the H3N2 and H5N1 viruses increase 
more dramatically than the lung weights from mice infected with the p-H1N1 and H1N1 viruses.  
These differences in lung weights do not show up until the latter part of the infection but does 
indicate that there is a significant difference between the two H1N1 viruses and the H3N2 and 
H5N1 viruses.  The lung weights are a measure of the amount of inflammation and consolidation 
associated with infection and the more rapid increases likely show that the influenza infection is 
progressing more rapidly with the H3N2 and H5N1 viruses.   
 The histological lesion scores roughly reflect the differences shown by the gross lung 
scores.  Differences are seen early and the histological lesion scores are higher at 24 h post-
infection with the H3N2 and H5N1-infected mice.  At 36 h post-infection the histological lesions 
scores are highest in the H3N2-infected mice but are closely followed by the H5N1-infected mice.  
The histological lesions scores are higher in the p-H1N1-infected mice than in the H1N1-infected 
mice at 36 h post-infection as well.  After these early time points, the histological lesion scores 
are very similar at 48 and 72 h post-infection.  These early differences in histological lesion score 
correlate well with the differences seen in lung weights and also help explain the differences in 
susceptibility to oseltamivir treatment shown by mice infected with each strain of influenza. 
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CHAPTER VI 
 
INFLUENZA INFECTION AND COMPLETE BLOOD COUNTS OF MICE 
 
Effect of Influenza Virus Infection on Complete Blood Counts 
 
 Infection from influenza viruses produces a severe inflammatory reaction in the lungs and 
thus has an impact on body functions systemically.  Without any published data on the effects of 
influenza infection on complete blood counts and blood chemistry, we utilized each test to 
discover if the assay would help in determining severity of disease for influenza infections and for 
comparing host reactions to different strains.   
 
Total White Blood Cell Count 
Only day 1 showed any significant differences in the WBC count of influenza-infected 
mice (Figure 20).  Differences between the WBC counts in mice infected with each strain were 
analyzed by two-way ANOVA (Table A.21).  At day 1, the WBC count from H1N1-infected mice 
was significantly lower compared to the WBC count from mice infected with the H3N2 virus and 
the H5N1 virus.  No significant differences were seen between the WBC counts of mice infected 
with any of the viruses from day 2 through 6. 
Though we did not see many significant differences between mice infected with different 
virus strains, all infected mice were compared to uninfected mice to determine if influenza 
infection significantly alters the WBC counts (Table 3).  Statistical significance was determined by 
analyzing the data using a two-way ANOVA (Table A.22).  The WBC counts from p-H1N1-
infected mice were lower than the WBC counts from uninfected mice at day 4.  The WBC counts 
from H1N1-infected mice were lower than the WBC counts of uninfected mice at day 1, day 3 
through 5, and day 6.  The WBC counts from H3N2-infected mice were lower than the WBC 
counts from uninfected mice at day 4 and 6.  When compared to uninfected mice, the WBC 
counts from H5N1-infected were significantly lower on day 4. Overall, the only WBC counts  
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Figure 20 White Blood Cell Counts in Influenza-Infected Mice.  On day 1, the WBC count of 
H1N1-infected mice was significantly lower than the WBC count compared to mice infected with 
H3N2 virus (P<0.05) and H5N1 virus (P<0.01).  No other significant differences were observed.  
Unless noted otherwise, differences are significant compared to all other infected groups. 
   
that were significantly altered by infection were seen in the mice infected with the H1N1 virus.  
The WBC count seemed to drop for all infected mice throughout the infection, but not always to a 
significant level.  Even a severe respiratory infection such as the one seen with the influenza virus  
 
Table 3 White Blood Cells Counts in Infected vs. Uninfected Mice.  Means, standard 
deviations and statistical significance compared to uninfected mice are shown.  WBC counts were 
lower in p-H1N1-infected mice than in uninfected mice on day 4 (P<0.01).  WBC counts were 
lower in H1N1-infected mice than in control mice at day 1 (P<0.05), day 3, 4, and 5 (P<0.01) and 
day 6 (P<0.05).  WBC counts were lower in H3N2-infected mice than in uninfected mice on day 4 
and 6 (P<0.01).  WBC counts were significantly lower in H5N1-infected mice than in uninfected 
mice at day 4 (P<0.05).  Legend: ns = not significant, * = P<0.05, ** = P<0.01.   
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does not deplete the overall WBC count significantly, at least in the first 6 days of infection.  
Monitoring WBC counts in mice might be interesting but may be difficult in a short-term infection 
like influenza. 
 
Lymphocytes as a Percentage of Total White Blood Cells  
  Lymphocytes as a percentage of WBC count were measured for each infected group for 
6 days (Figure 21).  Comparisons between lymphocytes percentages of mice infected with each 
strain were again done by two-way ANOVA (Table A.23).  Once again, there were not significant  
 
 
Figure 21 Lymphocyte Counts in Influenza-Infected Mice.  Lymphocyte percentages were 
lower in H3N2-infected mice compared to mice infected with any of the other strains (P<0.001).  
No significant differences were seen at day 2.  On day 3, the lymphocyte percentages from p-
H1N1-infected mice were lower than the lymphocyte percentages from H3N2-infected mice 
(P<0.01).  On day 4, the lymphocyte percentages from mice infected with the p-H1N1 and the 
H5N1 viruses were lower than the lymphocyte percentages from H3N2-infected mice (P<0.05 
and P<0.01 respectively).  On day 5, lymphocyte counts from H5N1-infected mice were lower 
than the lymphocyte counts from the p-H1N1 and H3N2-infected mice (P<0.001) as well as 
H1N1-infected mice (P<0.05).  Lymphocyte counts from H1N1-infected mice were also lower than 
the lymphocyte percentages from H3N2-infected mice on day 5 (P<0.001).  On day 6, lymphocyte 
percentages from H5N1-infected mice were lower than the lymphocyte percentages from mice 
infected with p-H1N1 (P<0.01) and H3N2 (P<0.001) viruses.  Unless noted otherwise, differences 
are significant compared to all other infected groups.   
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differences for the entire 6 days but the lymphocyte counts of infected mice were different at 
certain days.  The lymphocyte counts from H3N2-infected mice were significantly lower than the 
lymphocyte percentages from mice infected with any of the other viruses on day 1.  None of the 
differences were significant at day 2.  The lymphocyte percentages from p-H1N1-infected mice 
were significantly lower than the lymphocyte percentages from H3N2-infected mice at day 3.  On 
day 4, lymphocyte percentages were lower in p-H1N1-infected mice than in H5N1-infected mice 
and H3N2-infected mice. On day 5, the lymphocyte percentages from H1N1-infected mice were 
lower than the lymphocyte percentages from H3N2-infected mice.  Also at day 5, the lymphocyte 
percentages from H5N1-infected mice were significantly lower than the lymphocyte percentages 
from mice infected with any of the other three viruses.  On day 6, the lymphocyte counts from 
H5N1-infected mice were the lower than the lymphocyte percentages from mice infected with the 
p-H1N1 and the H3N2 virus.  While there are quite a few differences between infected groups at 
various times, there weren’t any visible trends that might explain the decreased oseltamivir 
susceptibility.  Mice infected with the H5N1 virus had lower lymphocyte percentages on days 4, 5 
and 6 compared to all other groups.  This may be significant when considering that these mice 
are in the terminal stages of the infection and many of the lymphocytes have probably migrated to 
the site of infection.  This lower percentage of lymphocytes may be an indicator of increased 
disease severity with the H5N1 infected mice.   
All the viruses were compared to uninfected mice to evaluate the use of lymphocyte 
percentage as a measure for disease progression (Table 4).  Two-way ANOVA was used to 
determine statistical significance (Table A.24).  As would be expected with a severe infection, 
lymphocyte counts were significantly lower for all infected mice at all time points with the 
exception of day 1 for the groups infected with the p-H1N1 and the H1N1 viruses.  Lower 
lymphocyte percentages are expected as the lymphocytes undergo extravasation to enter the 
infection site.  Lymphocyte percentages could be beneficial for determining disease severity with 
an infection such as influenza.  The fact that lymphocyte counts do not significantly change for 
the mice infected with either of the H1N1 viruses compared to uninfected mice might indicate a 
more severe response to infection in mice infected with the H3N2 and H5N1 viruses. 
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Table 4 Lymphocyte Counts in Infected vs. Uninfected Mice.  Means, standard deviations 
and statistical significance compared to uninfected mice are shown.  Lymphocyte counts were 
lower in p-H1N1-infected mice than uninfected mice from day 2 through 6 (P<0.001).  
Lymphocyte counts were lower in H1N1-infected mice than uninfected mice on day 2 through 6 
(P<0.001).  All six days of lymphocyte counts were significantly lower in H3N2-infected mice 
compared to uninfected mice (P<0.001).  Lymphocyte counts were lower in H5N1-infected mice 
than control mice for all 6 days (P<0.001).  Legend: ns = not significant, *** = P<0.001. 
 
 
 
Monocytes as a Percentage of Total White Blood Cells 
Monocyte percentages of total WBC counts varied slightly between infected groups 
(Figure 22).  Significant differences were calculated by two-way ANOVA (Table A.25).  At day 1, 
monocyte percentages from mice infected with the p-H1N1 virus were significantly higher than 
the monocyte percentages from all three other infected groups.  No significant differences were 
seen day days 2 or 3.  At day 4, the monocyte percentage from the p-H1N1-infected group was 
lower than the percentages seen in both H1N1 and H3N2-infected groups.  At day 5, the 
monocyte percentages from mice infected with the H1N1 virus were significantly higher than the 
monocyte percentages from all other infected mice.  Also on day 5, the monocyte percentages 
from H5N1-infected mice were lower than the monocyte percentages from H3N2-infected mice.  
At day 6, the monocyte percentages from the H5N1 group were again lower than the monocyte 
percentages from the H3N2 group.  As seen previously, the differences between infected groups 
were isolated to time points but were not significant when all six days were taken into account.  
There does not seem to be a strong relationship with the progression of the disease and the 
monocyte percentage.  As seen in the figure, monocytes make up a small percentage of the total 
WBC count so fluctuations are not easily seen with this relatively small overall number of cells. 
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Figure 22 Monocyte Counts in Influenza-Infected Mice.  On day 1, monocyte percentages 
were higher from p-H1N1-infected mice than any of the other infected mice (P<0.05).  No 
differences were seen between infected groups on day 2 or 3.  On day 4, monocyte percentages 
were lower in the p-H1N1-infected mice than in the H1N1 and H3N2-infected mice (P<0.05).  On 
day 5, monocyte percentages were higher in the H1N1-infected mice than any other infected 
group (P<0.001).  Also on day 5, the monocyte percentage was lower in H5N1-infected mice than 
H3N2-infected mice (P<0.05).  On day 6, the monocyte percentage was lower in H5N1-infected 
mice than H3N2-infected mice (P<0.05).  Unless noted otherwise, differences are significant 
compared to all other infected groups.   
   
Monocyte percentage of the total WBC count was compared for each infected group 
against uninfected mice (Table 5).  Comparison was done by two-way ANOVA (Table A.26).  
Monocyte percentages from p-H1N1-infected mice were significantly higher than the monocyte 
percentages from uninfected mice at day 1, but significantly lower on day 2 through 5.  No 
difference in monocyte counts was seen at day six when compared to healthy mice.  Mice 
infected with the H1N1 and H3N2 viruses did not have significantly different monocyte 
percentages at any time compared to uninfected mice.  Monocyte percentages from the influenza 
H5N1-infected mice were significantly lower than the monocyte percentages of uninfected mice at 
days 4, 5 and 6.  Lack of a relationship between the severity of the infection and the monocyte 
counts for all infected mice, likely makes the measurement irrelevant as an indicator of disease.  
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Statistical differences were seen at singular time points and even when compared to 
uninfected mice, a consistent trend was not seen with any of the viruses.  This is especially 
noticeable with the mice infected with the H3N2 and the H1N1 influenza viruses.  Neither of these 
groups demonstrated a noticeable change in monocyte percentages throughout the infection. 
 
Table 5 Monocyte Counts in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Monocyte percentages were 
higher in p-H1N1-infected mice than in uninfected mice at day 1 (P<0.01) but lower at day 2 and 
3 (P<0.01), day 4 (P<0.001), and 5 (P<0.05).  Monocyte percentages were significantly lower 
from H5N1-infected mice than from uninfected mice at day 4 (P<0.01), 5 (P<0.001) and day 6 
(P<0.01). Legend: ns = not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
 
 
Granulocytes as a Percentage of Total White Blood Cells 
 Granulocytes were calculated as a percentage of total WBCs and were fairly consistent 
between all infected groups (Figure 23).  Differences were analyzed using a two-way ANOVA 
(Table A.27).  On day 1, the granulocyte percentages from H3N2-infected mice were significantly 
higher than the granulocyte percentage from mice infected with the other three viruses.  No 
differences between groups were seen at day.  On day 3, granulocyte percentages from the p-
H1N1-infected mice were significantly higher than the granulocyte percentages from mice 
infected with the H1N1 and H3N2 viruses.  On day 4, granulocyte percentages from both the p-
H1N1-infected and H5N1-infected mice were significantly higher than the granulocyte 
percentages from H3N2-infected mice.  Granulocyte percentages were higher in H1N1-infected 
mice than H3N2-infected mice at day 5.  The H5N1-infected group had a higher percentage of 
granulocytes on day five when compared to both the H1N1-infected groups and the H3N2-
infected group.  On day 6, only the H5N1-infected mice showed significantly elevated granulocyte  
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Figure 23 Granulocyte Counts in Influenza-Infected Mice.  On day 1, granulocyte counts from 
H3N2-infected mice were significantly higher than those from mice infected with the other three 
strains (P<0.001).  On day 3, granulocyte counts from p-H1N1-infected mice were higher than the 
granulocyte percentages from mice infected with the H1N1 virus (P<0.05) and the H3N2 virus 
(P<0.01).  On day 4, granulocyte percentages from p-H1N1-infected mice and H5N1-infected 
mice were higher than the granulocyte percentages from the H3N2-infected group (P<0.01 and 
P<0.001 respectively).  On day 5, granulocytes counts from H1N1-infected mice were higher than 
granulocyte percentages from H3N2-infected mice (P<0.001).  Granulocyte percentages from 
H5N1-infected mice were also higher than the granulocyte percentages from both the H1N1 
groups (P<0.01) and the H3N2 group (P<0.001).  Day 6 showed granulocyte percentages from 
H5N1-infected mice were higher than granulocyte percentages from p-H1N1-infected mice 
(P<0.01), the H1N1-infected mice (P<0.05), and the H3N2-infected mice (P<0.001).  Unless 
stated otherwise, differences are significant against all other infected mice.   
  
counts compared to the other infected mice though the level of significance varied by strain.  That 
does seem to indicate a more severe infection with the H5N1-infected mice than the mice 
infected with any of the other strains. 
When compared against uninfected mice, the granulocyte percentages of the infected 
groups were consistently higher regardless of virus (Table 6).  Comparison of granulocyte 
 percentages was calculated by two-way ANOVA (Table A.28).  Granulocyte percentages from 
mice infected with the p-H1N1 virus were higher than granulocyte percentages of uninfected mice 
on day 2 through 6.  The granulocyte percentages were higher in H1N1-infected mice than 
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uninfected mice on 2 through 6.  Granulocyte counts were higher in H3N2-infected mice than 
control mice at all 6 days.  The granulocyte counts from H5N1-infected mice showed a similar 
trend with higher percentages than uninfected mice on day 1 through 6.  This may be the first 
CBC indicator than helps to illuminate why H5N1 and H3N2-infected mice show decreased 
susceptibility to oseltamivir treatment.  A higher percentage of granulocytes in the blood is 
indicative of infection and it may be significant that H5N1 and H3N2-infected mice both show 
increased granulocyte counts a day earlier than the other two viruses.  Increased granulocyte 
percentages on day 1 signifies a more advanced infection compared to the mice infected with the 
p-H1N1 and H1N1 influenza viruses.   
 
Table 6 Granulocyte Percentages in Infected vs. Uninfected Mice.  Means, standard 
deviations and statistical significance compared to uninfected mice are shown.  Granulocyte 
counts were higher in p-H1N1-infected mice than uninfected mice from day 2 through 6 
(P<0.001).  The granulocyte counts were higher in H1N1-infected mice than uninfected mice from 
day 2 through 6 as well (P<0.001).  Granulocyte counts were higher in H3N2-infected mice than 
uninfected mice at all 6 days (P<0.001).  Granulocyte percentages were higher in H5N1-infected 
mice than control mice at all 6 days (P<0.001).  Legend – ns = not significant, *** = P<0.001.  
 
 
Red Blood Cell Counts 
 The total counts of RBCs remained fairly constant regardless of infection (Figure 24).  
Only one difference was seen between infected groups after comparison by two-way ANOVA 
(Table A.29).  The RBC count from H1N1-infected mice was significantly lower than the RBC 
count from H5N1-infected mice at day 1.  The standard deviation for that time point is higher than 
all of the other samples taken afterwards and may not truly represent the actual value.  Overall, 
there were not any other significant differences between any of the time points when comparing  
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Figure 24 Red Blood Cell Counts in Influenza-Infected Mice.  The only significant difference 
between the RBC counts of mice infected with each strain of influenza was at day one where the 
RBC count from H1N1-infected mice was lower than RBC count from H5N1-infected mice 
(P<0.01).  No other differences were statistically significant.     
 
the infected groups to each other.  The RBC count seemed to change approximately equally for 
all infected groups regardless of the virus strain used for infection.  
When the RBC counts from infected mice were compared to those that were uninfected, 
some differences were apparent (Table 7).  Two-way ANOVA was used to compare each infected 
group to uninfected mice (Table A. 30).  The RBC count from p-H1N1-infected mice was higher 
than the RBC count from uninfected mice at day 2, 4 and 6.  The RBC count from H1N1-infected  
mice was significantly lower than the RBC count from uninfected mice at day 1.  The RBC count 
was higher in H1N1-infected mice than uninfected mice at days 5 and 6.  The RBC count was 
higher in the H3N2-infected group than the uninfected mice at day 2, as well as days 5 and 6.  
The RBC count was higher in H5N1-infected mice than uninfected mice at day 2, again at day 4, 
as well as day 5 and 6.  Increased RBC counts within the first 6 days post-infection are most 
likely caused by dehydration rather than an actual increase in concentration.  As the infection 
becomes more severe, the mice become dehydrated and the decrease in overall fluid levels 
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would effectively concentrate the number of red blood cells into a lesser volume.  This is more 
likely than increased RBC production.  Increased production of RBCs is usually associated with 
long-term decreases in oxygenation of the blood and no significant differences were seen 
between mice infected with each virus strain. 
  
Table 7 Red Blood Cell Counts in Infected vs. Uninfected Mice.  Means, standard deviations, 
and statistical significance compared to uninfected mice are shown.  The RBC count was higher 
in p-H1N1-infected mice than uninfected mice at day 2 and 4 through 6.  The RBC count was 
lower in H1N1-infected mice than uninfected mice at day 1 (P<0.05) but higher at day 5 
(P<0.001) and 6 (P<0.05).  The RBC count was higher in H3N2-infected mice than uninfected 
mice at day 2 (P<0.01) and days 5 and 6 (P<0.001).  The RBC count was higher in H5N1-
infected mice than uninfected mice at days 2 (P<0.01), 4 (P<0.05), as well as 5 and 6 (P<0.001).  
Legend – ns = not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
 
 
Mean Corpuscular Volume 
 Overall, mean corpuscular volume changed very little.  Only two differences were seen 
when comparing virus strains (Figure 25).  Comparison was done by two-way ANOVA (Table 
A.29).  The mean corpuscular volume from influenza H1N1-infected mice was lower compared to 
the mean corpuscular volume from the other infected mice at day 1.  This is an isolated difference 
and not likely an indication of a difference between the virus strains.  The mean corpuscular 
volume was higher in H3N2-infected mice than in mice infected with the p-H1N1 and H1N1 virus.  
This is a small variation overall and does not likely reflect a large difference between the 
infections caused by any of these viruses.  Overall, the mean corpuscular volume stayed very 
consistent throughout the infection and did not seem to vary based upon the strain of virus or the 
day post-infection. 
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Figure 25 Mean Corpuscular Volumes in Influenza-Infected Mice.  At day one, the mean 
corpuscular volume of H1N1-infected mice was lower than the mean corpuscular volume of mice 
infected with any of the other strains (P<0.001).  At day two, the mean corpuscular volume of 
mice infected with the H3N2 virus was higher than the mean corpuscular volume than mice 
infected with the p-H1N1 or H1N1 virus (P<0.05).  No other significant differences were seen.   
 
When compared to uninfected mice the same two time points and infected groups stood 
out (Table 8).  They were both significant when compared by two-way ANOVA (Table A.30).  
These two points are questionable since a noticeably higher standard deviation is seen with both  
 
Table 8 Mean Corpuscular Volumes in Infected vs. Uninfected Mice.  Means, standard 
deviations, and statistical significance compared to uninfected mice are shown.  The mean 
corpuscular volume was lower in H1N1-infected mice than in uninfected mice at day 1 (P<0.001).  
Mean corpuscular volume was higher in H3N2-infected than uninfected mice at day 2 (P<0.001).  
Legend – ns = not significant, *** = P<0.001. 
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of these measurements.  Mean corpuscular volume was lower in the H1N1-infected mice than 
in uninfected mice at day 1.  Mean corpuscular volume was higher in H3N2-infected mice than 
uninfected mice day 2.  These are likely variations within the assay and would not be significantly 
different if the test were repeated multiple times.  Influenza infection does not seem to have an 
impact on mean corpuscular volume for the time points that were measured.  This would make 
sense since mean corpuscular volume is a measure of the average RBC size.   
 
Hematocrit 
 The hematocrit as a percentage of erythrocytes varied little between infected groups 
(Figure 26).  Comparison of the hematocrit counts from mice infected with the various influenza 
strains was done by two-way ANOVA (Table A.31).  The only difference between infected groups 
was seen at day 1 where the hematocrit from H1N1-infected mice was lower than the hematocrit 
  
 
Figure 26 Hematocrit Counts in Influenza-Infected Mice.  The only difference was significant 
was that the hematocrit count from H1N1-infected mice was lower than the hematocrit count from 
mice infected with the p-H1N1 (P<0.05), H3N2 (P<0.01), and H5N1 (P<0.001) viruses.  No other 
differences were significant.  
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of mice infected any of the other viruses.  This is the same value that has been different in the 
other assays and also has a fairly high standard deviation.  It is likely an inconsistent value and 
may not truly represent the hematocrit count from mice infected with the H1N1 virus on day 1.  
The hematocrit value observed with that group of mice at day 1 does not fit with any of the other 
values and no difference between the virus strains explains this difference in hematocrit counts.   
When the hematocrit from influenza-infected mice was compared to that from uninfected 
mice, differences were observed but a general trend was not visible (Table 9).  Two-way ANOVA 
was utilized to determine significance compared to uninfected mice (Table A.32).  The hematocrit 
count from p-H1N1-infected mice was higher than the hematocrit from uninfected mice at day 2, 
4, 5 and 6.  The hematocrit from H1N1-infected mice was significantly lower at day 1 than the 
hematocrit from control mice.  The hematocrit from H1N1-infected group was higher than the 
hematocrit from uninfected mice at day 5.  The hematocrit from H3N2-infected mice was higher 
than the hematocrit from control mice at days 2, 5 and 6.  The hematocrit from H5N1-infected  
mice was significantly higher than the hematocrit from uninfected controls at day 2, 4, 5 and 6.  
Hematocrit is usually tied to the RBC count so it should not be a surprise that increased  
 
Table 9 Hematocrit Counts in Infected vs. Uninfected Mice.  Means, standard deviations, and 
statistical significance compared to uninfected mice are shown.  Hematocrit counts were 
significantly higher in p-H1N1-infected mice than in uninfected mice at day 2 and 4 (P<0.05) as 
well as day 5 and 6 (P<0.001).  Hematocrit counts were lower in H1N1-infected mice than in 
uninfected mice at day 1 (P<0.001) but higher at day 5 (P<0.01).  Hematocrit counts were higher 
in H3N2-infected mice than in uninfected mice at day 2 (P<0.01) and days 5 and 6 (P<0.001).  
Hematocrit counts were higher in H5N1-infected mice than in control mice at day 2 (P<0.01), 4 
(P<0.05), 5 (P<0.001) and 6 (P<0.01).  Legend – ns = not significant, * = P<0.05, ** = P<0.01, ***  
= P<0.001. 
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hematocrit was seen with elevated RBC counts.  Despite seeing an elevated RBC count that is 
most likely tied to dehydration, the hematocrit counts were elevated at sporadic intervals and a 
clear trend was not visible.  The hematocrit does appear to vary along with the severity of 
disease, but is not correlated in a direct and consistent manner and would thus not be beneficial 
for use as an indicator of disease progression. 
 
Mean Corpuscular Hemoglobin 
 Mean corpuscular hemoglobin (MCH) remained consistent through the infection with 
influenza viruses (Figure 27).  Two-way ANOVA was used to determine differences between the 
MCH of groups infected with each strain of virus (Table A.33).  The only significant difference 
between infected mice was seen on day 1 where the MCH from H1N1-infected mice was higher 
than the MCH from mice infected with any of the other viruses.  This is set of mice stood out  
 
 
Figure 27 Mean Corpuscular Hemoglobin in Influenza-Infected Mice.  The only significant 
difference was shown at day 1 where the MCH from H1N1-infected mice was higher than the 
MCH from mice infected with any of the other three strains (P<0.05).  No other significant 
differences were seen. 
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previously and also has a higher standard deviation than any other group of infected mice.  
This does not likely represent a large difference between viruses. 
When compared to uninfected mice, the MCH from influenza-infected mice was not only 
significantly different at one time point (Table 10).  Two-way ANOVA was again used for 
comparison (Table A.34).  The same point, the MCH from H1N1-infected mice at day 1, was 
significantly higher than the MCH from uninfected mice.  Without any other significant differences 
in the MCH regardless of virus, it appears that infection with influenza does not have a significant 
effect on the mean corpuscular hemoglobin.  Though not entirely useful, it has been included 
since it is a part of a complete blood count and previous data could not be found regarding the 
impact of influenza infections on the MCH in mice. 
 
Table 10 Mean Corpuscular Hemoglobin in Infected vs. Uninfected Mice.  Means, standard 
deviations, and statistical significance compared to uninfected mice are shown.  The MCH was 
higher in H1N1-infected mice than uninfected mice at day 1 (P<0.001).  No other differences 
were significant.  Legend – ns = not significant, *** = P<0.001. 
 
 
 
Mean Corpuscular Hemoglobin Concentration 
 The mean corpuscular hemoglobin concentration (MCHC) is another measure of the 
amount of hemoglobin in the red blood cells and was similar to the results from the MCH (Figure 
28).  Similar differences were seen when analyzed by two-way ANOVA (Table A.35).  The MCHC 
is based upon the mean corpuscular hemoglobin and varies directly with the measurement of 
MCH.  The MCHC from H1N1-infected mice was higher than the MCHC from mice infected with 
any other strain at day 1.  This value has a high standard deviation and does not likely represent  
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Figure 28 Mean Corpuscular Hemoglobin Concentrations in Influenza-Infected Mice.  The 
only significant difference was seen on day one as H1N1-infected mice had a higher MCHC 
compared to mice infected with any other strain (P<0.01).  No other differences were significant. 
 
a difference in impact of influenza virus on the MCHC in mice.  Other than that solitary difference, 
the MCHC remains consistent regardless of virus strain and day post-infection.  This is not 
surprising since only one difference was observed with the MCH. 
When compared to controls, mice infected with influenza showed similar results to those 
seen with the MCH (Table 11).  Comparison was done by two-way ANOVA (Table A.36).  The 
only significant difference was seen with MCHC from H1N1-infected mice that had a MCHC that 
was significantly higher than the MCHC from uninfected mice at day 1.  Since it is tied to the MCH 
it also likely has little value for measuring disease progression in an influenza infection. 
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Table 11 Mean Corpuscular Hemoglobin Concentrations in Infected vs. Uninfected Mice.  
Means, standard deviations, and statistical significance compared to uninfected mice are shown.  
The MCHC was higher in H1N1-infected mice than in uninfected mice at day 1 (P<0.001).  No 
other differences were significant.  Legend – ns = not significant. * = P<0.001. 
 
 
Red Blood Cell Distribution Width 
 Red blood cell distribution width (RDW) is largely used as a measurement for certain 
types of anemia so it is not surprising that infection with influenza did not produce much change 
in the RDW (Figure 29). Analysis was done by two-way ANOVA (Table A.37).  The solitary 
  
 
Figure 29 Red Blood Cell Distribution Widths in Influenza-Infected Mice.  The only difference 
between mice infected with each strain was that the RDW from H1N1-infected mice was lower 
than the RDW from H5N1-infected mice (P<0.01).  No other differences were significant. 
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difference between viruses was the RDW from H1N1-infected mice was lower than the RDW 
from H5N1-infected mice at day 1.  This was the only difference between infected groups and 
indicates that influenza infection does not alter the RDW in mice. As stated previously, influenza 
infection has not been shown to impact RBCs in any way so changes in the distribution of the 
RBCs would be surprising. 
No differences were observed between any of the infected groups when compared to 
uninfected mice (Table 12).  Two-way ANOVA was used for statistical analysis (Table A.38).  No 
significant differences were seen between the RDW from any of the infected mice and the RDW 
from uninfected mice.  Since infection with influenza does not impact the RDW of mice, the RDW 
is likely not useful as an indicator of disease.   
 
 
Table 12 Red Blood Cell Distribution Widths in Infected vs. Uninfected Mice.  Means, 
standard deviations, and statistical significance compared to uninfected mice are shown.  No 
significant differences were seen when infected mice with any strain were compared to uninfected 
mice.  Legend – ns = not significant. 
 
 
Hemoglobin 
 Influenza infection only produced two significant changes in the hemoglobin 
concentrations of infected mice (Figure 30).  Comparison of the hemoglobin concentrations in 
mice was done by two-way ANOVA (Table A.37).  In both cases, day 4 and 6, the hemoglobin 
concentrations in the H3N2-infected mice were higher than the hemoglobin concentrations from 
the H1N1-infected mice.  This could be caused by a more severe infection with the H3N2 
influenza virus.  As the infection progresses, the mice become dehydrated which causes an  
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Figure 30 Hemoglobin Concentrations in Influenza-Infected Mice.  Two significant differences 
were seen between mice infected with different influenza strains.  Hemoglobin concentrations 
were higher in H3N2-infected mice than in H1N1-infected mice at day 4 and 6 (P<0.05).  No other 
differences were significant. 
 
artificial rise in hemoglobin concentration as the constant amount of hemoglobin is compacted 
into a smaller volume of fluid.  Since the infection seems to progress more rapidly with the  
H3N2-infected mice, the rise in hemoglobin concentrations happens sooner than in H1N1-
infected mice.  No other changes in the hemoglobin concentrations were observed throughout the 
infection.   
When compared to uninfected mice, a trend was seen with all four infected groups.  While the 
concentrations of hemoglobin remained consistent in uninfected mice, while the hemoglobin 
concentrations from infected mice steadily increased following infection (Table 13).  Two-way 
ANOVA was used for statistical analysis (Table A.38).  The hemoglobin concentrations from p-
H1N1-infected mice were similar to hemoglobin concentrations from uninfected mice at days 1 
and 2 but significantly higher concentrations were seen at day 3, 4, 5 and 6.  Hemoglobin 
concentrations of H1N1-infected mice seemed to lag behind the other viruses since the 
concentrations were not different than uninfected mice at days 1 through 4 but were significantly 
Hemoglobin
0
5
10
15
20
25
H1N1
H3N2
H5N1
p-H1N1
Uninfected
1 2 3 4 5 6
*
H1N1
*=P<0.05
Day Post-Virus Exposure
He
mo
glo
bin
 (g
/dL
) *
H1N1
 82 
elevated at days 5 and 6.  Hemoglobin concentrations from H3N2-infected mice were not 
significantly different from the concentrations in uninfected mice at day 1 or 2, but were 
significantly higher starting at day 3 through day 6.  The concentrations of hemoglobin from 
H5N1-infected mice were similar to the hemoglobin concentrations from uninfected mice at days 
1, 2, and 3 but then were significantly increased at days 4, 5, and 6.  This data makes sense 
when compared with the increased red blood cell counts seen with all four of the virus strains.  As 
explained before, this is likely an artificial increase in hemoglobin concentration caused by 
dehydration rather than an actual effect of influenza infection. 
 
Table 13 Hemoglobin Concentrations in Infected vs. Uninfected Mice.  Means, standard 
deviations, and statistical significance compared to uninfected mice are shown.  Hemoglobin 
concentrations were higher in p-H1N1-infected mice than in uninfected mice at day 3 and 4 
(P<0.05) and day 5 and 6 (P<0.001).  Hemoglobin concentrations were higher in H1N1-infected 
mice than in uninfected mice at days 5 and 6 (P<0.001).  Hemoglobin concentrations were higher 
in H3N2-infected mice than in uninfected mice at day 3 (P<0.01), and day 4 through 6 (P<0.001).  
Hemoglobin concentrations were higher in H5N1-infected mice than uninfected mice at day 4 
(P<0.05), as well as day 5 and 6 (P<0.001).  Legend – ns = not significant, * = P<0.05, ** = 
P<0.01, *** = P<0.001. 
 
 
Platelet Counts 
 Platelet counts from mice infected with influenza virus showed two significant differences 
between infected groups (Figure 31).  Comparison of platelet counts between mice infected with 
each influenza virus strain was performed using a two-way ANOVA (Table A.39).  When 
comparing the mice infected with each virus strain, the only significant difference was observed 
on day five, where H1N1-infected mice and p-H1N1-infected mice had significantly higher platelet 
counts than mice infected with the H3N2 virus.  With such a high degree of variability within the 
readings, it is difficult to say that these differences are truly significant.  Determination of a true  
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Figure 31 Platelet Counts in Influenza-Infected Mice.  The only difference in platelet counts 
the mice occurred at day five where the platelet counts from H3N2-infected mice were lower than 
the platelet counts from mice infected with p-H1N1 (P<0.05) and H1N1 (P<0.001) viruses.  No 
other significant differences were seen. 
 
platelet count is largely impacted by the ability to test the sample before any coagulation occurs.  
Despite our best efforts, we had difficulty in consistently running the complete blood count without 
some coagulation occurring in a few of the samples.  Any coagulation decreases the number of 
platelets that can accurately be counted and thus impacts the precision of the assay.   
When compared to uninfected mice, differences in the platelet counts were observed but 
without a trend following infection (Table 14).  Two-way ANOVA was used for statistical analysis 
of platelet counts of influenza-infected mice (Table A.40).  Differences were observed but nothing 
that could be used to indicate the severity of infection. Mice infected with the p-H1N1 virus 
showed the greatest amount of difference when compared to healthy mice since the platelet 
counts were higher at day 2 as well as day 5 and 6.  Platelet counts from H1N1-infected mice 
were higher than the platelet counts from uninfected mice at day 5.  Platelet counts from H3N2-
infected mice were higher than the platelet counts from uninfected mice at day 2.  Platelet counts 
from H5N1-infected mice were higher than platelet counts from control mice at day 2.  As stated 
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previously, since there is such a high degree of variability with each of the measurements, it is 
hard to believe the relatively small differences observed between groups of infected mice.  
Platelet counts might also be slightly impacted by dehydration as the mice show more signs of 
severe infection.  Also, as seen with some of the previous parameters, a clear trend was not 
visible following influenza infection.  Without a clear impact on the measurement, the usefulness 
of a platelet count for influenza infection is questionable.  Platelet count would be affected in a 
disease that impacts the circulatory system so the results are not surprising. 
 
Table 14 Platelet Counts in Infected vs. Uninfected Mice.  Means, standard deviations, and 
statistical significant compared to uninfected mice are shown.  Platelet counts were higher in the 
p-H1N1-infected mice than in uninfected mice at day 2 (P<0.001) and days 5 and 6 (P<0.05).  
Platelet counts were higher in H1N1-infected mice than in uninfected mice at day 5 (P<0.001).  
Platelet counts were higher in H3N2-infected mice than in uninfected mice at day 2 (P<0.05). 
Platelet counts from H5N1-infected mice were higher than from uninfected mice at day 2 
(P<0.01).  Legend – ns = not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
 
 
Mean Platelet Volume 
 The mean platelet volume (MPV) from mice infected with the four strains of influenza did 
not change dramatically depending on the virus (Figure 32).  Five differences in the MPV were 
seen after comparison by two-way ANOVA (Table A.41).  The differences between mice infected 
with each strain of the viruses occurred at days 4, 5, and 6.  At day 4, the MPV from H1N1-
infected mice and the MPV from H3N2-infected mice were both significantly higher than the MPV 
from mice infected with the p-H1N1 virus as well as the H5N1 virus.  On day 5, the MPV from 
H1N1-infected mice was higher than the MPV from p-H1N1-infected mice.  The MPV from H3N2-
infected mice was higher than the MPV from the p-H1N1-infected group and the H5N1-infected 
group.  On day 6, the MPV from H1N1-infected mice was higher than the MPV from the p- 
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Figure 32 Mean Platelet Volumes in Influenza-Infected Mice.  The MPVs from H1N1-infected 
mice and H3N2-infected mice virus were higher than the mean platelet volumes from p-H1N1-
infected mice (P<0.001) and H5N1-infected mice (P<0.05) on day 4.  On day 5, the MPV from 
H1N1-infected mice was higher than the MPV from p-H1N1-infected mice (P<0.05).  The MPV 
was higher in H3N2-infected mice than in p-H1N1-infected (P<0.001) and H5N1-infected mice 
(P<0.05) on day 5 as well.  On day 6, the MPV was higher in H1N1-infected mice than in p-H1N1 
infected mice (P<0.05).  No other differences were significant. 
 
H1N1-infected mice.  These differences appear to be randomly spread throughout the infection; 
therefore, influenza infection does not seem to impact the MPV of infected mice regardless of the 
virus used for infection. 
  Compared to uninfected controls, the mean platelet volume from infected mice was 
significantly different at six different points (Table 15).  Two-way ANOVA was used for statistical 
analysis (Table A.42).  The MPV from p-H1N1-infected mice was lower than the MPV from 
uninfected mice at days 2 and 3 but not at any other day.  The MPV from H1N1-infected mice 
was only significantly higher than the MPV from uninfected mice at day 6.  The MPV from H3N2- 
infected mice was significantly lower than the MPV from uninfected mice at day 2, but was 
significantly higher at days 5 and 6. The MPV from H5N1-infected mice was not significantly 
different from the MPV from uninfected mice at any time point.  Mean platelet volume showed a 
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slight degree of variability in the measurement but is not expected to be impacted by an 
influenza infection.  The small differences seen in the assay would likely not be seen if the study 
was repeated with a greater number of mice.  Without a clear impact from influenza infection, 
utilizing mean platelet volume to characterize the severity of influenza infection would be difficult.   
 
Table 15 Mean Platelet Volumes in Infected vs. Uninfected Mice.  Means, standard 
deviations, and statistical significance compared to uninfected mice are shown.  The MPV was 
higher in p-H1N1-infected mice than in uninfected mice at day 2 and 3 (P<0.05).  The MPV was 
higher in H1N1-infected mice than in uninfected mice at day 6 (P<0.01).  The MPV was lower in 
H3N2-infected mice than in uninfected mice at day 2 (P<0.05) but higher at day 5 and 6 (P<0.05).  
Legend – ns = not significant, * = P<0.05, ** = P<0.01. 
 
 
Platelet Hematocrit 
 The platelet hematocrit of influenza-infected mice showed one significant different 
following influenza infection (Figure 33). There was a lot of variation between groups of mice 
infected with each strain but not many of the differences were significant.  Comparison of platelet 
hematocrit counts was done by two-way ANOVA (Table A.43).  The only significant difference 
when comparing the infected groups to each other was evident on day five where the platelet 
hematocrit from the H1N1-infected mice was significantly higher than the platelet hematocrit from 
the H3N2-infected group.  Previous problems obtaining platelet counts have been discussed.  
There was a great deal of variation between days even within the same group so the platelet 
hematocrit data is somewhat suspect.  The one difference that seems to be consistent is a 
general elevation of the platelet hematocrit following infection with the influenza virus.  This is 
likely due to dehydration of mice rather than an actual increase in the platelet hematocrit.   
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Figure 33 Platelet Hematocrit in Influenza-Infected Mice.  Platelet hematocrit counts were the 
only significant different on day 5 where the platelet hematocrit from H1N1-infected mice was 
higher than the platelet hematocrit from H3N2-infected mice (P<0.001).  No other significant 
differences were visible.   
 
As stated before, influenza infection is not known to have any impact on the circulatory system 
other than possibly a decreased overall fluid volume due to the severity of the respiratory 
infection. 
When compared to uninfected mice, significant differences in the platelet hematocrit 
counts were observed (Table 16).  Comparison of platelet hematocrit counts was done by two-
way ANOVA (Table A.44).  All significant differences showed that infected mice had a higher 
platelet hematocrit, which is likely since dehydration would have increased the platelet hematocrit 
counts.  The platelet hematocrit from p-H1N1-infected mice was higher than the platelet 
hematocrit from uninfected mice at day 2 as well as days 5 and 6.  The platelet hematocrit from 
H1N1-infected mice was higher than the platelet hematocrit from uninfected mice at day 5. The 
platelet hematocrit from H3N2-infected mice was not significantly different compared to the 
platelet hematocrit from uninfected mice throughout the 6 measured days.  The platelet 
hematocrit from H5N1-infected mice was significantly higher than the platelet hematocrit from 
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control mice at days 2 and 5.  These differences do not seem to correlate in any manner with 
the day post-infection.  This likely means that influenza infection does not have a significant 
impact on the platelet hematocrit of mice and would not be useful for tracking disease severity.  
The only visible trend was that all differences were higher than uninfected mice.  Platelet 
hematocrit would be impacted by dehydration as were the measurements that have been 
previously discussed.  
 
Table 16 Platelet Hematocrit Counts in Infected vs. Uninfected Mice.  Means, standard 
deviations, and statistical significance compared to uninfected mice are shown.  Platelet 
hematocrit was higher in p-H1N1-infected mice than in uninfected mice at day 2 (P<0.01) and 
days 5 and 6 (P<0.05).  Platelet hematocrit was higher in H1N1-infected mice than in uninfected 
mice at day 5 (P<0.001).  Platelet hematocrit was higher in H5N1-infected mice than in uninfected 
mice at day 2 (P<0.01) and day 5 (P<0.05).  Legend - ns = not significant, * = P<0.05, ** = 
P<0.01, *** = P<0.001. 
 
  
Platelet Distribution Width 
 The final parameter obtained from the CBC measurements was the platelet distribution 
width (PDW).  Platelet distribution width is a measurement of the size of platelets and is used as 
an indicator for platelet release.  The impact of infection with the four strains of influenza did not 
produce noticeable changes when infected groups were compared to each other (Figure 34).  
Comparison by two-way ANOVA did not show any significant differences between infected 
groups (Table A.45).  This makes sense because the platelet distribution width is based upon the 
platelet count and the mean platelet volume, neither of which displayed a visible trend following 
influenza infection.  There were slight variations between time points, but there was not a 
noticeable effect following influenza infection.  Influenza viruses have not been indicated to have 
any impact on the circulatory system or blood clotting.   
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Figure 34 Platelet Distribution Widths in Influenza-Infected Mice.  No significant differences 
in platelet distribution widths were seen when comparing mice infected with any of the four 
influenza virus strains.   
 
When infected mice were compared to uninfected mice, there were not any significant 
differences at any day post-infection (Table 5-15).  As previously discussed, platelet distribution 
width does not seem to be affected by influenza infection.  Measuring platelet distribution width 
would not likely be beneficial for monitoring an influenza infection. 
 
Table 17 Platelet Distribution Width in Infected vs. Uninfected Mice.  Means, standard 
deviations and statistical significance compare to uninfected mice are shown.  No significant 
differences in the platelet distribution width were seen for any of the infected mice compared to 
uninfected mice.  Legend – ns = not significant. 
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Conclusions 
 
The white blood cell counts from infected mice were altered by infection but there were 
not differences between the different infected groups.  On day 2, the WBC counts of H3N2 and 
H5N1-infected mice were lower than the WBC counts from mice infected with the p-H1N1 and 
H1N1 viruses.  This difference was not statistically significant but might indicate that the infection 
is more severe with these viruses since the WBCs have started to leave the bloodstream and 
enter the infected tissue.   
The lymphocyte counts dropped in all infected groups after infection.  The decrease in 
lymphocyte percentages was more severe at day one with the H3N2-infected mice than it was 
with any of the other infected groups.  By day 2, the lymphocyte percentages were lower in 
infected mice than uninfected mice, but roughly equal for all four infected groups.  The difference 
at day 1 may show that the mice infected with the H3N2 virus were more affected by infection, but 
that was the only interesting change in lymphocyte percentages. 
The monocyte percentages in influenza-infected mice seemed to decrease slightly at day 
2, but overall did not show a large impact from infection.  Changes in the monocyte percentage 
were seen in all the infected groups and do not explain the differences between virus strains. 
The percentage of granulocytes in the blood in infected mice increased according to the 
day post-infection.  The earliest change was seen in the H3N2-infected mice as granulocyte 
percentages were increased compared to the percentages from the other infected groups.  At 
days 5 and 6, the granulocyte counts from the H5N1-infected mice remained high even though 
the counts had started to decline in the other infected mice.  Since high granulocyte percentages 
are indicative of an infection, the differences seen here may indicate that the infection is more 
severe in the early stages in the mice infected with the H3N2 and H5N1 viruses and is worse in 
the later stages with the H5N1-infected mice. 
The RBC counts from influenza-infected mice increased slightly following infection but 
this is likely an artificial increase due to dehydration rather than an actual increase in RBC 
production of infected mice.  Changes in RBC production are usually the result of chronic 
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infection and take weeks to become evident.  Since these changes occur in days rather than 
weeks, dehydration is likely the cause of the increases in RBCs in infected mice. 
Mean corpuscular volumes of mice were not significantly impacted by influenza infection.  
This is not surprising since changes in mean corpuscular volumes are often associated with 
certain forms of anemia. 
The hematocrit count of infected mice did change slightly after infection, but the 
increases in the hematocrit were not correlated with the severity of the infection.  As previously 
stated, changes in the amount of RBCs usually take more time to be impacted by disease than is 
possible with an influenza infection. 
Mean corpuscular hemoglobin measurements and MCH concentrations are directly tied 
to each other and were not impacted by infection with the influenza viruses.  Both of these 
measurements are linked to the amount of hemoglobin in the RBCs and it makes sense that they 
are not affected by infection. 
Red blood cell distribution width did not change significantly in mice infected with the 
influenza viruses.  Since this refers to the volume distribution of the RBCs and not the physical 
width of the cells, this fits well considering the fact that changes are most often seen in certain 
types of anemia. 
Changes in the amount of hemoglobin did not vary between the infected groups but the 
overall amount did increase in all infected mice as the infection became more severe.  This is 
likely due to the impact from dehydration that is effectively concentrating the amount of 
hemoglobin in the mice.  The amount of hemoglobin decreased in roughly the same manner in all 
the infected groups. 
Platelet counts varied widely with each infected group but did not appear to be correlated 
in any manner to the severity of the infection.  Influenza infection does not impact clotting or 
bleeding so an effect on platelet counts would be out of the ordinary. 
Mean platelet volumes were within normal levels and were not affected by the infection.  
There was some variability in the measurements but nothing that correlated to the day post-
infection. 
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Platelet hematocrit is directly tied to the platelet counts so the lack of impact from 
infection seems appropriate.  Even when compared to uninfected mice, the platelet hematocrits of 
infected mice were almost the same. 
The platelet distribution width did not change in influenza-infected mice.  An effect on the 
size of platelets would indicate a higher turnover of platelets in the blood.  Without any bleeding 
or hemorrhaging associated with infection, changes in platelet size would not fit with the other 
data. 
While there were some interesting differences seen from the CBC data, there weren’t any 
large differences that were unique to only one or two of the viruses.  Differences were isolated to 
one or two time points and did not seem to correlate with the findings from a prior study that 
showed that the H5N1 and H3N2 viruses were less susceptible to oseltamivir.  None of the CBC 
data seemed to explain the differences between the viruses.  While there are a few parameters 
that might be interesting to follow in future studies, such as the granulocyte or lymphocyte counts, 
the CBC was not deemed useful for comparing these four virus strains.  Any differences after 
infection with the CBC measurements was seen in all the infected groups and was not more 
severe in only one or two of the infected groups. 
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CHAPTER VII 
PRODUCTION OF CYTOKINES IN INFLUENZA-INFECTED MICE 
 
Comparison of Cytokine Levels in Influenza-Infected Mice 
 
Interleukin-1α  
 When levels of the cytokine IL-1α were compared to each other, there were a few 
noticeable differences (Figure 35).  Comparison of IL-1α levels following influenza infection in 
mice was done by two-way ANOVA (Table A.47).  On day 1, levels of IL-1α in the H3N2-infected 
mice were significantly higher than the levels of IL-1α from mice infected with any other viruses.   
 
 
Figure 35 IL-1α  Levels in Influenza-Infected Mice.  On day 1, levels of IL-1α from H3N2-
infected mice were higher than IL-1α levels of mice infected with any other strain (P<0.05).  At 
day 2, levels of IL-1α from the p-H1N1-infected mice were higher than IL-1α levels seen in all 
other infected groups (P<0.001).  Levels of IL-1α in H1N1-infected mice were higher levels than 
those seen in H5N1-infected mice at day 2 as well (P<0.01).  On day 3, levels of IL-1α from p-
H1N1-infected mice were higher than IL-1α levels from H3N2-infected mice (P<0.05).  On day 5, 
levels of IL-1α from the p-H1N1-infected mice were higher than the IL-1α levels from all other 
infected groups (P<0.01).   
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On day 2, the levels of IL-1α seen in the p-H1N1-infected mice were significantly higher than 
the IL-1α concentrations from all other infected groups.  On the same day, the levels of IL-1α 
from H1N1-infected mice were significantly higher than the levels of IL-1α levels from H5N1-
infected mice.  On day 3, IL-1α levels from p-H1N1-infected mice were increased significantly 
compared to the H3N2-infected group.  There were no significant differences between any of the 
infected groups on day 4.  On day 5, levels of IL-1α from p-H1N1-infected mice were significantly 
higher than IL-1α levels from all other infected groups.  On day 6, there were no significant 
differences between infected mice.  While there are a number of noticeable differences between 
viruses, they largely involve levels of IL-1α surrounding the p-H1N1 infection.  Influenza p-H1N1-
infected mice had large increases in IL-1α levels at day 2, 3 and 5.  None of these differences are 
indicative of a trend that would explain the failure to respond to oseltamivir treatment.   
When infected mice were compared to uninfected mice, there were some slight differences 
(Table 18).  Comparison was done by two-way ANOVA (Table A.48). IL-1α levels from p-H1N1-
infected mice varied the most from uninfected mice and IL-1α levels were significantly higher at 
day 2, 3, and 5.  Levels of IL-1α were elevated in H1N1-infected mice compared to control mice 
but only significantly at day 2.  Levels of IL-1α from the H3N2-infected mice were higher than IL-
1α levels from uninfected mice at day 1 and 2.  Levels of IL-1α from H5N1-infected mice were not 
significantly different than levels in uninfected controls at any time point. This is interesting 
because it shows a less severe inflammatory response in the mice infected with the H5N1 virus.  
While these differences may be significant and are likely indicative of the host response to 
infection, they do not show evidence of a cytokine storm.  We expected to see a large increase in 
pro-inflammatory cytokines that would indicate an excessive inflammatory reaction to influenza 
virus infection.  The levels of IL-1α that were seen in lung homogenates following an influenza 
infection do show an increase compared to healthy mice, but it did not correspond to the 
susceptibility to oseltamivir. 
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Table 18 IL-1α  Levels of Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-α were higher in the 
p-H1N1-infected mice than in uninfected mice at day 2, 3 and 5 (P<0.001).  Levels of IL-1α were 
higher in H1N1-infected mice than uninfected mice at day 2 (P<0.001).  IL-1α was present at 
higher concentrations in H3N2-infected than uninfected mice at day 1 (P<0.001) and day 2 
(P<0.01).  Legend - ns = not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
 
 
Interleukin-1β  
 Levels of IL-1β remained lower than those of IL-1α but were still stimulated by influenza 
infection (Figure 36).  Comparison by two-way ANOVA only revealed two significant differences 
between levels of IL-1β from mice infected with each virus strain (Table A.49).  The only 
differences were seen at day 1.  IL-1β levels from H3N2-infected mice were higher than the IL-1β 
levels from all other infected groups at day 1.  Levels of IL-1β from H5N1-infected mice were 
lower than those observed in the H3N2-infected mice, but were still significantly higher than levels 
seen in mice infected with the p-H1N1 and H1N1 viruses.  Levels of IL-1β in mice are clearly less 
affected by influenza infection than the levels of IL-1α that were shown previously.  Despite the 
noticeable difference shown by the mice infected with the p-H1N1 virus, most of the IL-1β levels 
are comparable to the levels of IL-1α that were seen.  It is interesting to note that IL-1α and IL-1β 
are stimulated in approximately equal quantities since IL-1β is the predominant form in mice and 
has previously been noted to be essential to mice for defense against influenza infections (42).  
This suggests that all of these viruses are capable of stimulating sufficient levels of IL-1α and IL-
1β to generate an immune response to influenza infection.  While we did not discover a large 
difference in cytokine levels with either form of IL-1, we did note a similar response in the mice to 
all four virus strains that were used.  It is worth noting that the largest increase in levels of IL-1α 
was seen with the p-H1N1-infected mice that also correlated with the lowest levels of IL-1β.  It  
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Figure 36 IL-1β  Levels in Influenza-Infected Mice.  On day 1, IL-1β levels from H3N2-infected 
mice were higher than the IL-1β levels from all other infected groups (P<0.001).  IL-1β levels from 
H5N1-infected mice were also slightly higher than IL-1β levels from the p-H1N1 and the H1N1-
infected mice (P<0.05).  No other differences were significant. 
 
may be significant that the levels of both forms of IL-1 were elevated early in the infection with the 
H3N2 virus. 
When levels of IL-1β from infected mice were compared to uninfected mice there were 
still only a few differences (Table 19).  Statistical comparison was done by two-way ANOVA 
(Table A.50).  Levels of IL-1β from p-H1N1-infected mice were not significantly different from the 
levels seen in uninfected mice at any of the 6 days post-infection.  Levels of IL-1β from the H1N1-
infected mice were significantly higher than the levels of IL-1β from uninfected mice but only at 
day 2.  Levels of IL-1β from the H3N2-infected mice were higher than levels of IL-1β from the 
uninfected mice at day 1 but were not different at the other days.  Levels of IL-1β were higher in 
the H5N1-infected mice than the uninfected mice at day 1 but were not significantly different from 
day 2 through 6.  Even more apparent with the levels of IL-1β was the lack of differences between 
infected groups.  With the only differences between viruses observed on day one, it seems that 
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influenza infection does not have a large impact on IL-1β levels.  Levels of IL-1β did not show 
any evidence the cytokine storm referenced previously.  The cytokine storm theorizes that there 
are markedly higher levels of pro-inflammatory cytokines that are up regulated with specific 
viruses (12, 14).  This has not been seen so far. 
 
Table 19 IL-1β  Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  IL-1β levels were higher in 
H1N1-infected mice than in healthy mice at day 2 (P<0.05).  Levels of IL-1β were higher in H3N2-
infected mice than in uninfected mice at day 1 (P<0.001).  IL-1β levels were higher in H5N1-
infected mice than in uninfected mice at day 1 (P<0.001).  Legend - ns = not significant, * = 
P<0.05, *** = P<0.001. 
 
 
Interleukin-2 
 Levels of IL-2 were significantly increased in one infected group following influenza 
infection (Figure 37).  Comparison was done by two-way ANOVA (Table A.51).  Only one 
significant difference was seen after comparison of all of the infected groups.  At day 5, IL-2 
levels from the mice infected with the p-H1N1 virus were significantly higher than the levels of IL-
2 seen in any other infected group.  This is likely not a real difference between a response to the 
p-H1N1 virus and the other viruses since the measurement also has a high standard deviation 
associated with that time point.  Two out of the five mice evaluated at that day are responsible for 
the high level of IL-2 that was seen.  Other than that one point, levels of IL-2 in mice do not seem 
to be greatly impacted by infection with influenza viruses.  There is definitely not a large 
difference between infected groups.  Infection, regardless of the virus, does not increase IL-2 
levels dramatically compared to uninfected groups.  The slight increases in levels of IL-2 that  
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Figure 37 IL-2 Levels in Influenza-Infected Mice.  The only difference in IL-2 levels of 
influenza-infected mice was seen on day 5 where IL-2 levels from p-H1N1-infected mice were 
higher than the IL-2 levels from all other infected groups (P<0.001).  No other significant 
differences were seen. 
 
were observed happen even in uninfected mice and none of the infected groups seem to vary 
based upon the time post-infection. 
When compared to uninfected mice, the p-H1N1-infected mice were the only group to 
show a significant change in levels of IL-2 following infection (Table 20).  Comparison was done 
by two-way ANOVA (Table A.52).  The only difference in IL-2 levels between infected and 
uninfected mice was at day 5 in mice infected with the p-H1N1 virus.  IL-2 levels of mice infected 
with the H1N1, H3N2, and H5N1 viruses were not significantly altered compared to the levels of 
IL-2 seen in the control mice.  With that being the only difference between control mice and those 
infected with influenza, it appears that influenza does not significantly impact levels of IL-2.  It was 
mentioned previously that influenza specific CD8+ T cells produce IL-2 (47).  The study 
mentioned utilized T cells that were isolated from human donors.  The differences in cytokines 
profiles produced by an influenza infection in human and in mice have not been fully examined.  
While influenza may up-regulate one cytokine in humans, it is not clear whether that cytokine will 
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be up-regulated in mice as well.  Our data showed that influenza infection in mice does not 
significantly affect the levels of IL-2 seen in lung homogenates. 
 
Table 20 IL-2 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-2 were higher in p-
H1N1-infected mice than in uninfected mice on day 5 (P<0.001).  None of the other differences 
were significant.  Legend – ns = not significant, *** = P<0.001.  
 
 
Interleukin-3 
 Levels of IL-3 did not change dramatically between viruses following infection (Figure 38).  
Statistical analysis of the levels of IL-3 following influenza infection in mice was performed by two-
way ANOVA (Table A.53).  The only difference was visible on day 2, where IL-3 levels of H1N1-
infected mice were significantly higher than the IL-3 levels from H5N1 and p-H1N1-infected mice.  
However, the levels of IL-3 seen in the H1N1-infected mice were not significantly higher than 
levels seen in the H3N2-infected group.  That solitary measurement may indicate a slight 
difference in the host response to the H1N1 virus but it also has a fairly high standard deviation.  
With only one significant difference the levels of IL-3 seen in mice infected with each strain of the 
influenza virus, it does not appear that IL-3 is a critical cytokine for determining the severity of 
influenza infection in mice.  Overall, the levels of IL-3 in influenza-infected mice remain fairly low 
throughout the infection and do not seem to increase with the severity of the infection.   This is 
only true for the first 6 days of the infection.  Levels of IL-3 are not increased dramatically in mice 
following infection with influenza viruses. 
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Figure 38 IL-3 Levels in Influenza-Infected Mice.  Levels of IL-3 seen in H1N1-infected mice 
were higher than the IL-3 levels from mice infected with the p-H1N1 and H5N1 viruses (P<0.05).  
No other differences were significant. 
 
When infected mice were compared to uninfected mice the change in IL-2 levels from 
H1N1-infected mice at day 2 was significant (Table 21).  Comparison by two-way ANOVA only 
revealed one significant difference (Table A.54).  The only significant difference was seen at day 
two where higher levels of IL-3 were seen in the H1N1-infected mice compared to the uninfected 
mice.  Lack of difference between infected and uninfected mice is probably an indicator that IL-3 
does not play an important role in influenza infection in mice.  As mentioned before, IL-3 provides 
a link between the immune system and the hematopoietic system.  Typically, diseases that affect 
the hematopoietic system are usually more chronic in nature and may take more than six days to 
see effects.  If IL-3 levels were impacted by influenza infection, it would most likely be much later 
in the infection and would not be valuable as an early indicator of disease severity.  It might be 
interesting to follow cytokine levels throughout the full course of infection to monitor whether or 
not IL-3 is impacted by infection. 
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Table 21 IL-3 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  On day 2, levels of IL-3 were 
higher in H1N1-infected mice than uninfected mice (P<0.05).  No other significant differences 
were seen.  Legend – ns = not significant, * = P<0.05. 
 
 
Interleukin-4 
 Levels of the cytokine IL-4 varied in influenza-infected mice (Figure 39).  Two-way 
ANOVA was used to compare levels of IL-4 in infected mice (Table A.55).  None of the 
differences in levels of IL-4 were statistically significant.  On the graph, some of these  
 
 
Figure 39 IL-4 Levels in Influenza-Infected Mice.  No significant differences in IL-4 levels were 
observed among the groups of mice infected with each strain of influenza. 
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differences look as though they should be significant, but they are all associated with higher 
standard deviation and thus negate any expected significance. 
Levels of IL-4 were similar in infected and uninfected mice (Table 22).  Two-way ANOVA 
was used for statistical analysis of the levels of IL-4 (Table A.56).  None of the differences 
between infected and uninfected mice were significant.  Without any large differences between 
the infected and uninfected groups, it does not appear that influenza infection has a significant 
impact on IL-4 production in mice.  IL-4 is an anti-inflammatory cytokine that may have an impact 
on viral replication so it is surprising that it is not up-regulated at least to a small degree by one of 
the virus strains.  IL-4 also helps to determine whether the body produces a Th1 or a Th2 
response.  Balb/C mice were used for this study and are prone to a Th2 response.  The fact that 
they are genetically predisposed to a Th2 response may be the reason for a lack of IL-4 response 
in Balb/C mice.  Measuring the cytokine profiles of other breeds of mice would help to clarify 
whether this is true or not.  A full characterization of the cytokine profiles in different breeds of 
mice following influenza infection might also determine if there is another breed of mice that 
produces a cytokine profile more similar to one seen in human influenza infections.  The 
application of cytokines in infectious diseases is still relatively new and very little work has been 
done to compare cytokine profiles across species.   
 
Table 22 IL-4 Levels in Infected and Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-4 did not significantly 
change when uninfected mice were compared to infected mice.  Legend – ns = not significant. 
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Interleukin-5 
 Levels of IL-5 were similar to the levels of IL-4 since they showed differences that look 
significant at first glance, but were not statistically significant (Figure 40).  Two-way ANOVA did 
not show any significant differences (Table A.57).  On day 2 there is a level of IL-5 seen in the p-
H1N1 infected mice that looks to be significantly higher than the other viruses but has a high 
standard deviation as well.  There are a couple of points that are slightly elevated, but overall the 
levels of IL-5 don’t vary much from uninfected mice.   
When compared to uninfected mice, only one virus had any significantly different levels of 
IL-5 (Table 23).  Comparison by two-way ANOVA revealed the only significant difference in levels 
of IL-5 (Table A.58).  Only the mice infected with the p-H1N1 virus showed any change in the 
levels of IL-5 compared to uninfected mice.  On day 2, IL-5 levels from p-H1N1-infected mice 
were higher than the levels of IL-5 from uninfected mice.  Levels of IL-5 did not change 
significantly in the mice infected with the H1N1, H3N2, and H5N1 viruses. With that being the 
only significant difference, influenza infection does not appear to significantly alter levels of IL-5 in  
 
 
Figure 40 IL-5 Levels in Influenza-Infected Mice.  No significant differences were seen in levels 
of IL-5 following influenza infection in mice.   
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mice.  The cytokine IL-5 is largely associated with allergic reactions and helminth infections so 
increased production would not be expected in an influenza virus infection.  IL-5 was shown to be 
up-regulated in human pandemic influenza infections but only in patients that had developed 
bacterial pneumonia (70).  IL-5 levels from human patients were measured in the serum.  It is not 
clear whether lack of IL-5 production in mice is a factor of the animal model or the fact that 
cytokine levels in lung homogenates were measured in the mice instead of the serum.  Further 
research would need to be done to determine if IL-5 plays a significant role in mice, but the initial 
data does not suggest that IL-5 is a vital determinant of influenza pathogenicity.    
 
Table 23 IL-5 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-5 were higher in p-
H1N1-infected mice than uninfected mice at day 2 (P<0.05).  No other differences were 
significant.  Legend – ns = not significant, * = P<0.05. 
 
 
Interleukin-6 
 IL-6 is one of the only cytokines that seems to correlate with disease severity (82) and 
that was confirmed by our data (Figure 41).  Comparison by two-way ANOVA revealed many 
significant differences between the IL-6 levels of infected mice (Table A.59).  At day 1, IL-6 levels 
were higher in the H3N2-infected than any of the other three infected groups.  Also on day 1, the 
levels of IL-6 from H5N1-infected were significantly higher than the levels seen in the H1N1 and 
p-H1N1-infected mice.  On day 2, IL-6 concentrations from p-H1N1-infected mice were 
significantly higher than the levels from mice infected with any of the other three viruses.  An 
identical difference was seen at day 3 where the IL-6 levels from p-H1N1-infected mice were  
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Figure 41 IL-6 Levels in Influenza-Infected Mice.  On day 1, levels of IL-6 were higher in H3N2-
infected mice compared to all other infected groups (P<0.01).  Also on day 1, levels of IL-6 were 
higher in H5N1-infected mice than in p-H1N1 and H1N1-infected mice (P<0.01).  On day 2, levels 
of IL-6 were higher in p-H1N1-infected mice than all other infected mice (P<0.001).  On day 3, IL-
6 levels were higher in p-H1N1-infected mice than mice infected with all other viruses (P<0.001).  
On day 4, levels of IL-6 were higher in p-H1N1-infected mice than H1N1 and H3N2-infected mice 
(P<0.01).  On day 5, the IL-6 levels were higher in H5N1-infected mice than mice infected with 
the H1N1 and H3N2 viruses (P<0.05).  No significant differences were seen on day six. 
 
higher than the concentrations of IL-6 from the other three infected groups.  On day 4, IL-6 levels 
from p-H1N1-infected were still significantly higher than the levels of IL-6 seen in the H1N1 and 
H3N2-infected groups.  On day 5, levels of IL-6 from H5N1-infected mice were higher than the IL-
6 levels from the H1N1 and H3N2-infected mice but not when compared to the group infected 
with the p-H1N1 virus.  No significant differences were observed on day six.  While there are 
quite a few significant differences between infected groups, it is important to remain focused on 
the differences that might explain the difference in susceptibility to oseltamivir.  Keeping that in   
mind, it is important to notice that the levels of IL-6 are the highest in H3N2 and H5N1-infected 
mice on day 1.  This is one possible indicator of the reason for the severity of the infection with 
the H3N2 and H5N1 viruses.  It shows that the infection is more severe early, and may possibly 
be important in determining whether or not the infection is fatal in mice.  The infected group that is 
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most unusual is the p-H1N1-infected group.  Mice infected with that particular virus had higher 
levels of IL-6 at days 2 and 3 compared to all other infected groups.  The p-H1N1-infected mice 
also had higher levels of IL-6 at day 4 but only compared to the H1N1 and H3N2-infected mice.  It 
is strange that IL-6 levels are so high in mice infected with the p-H1N1 virus since it is still 
susceptible to oseltamivir treatment.  The differences at day 1 seem to make sense in explaining 
the differences in survival following oseltamivir treatment.   
The pro-inflammatory cytokine IL-6 was increased in all four groups of infected mice 
(Table 24).  Comparison by two-way ANOVA showed many significant differences in IL-6 levels of 
infected and uninfected mice (Table A.60).  The levels of IL-6 from the p-H1N1-infected mice 
were elevated compared to the IL-6 levels from uninfected mice at day 2, 3, and 4 as well as day 
5.  IL-6 levels from H1N1-infected mice were higher than the levels seen in healthy controls only 
at day 2.  IL-6 levels in H3N2-infected mice were significantly higher than the IL-6 levels in control 
mice at day 1, day 2, and day 3 but not the remaining three days.  IL-6 levels from H5N1-infected 
mice were higher than levels from uninfected mice at day 1 through 5 but not at day 6. IL-6 has 
been shown to be up-regulated in human influenza infections (12).  IL-6 along with TNF-α are the 
two cytokines usually blamed for the deleterious effects associated with the inflammatory 
response.  It is interesting that the two viruses with decreased susceptibility to oseltamivir both  
 
Table 24 IL-6 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-6 were higher in p-
H1N1-infected mice than in uninfected mice at day 2 through 4 (P<0.001) as well as day 5 
(P<0.05).  IL-6 levels were higher in H1N1-infected mice than in uninfected mice at day 2 
(P<0.001).  IL-6 levels were higher in H3N2-infected mice than in uninfected mice at day 1 
(P<0.001), 2 (P<0.01) and 3 (P<0.05).  Levels of IL-6 were higher in H5N1-infected mice than in 
control mice at day 1 (P<0.001), 2 and 3 (P<0.05), 4 (P<0.01) and day 5 (P<0.001). Legend - ns 
= not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
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display increased concentrations of IL-6 starting at day 1.  Levels of IL-6 remain higher in H5N1-
infected mice when compared to the H3N2-infected mice.  While this would seem to explain part 
of the problem, the data obtained from the p-H1N1-infected mice does not seem to fit.  Levels of 
IL-6 exceed that of all other viruses, yet the p-H1N1-infected mice remain susceptible to 
oseltamivir treatment.  IL-6 may not be fully responsible for the decreased susceptibility to 
oseltamivir, but certainly appears to be a factor.  The H1N1-infected group shows the lowest 
levels of IL-6 possibly indicating a less severe infection than with the other viruses.     
 
Interleukin-10 
 The levels of the regulatory cytokine IL-10 were up-regulated in mice infected with all four 
influenza viruses (Figure 42).  Two-way ANOVA was used for statistical analysis of the levels of 
IL-10 between infected mice (Table A.61).  However, levels of IL-10 were in relatively low 
concentrations overall and thus had higher standard deviations at the times that were measured.   
 
  
Figure 42 IL-10 Levels in Influenza-Infected Mice.  No significant differences were seen 
between groups of mice infected with each strain of influenza virus.   
1 2 3 4 5 6
0
500
1000
1500
2000 H1N1
H3N2
H5N1
p-H1N1
Uninfected
IL-10
Unless noted otherwise, differences are significant against all other viruses.  Uninfected shown as a reference.
Day Post-Virus Exposure
pg
/g
 Lu
ng
 Ti
ss
ue
 108 
None of the differences in levels of IL-10 were statistically significant.  There seem to be 
some random mice that show elevated levels of IL-10 while others do not but this does not 
appear to be virus strain specific.  
Levels of IL-10 were increased in infected mice but also at high levels in uninfected mice 
(Table 25).  Two-way ANOVA was used to compare significant differences (Table A.62).  
None of the infected mice had IL-10 levels that were significantly different than uninfected 
controls through day 6.  IL-10 is an regulatory cytokine that was shown to be detrimental in 
influenza infections with a high challenge dose (50).  We did not find highly elevated levels of IL-
10 in mice with any of the viruses used, however we also had a high degree of variability in the 
levels of IL-10 that were measured.   
 
Table 25 IL-10 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  None of the virus-infected groups 
had significantly higher levels of IL-10 compared to uninfected control mice.  Legend – ns = not 
significant. 
 
 
Interleukin-12p70 
 IL-12 has been indicated as unimportant for influenza infection and as an up-regulated 
cytokine with the pandemic influenza.  Levels of IL-12p70 were evaluated in influenza-infected 
mice (Figure 43).  Two-way ANOVA was utilized to compare IL-12p70 levels between mice 
infected with each strain (Table A.63).  The only difference that was significant was that the levels 
of IL-12p70 from H1N1-infected mice were significantly higher than the levels of IL-12 from mice 
infected with the p-H1N1 and H5N1 viruses on day 2.  Levels of IL-12 from H1N1-infected mice  
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Figure 43 IL-12p70 Levels in Influenza-Infected Mice.  The only significant difference was seen 
on day two where levels of IL-12 from the H1N1-infected mice were higher than the levels of IL-
12p70 of the p-H1N1 and H5N1-infected mice (P<0.05).  No other differences were significant. 
 
were not significantly higher than the levels seen in the H3N2-infected mice.  No other differences 
were significant. 
When contrasted with uninfected mice, levels of IL-12p70  in influenza infected mice were 
similar (Table 26). Two-way ANOVA was for statistical analysis (Table A.62).  Levels of IL-12p70 
from H1N1-infected mice were higher than the levels of IL-12p70 in uninfected mice on day 2.    
 
Table 26 IL-12p70 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IL-12p70 were higher 
in H1N1-infected mice were higher than in uninfected mice at day 2 (P<0.01).  No other 
differences were significant.  Legend – ns = not significant, ** = P<0.01. 
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No other infected group had significantly different levels of IL-12 compared to uninfected 
mice.  While there were some differences, IL-12 production in mice does not seem to be strongly 
impacted by influenza infection.  The exact role it plays with influenza is unknown and it may yet 
prove important for the determination of viral pathogenicity.  In this study, it did not appear to be 
one of the more crucial cytokines based upon a lack of differences between mice infected with 
each strain of viruses and only a solitary difference between infected and uninfected mice.   
  
Interleukin-17 
 IL-17 is a pro-inflammatory cytokine that was moderately impacted by influenza infection 
(Figure 44).  Comparison was done by two-way ANOVA (Table A.65).  On day 2, levels of IL-17 
from p-H1N1-infected mice were significantly higher than levels of IL-17 from the H3N2-infected 
group and the H5N1-infected group but were not significantly different levels seen with the H1N1-
infected mice.  On day 2 as well, levels of IL-17 from H1N1-infected mice were significantly higher  
 
 
Figure 44 IL-17 Levels in Influenza-Infected Mice.  On day 2, IL-17 levels were higher in p-
H1N1-infected mice than in mice infected with the H3N2 and H5N1 virus (P<0.01).  Also at day 2, 
levels of IL-17 were higher in H1N1-infected mice than in H3N2-infected mice (P<0.05).  No other 
significant differences were seen. 
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than levels of IL-17 from H3N2-infected mice.  No other differences were seen between any 
of the infected groups on any day.  IL-17 appears to be slightly induced following influenza 
infection but it is not consistent for any virus and seems to even vary between mice within the 
same group.  IL-17 is a pro-inflammatory cytokine that is supposedly an upstream regulator of 
inflammation but does not seem to be greatly increased following influenza infection in mice.  
Levels of IL-17 are slightly increased in infected mice, but none of the viruses induce much larger 
amounts of IL-17. 
Levels of IL-17 were compared in infected and uninfected mice (Table 27).  A two-way 
ANOVA was used for statistical analysis of IL-17 levels (Table A.66).  Levels of IL-17 from the p-
H1N1-infected groups were significantly increased compared to uninfected controls at day 2.  The 
IL-17 concentrations were higher in H1N1-infected mice than healthy mice at day 2 as well.  
While this difference appears with two viruses, both have a higher degree of error with that 
particular measurement.  It is hard to believe that an increase in cytokine concentrations would be 
not be seen on day 1, be apparent on day 2, and resolve itself by day 3.  IL-17 is an upstream 
regulator of pro-inflammatory cytokines but the role in influenza infection has not been 
determined.  It would be interesting to determine the downstream effects of IL-17 up-regulation in 
mice.   
 
Table 27 IL-17 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  IL-17 levels were increased in p-
H1N1-infected mice compared to uninfected mice at day 2 (P<0.001).  Levels of IL-17 were 
higher in H1N1-infected mice than in uninfected mice at day 2 (P<0.001).  Legend – ns = not 
significant, *** = P<0.001. 
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Monocyte Chemotactic Protein-1 
 The levels of MCP-1 were compared following infection with all four virus strains (Figure 
45).  Significant differences were seen after analysis by two-way ANOVA (Table A.67).  On day 1, 
levels of MCP-1 from H3N2-infected mice were significantly higher than the MCP-1 levels from all 
three groups of infected mice.  Day 2 showed dramatic differences in the levels of MCP-1.  Levels 
of MCP-1 from the p-H1N1-infected mice were higher than the levels of MCP-1 seen in the mice 
infected with the H3N2 and H5N1 viruses.  Levels of MCP-1 from mice infected with the H1N1 
and H3N2 viruses were still significantly higher than the MCP-1 levels of the H5N1-infected group  
 
 
Figure 45 MCP-1 Levels in Influenza-Infected Mice.  At day 1, MCP-1 levels were higher in 
H3N2-infected mice than from all other infected groups (P<0.001).  At day 2, MCP-1 levels were 
higher in p-H1N1-infected mice than in H3N2-infected mice (P<0.05) and in H5N1-infected mice 
(P<0.01).  On day 2, the MCP-1 levels were higher in p-H1N1-infected mice than in H3N2 
(P<0.05) and H5N1-infected mice (P<0.01).  MCP-1 levels were higher in H1N1-infected mice 
than in H5N1-infected mice (P<0.01).  Also on day 2, MCP-1 levels were higher in H3N2-infected 
mice than in H5N1-infected mice (P<0.05).  On day 3, levels of MCP-1 were higher in p-H1N1-
infected mice than in all other infected groups (P<0.001).  On day 4, levels of MCP-1 were higher 
in p-H1N1 and H1N1-infected mice than in H3N2 (P<0.05) and H5N1-infected (P<0.001) mice.  
On day 6, all three infected groups had higher levels of MCP-1 than the H5N1-infected group.  
The difference was more significant for both the H1N1-infected groups (P<0.001) than for the 
H3N2-infected group (P<0.05). 
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on day 2 as well.  On day 3, levels of MCP-1 in p-H1N1-infected mice were significantly 
elevated compared to the MCP-1 levels of all other infected groups.  On day 4, MCP-1 levels 
from p-H1N1 and H1N1-infected groups were both higher than the levels from mice infected with 
the H3N2 and H5N1 viruses.  The infected groups did not have significantly different levels of 
MCP-1 on day 5.  Day 6 showed higher MCP-1 levels in all three infected groups compared to the 
H5N1-infected group.  It is clear that there are many significant differences in the levels of MCP-1 
seen with each infected group.  It is interesting that the MCP-1 levels are highest in the H3N2-
infected group on day 1.  H5N1-infected mice also showed an elevated level of MCP-1 compared 
to the two H1N1-infected groups but the difference was not significant.  The increase in MCP-1 
early is suggestive of a more rapid infection with the H3N2 and H5N1 viruses.  It is also 
interesting that the virus-infected groups that remain consistently higher throughout the infection 
are the groups infected with the p-H1N1 and H1N1 viruses.  It seems that the elevated levels of 
MCP-1 that are seen with the infected groups are suggestive of an effective immune response 
and not necessarily an overstimulation of a pro-inflammatory response to influenza infection.  
Elevated levels of MCP-1 in the lungs seem to indicate that the mice are able to combat the 
infection and eventually recover.  This is contrary to the cytokine storm theory that has been 
proposed (14, 15).  It should also be noted that the two infected groups that had the lowest levels 
of MCP-1 after day 1 were the H3N2 and H5N1-infected groups.   
Levels of MCP-1 were compared in infected and uninfected mice (Table 28).  Statistical 
analysis was done using a two-way ANOVA (Table A.68).  MCP-1 levels from mice infected with 
the p-H1N1 virus were higher compared to the levels from uninfected mice from day 2 until 6.  
MCP-1 levels from H1N1-infected mice were higher than in uninfected mice from day 2 until day 6 
as well.  Levels of MCP-1 were higher from the H3N2-infected mice than from the uninfected 
mice at all 6 days.  MCP-1 levels were higher in the H5N1-infected mice than the uninfected mice 
at day 2 through 5.  Increased levels of MCP-1 from influenza infected lungs is not surprising 
since MCP-1 is secreted by epithelial cells in response to infection and plays a crucial role in 
initiating the pro-inflammatory response.  While the increase in MCP-1 is interesting, it is not  
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Table 28 MCP-1 Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  MCP-1 levels were higher in p-
H1N1-infected mice than in uninfected mice on days 2 through 6 (P<0.001).  MCP-1 levels were 
higher in H1N1-infected mice than uninfected mice on days 2 through 6 (P<0.001).  Levels of 
MCP-1 were higher in H3N2-infected mice than in uninfected mice on all 6 days (P<0.001).  
MCP-1 concentrations were higher in H5N1-infected mice than in uninfected mice on days 2 
through 5 (P<0.001).  Legend – ns = not significant, *** = P<0.001. 
 
 
limited to any of the viruses in particular.  MCP-1 is elevated in a pro-inflammatory response and 
seems to be increased regardless of virus strain.  It does not appear to be significantly different 
with a specific strain as might be expected from a “cytokine storm.” 
 
Interferon-γ  
 Levels of IFN-γ were compared between infected groups (Figure 46).  Comparison of 
IFN-γ levels was done using a two-way ANOVA (Table A.69).  Days 1, 2 and 3 did not show any 
significant differences in IFN-γ levels.  On day 4, levels of IFN-γ from H1N1-infected mice were 
significantly elevated compared to the other three infected groups.  On day 5, the levels of IFN-γ 
from the H3N2-infected group were higher than the levels of IFN-γ from all three other infected 
groups.  IFN-γ levels in H5N1-infected mice were also significantly higher than the levels from the 
H1N1 and p-H1N1-infected mice.  On day 6, levels of IFN-γ were higher in the H1N1-infected 
mice than in the other three infected groups.  Levels of IFN-γ from the H3N2-infected were higher 
than the IFN-γ levels seen in the mice infected with the p-H1N1 and H5N1 viruses.  It does 
appear that levels of IFN-γ vary slightly according to virus.  While these differences remain 
isolated to specific time points, they may be important in the host response to influenza.  Though 
it is later in the infection than the other times that have been observed previously, both the H3N2 
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Figure 46 IFN-γ  Levels in Influenza-Infected Mice.  On day 4, levels of IFN-γ were higher in the 
H1N1-infected mice than in mice infected with the p-H1N1 (P<0.01) as well as the H3N2 and 
H5N1 (P<0.05) viruses.  On day 5, levels of IFN-γ were higher in H3N2-infected mice than all 
three other groups (P<0.001).  Levels of IFN-γ were also higher in the H5N1-infected mice than 
either of the H1N1-infected groups (P<0.01).  On day 6, levels of IFN-γ were higher in the H1N1-
infected mice than all other infected groups (P<0.001).  Levels of IFN-γ from H3N2-infected mice 
were higher than the levels seen in mice infected with the p-H1N1 and H5N1 viruses (P<0.01).   
 
and H5N1-infected mice show levels of IFN-γ on day 5 that are higher than either of the H1N1-
infected groups.  This might show that those two strains of influenza are eliciting a more severe 
response following infection than is seen with either of the H1N1 virus strains. 
Levels of IFN-γ were compared in infected and uninfected mice (Table 29).  Comparison 
was done by two-way ANOVA (Table 70).  Levels of IFN-γ were higher in the p-H1N1-infected 
mice than in uninfected mice at day 2 and 6.  Levels of IFN-γ were higher in H1N1-infected mice 
than in uninfected mice on day 4, 5 and 6.  IFN-γ levels were higher in H3N2-infected mice than 
in uninfected mice at days 5 and 6.  The levels of IFN-γ were higher in H5N1-infected mice than 
in uninfected mice at day 2, 5, and 6.  Even with these differences it is difficult to say how large of  
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Table 29 IFN-γ  Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of IFN-γ were higher in p-
H1N1-infected mice than uninfected mice at day 2 (P<0.001) and 6 (P<0.05).  Levels of IFN-γ 
were higher in H1N1-infected mice than in uninfected mice at day 4 (P<0.05), 5 (P<0.01) and 6 
(P<0.001).  Levels of IFN-γ were higher in H3N2-infected mice than in uninfected mice at days 5 
and 6 (P<0.001).  Levels of IFN-γ were higher in H5N1-infected mice than in uninfected mice at 
day 2 (P<0.01), 5 (P<0.001) and 6 (P<0.05).  Legend – ns = not significant, * = P<0.05, ** = 
P<0.01, *** = P<0.001. 
 
 
a role IFN-γ plays in influenza infection in mice.  It is clear that there are higher levels of IFN-γ 
observed later in the infection, regardless of virus strain.  There does not seem to be significantly 
higher concentrations IFN-γ levels induced by one virus compared to the others.  The changes in 
levels of IFN-γ all happened later in the infection than has been seen with the other cytokines.  
Previous elevations in cytokines have taken place in the first 3 days while increases in IFN-γ do 
not occur until day 4, 5, and 6 post-infection. 
 
Tumor Necrosis Factor-α  
 The levels of TNF-α were compared between infected groups (Figure 47).  Two-way 
ANOVA was used to determine statistical significance (Table A.71).  None of the infected groups 
showed significant changes in TNF-α levels on day 1.  On day 2, levels of TNF-α from H1N1-
infected and H3N2-infected mice were both higher than the levels of TNF-α from p-H1N1-infected 
mice.  On day 3, levels of TNF-α were higher in the H1N1-infected mice compared to the p-
H1N1-infected mice.  No other differences were significant throughout the infection.  The 
differences in TNF-α levels on day 2 may be important but do not help to explain the differences 
in oseltamivir susceptibility since it is the mice infected with H1N1 and H3N2 viruses that showed  
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Figure 47 TNF-α  Levels in Influenza-Infected Mice.  On day 2, levels of TNF-α from H1N1-
infected mice and H3N2-infected mice were significantly higher than the levels of TNF-α from p-
H1N1-infected mice (P<0.01).  On day 3, the TNF-α levels from H1N1-infected mice were higher 
than the levels of TNF-α from p-H1N1-infected mice (P<0.05).  No other differences were 
significant. 
 
the highest cytokine levels.  Levels of TNF-α from the H5N1-infected mice also had slightly 
elevated levels of TNF-α at day 2 as well but the levels were not significantly different from any of 
the other infected groups.  Overall, the only real increases in levels of TNF-α were seen at day 2, 
but otherwise the levels of TNF-α were not greatly impacted by influenza infection.  This is 
surprising since TNF-α is one of the primary cytokines for pro-inflammatory events. 
The levels of TNF-α were compared for infected and uninfected mice to determine the 
impact of influenza infection on levels of TNF-α (Table 30).  Comparison was done by two-way 
ANOVA (Table A.72).  Levels of TNF-α were not significantly different when the p-H1N1-infected 
mice were compared to healthy mice at any of the 6 days.  Levels of TNF-α were higher in the 
H1N1-infected mice than in the uninfected mice at day 2.  Levels of TNF-α were significantly   
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Table 30 TNF-α  Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  TNF-α levels were higher in 
H1N1-infected mice than in uninfected mice at day 2 (P<0.01).  Levels of TNF-α were higher in 
H3N2-infected mice than in uninfected mice at day 2 (P<0.01).  Legend – ns = not significant, ** = 
P<0.01. 
 
 
higher in the H3N2-infected mice than in uninfected mice but only at day 2.  The levels of TNF-α 
from the H5N1-infected mice did not differ significantly from levels of TNF-α from uninfected mice 
at any time point.  The differences in TNF-α levels between infected and uninfected mice were  
only significant at day 2 and that was only for the H1N1 and H3N2-infected mice. Overall, the 
levels of TNF-α were not impacted greatly by infection with any influenza strain.  With the four 
viruses used, there certainly wasn’t any evidence of a cytokine storm in mice involving TNF-α.  
This is significant because TNF-α is one of the cytokines implicated in the increased tissue 
damage due to excessive pro-inflammatory events. 
 
Macrophage Inflammatory Protein-1α  
 Levels of MIP-1α were compared between infected groups to determine the effect of 
influenza infection (Figure 48).  Statistical differences were compared by two-way ANOVA (Table 
A.73).  On day 1, levels of MIP-1α were higher in H3N2-infected mice than in p-H1N1-infected 
mice and H1N1-infected mice.  On day 2, the levels of MIP-1α in mice infected by the p-H1N1 
virus were significantly higher than levels seen in all three other infected groups.  There weren’t 
any significant differences in the levels of MIP-1α between the infected groups on days 3, 4, and 
5.  On day 6, levels of MIP-1α were higher in the H1N1-infected mice than in the p-H1N1-infected  
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Figure 48 MIP-1α  Levels in Influenza-Infected Mice.  On day 1, levels of MIP-1α were higher in 
the H3N2-infected mice than in the mice infected with the p-H1N1 (P<0.001) and the H1N1 
(P<0.01) viruses.  On day 2, MIP-1α levels were higher in the p-H1N1-infected mice compared to 
the mice infected with the H1N1 (P<0.05), H3N2 (P<0.05) and H5N1 (P<0.01) viruses.  On day 6, 
levels of MIP-1α were higher in H1N1-infected mice than in mice infected with the p-H1N1 
(P<0.05) and H5N1 (P<0.001) viruses.  Levels of MIP-1α from H3N2-infected mice were also 
higher than levels from H5N1-infected mice (P<0.05). 
 
mice and the H5N1-infected mice.  Levels of MIP-1α were higher in the H3N2-infected mice than 
the levels observed in the H5N1-infected mice.  The differences between viruses are isolated to 
specific times so it makes interpretation of the effects difficult.  Regardless of other differences 
seen, there was not a dramatic difference in levels of MIP-1α between any of the infected groups. 
Levels of MIP-1α were compared between infected and uninfected mice for each virus 
strain (Table 31).  Comparison by two-way ANOVA revealed only a few differences (Table A.74).  
Levels of MIP-1α were higher in the p-H1N1-infected mice than in the uninfected mice at day 2, 
but at no other time points.  Levels of MIP-1α were significantly increased in H1N1-infected mice 
compared to uninfected mice at days 2 and 6, but not at the other days.  The levels of MIP-1α 
from H3N2-infected mice were significantly higher than the levels of MIP-1α from control mice at 
days 1, 2, 5 and 6.  The levels of MIP-1α from the H5N1-infected group were significantly higher  
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Table 31 MIP-1α  Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of MIP-1α were higher in 
the p-H1N1-infected mice than in uninfected mice at day 2 (P<0.001).  MIP-1α levels were higher 
in H1N1-infected mice than in control mice at days 2 (P<0.05) and 6 (P<0.001).  Levels of MIP-1α 
were higher in H3N2-infected mice than in uninfected mice at day 1 (P<0.001), 2 (P<0.01), 5 
(P<0.01) and 6 (P<0.001).  MIP-1α levels were higher in H5N1-infected mice than in uninfected 
mice at day 2 (P<0.05).  Legend – ns = not significant, * = P<0.05, ** = P<0.01, *** = P<0.001. 
 
 
than the levels of MIP-1α from uninfected mice at day 2.  Despite these differences, there aren’t 
any clear trends that make the effect of influenza infection on the levels of MIP-1α easy to 
distinguish.  The general trend seems to be an increase in MIP-1α levels, but even that does not 
remain consistent throughout the 6 days that we measured.  It is also important to note that the 
levels of MIP-1α were increased most dramatically on day one with the H3N2 and H5N1-infected 
mice.   
 
Granulocyte Macrophage-Colony Stimulating Factor 
 The impact of influenza infection on levels of GM-CSF was evaluated in mice (Figure 49).  
Comparison was again done by two-way ANOVA (Table A.75).  No significant differences were 
seen in the levels of GM-CSF when infected groups were compared on any of the 6 days.  The 
levels of GM-CSF of infected mice were higher compared to uninfected mice but approximately 
equal across the infected groups.  The cytokine GM-CSF does not appear to be involved in any 
type of a cytokine storm that would be different between mice infected with each strain of virus.  
Once again, GM-CSF levels at day one were at the highest concentrations in the lung 
homogenates of the H3N2 and H5N1-infected mice.  This is possibly an indicator of a more rapid  
infection with each of these viruses.  Many of these cytokines been observed at higher levels  
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Figure 49 GM-CSF Levels in Influenza-Infected Mice.  No significant differences were seen in 
the levels of GM-CSF in mice following infection with the four strains of influenza virus. 
 
on day 1, but only in the mice infected with the H3N2 and H5N1 viruses.  Day 2 also had fairly 
levels of GM-CSF observed in infected mice, but that seemed to be approximately equal with all 
infected groups. 
Levels of GM-CSF were compared in infected and uninfected mice (Table 32).  Statistical 
analysis was done by two-way ANOVA (Table A.76).  Only two viruses showed differences that 
were statistically significant.  The levels of GM-CSF of p-H1N1-infected mice were significantly 
increased compared to GM-CSF levels in uninfected mice at day 2 and 5.  The levels of GM-CSF 
from the H1N1 and H3N2-infected groups were not significantly different from the levels seen in 
healthy mice at any of the 6 days post-infection.  Levels of GM-CSF were increased in H5N1-
infected mice compared to uninfected mice at day 3.  The small amount of significant differences 
likely indicates that influenza infection in mice does not greatly impact levels of GM-CSF for the 
viruses that were tested.  Only the mice infected with two of the viruses showed any differences 
compared to the amounts of GM-CSF that were seen in uninfected mice.  Levels of GM-CSF 
were slightly increased in all four infected groups at day 2, but only two of those differences were 
1 2 3 4 5 6
0
2000
4000
6000
8000
10000 H1N1
H3N2
H5N1
p-H1N1
Uninfected
GM-CSF
Unless noted otherwise, differences are significant against all other viruses.  Uninfected shown as a reference.
Day Post-Virus Exposure
pg
/g
 Lu
ng
 Ti
ss
ue
 122 
significant.  The measurement of GM-CSF seemed to have a fairly large amount of variability 
within groups that likely kept any differences from being statistically significant.   
 
Table 32 GM-CSF Levels in Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  Levels of GM-CSF were higher 
in p-H1N1-infected mice than in uninfected mice at day 2 (P<0.05) and day 5 (P<0.01).  GM-CSF 
levels were higher in H5N1-infected mice than in uninfected mice at day 3 (P<0.05).  Legend – ns 
= not significant, * = P<0.05, ** = P<0.01. 
 
 
 
RANTES 
 The last cytokine that was measured was RANTES.  Levels of RANTES were compared 
in influenza-infected mice to determine the impact of infection on cytokine production (Figure 50).  
Comparison of RANTES levels of infected groups was done by two-way ANOVA (Table A.77).  
On day 1, RANTES levels from H3N2-infected mice were higher than the RANTES levels from 
the other infected groups.  On day 2, levels of RANTES were higher in the p-H1N1-infected mice 
than the other three infected groups.  The levels of RANTES in H1N1-infected mice were 
significantly higher than RANTES levels in H5N1-infected mice at day 2.  Day 3 was nearly 
identical to day 2.  The RANTES concentrations were higher in p-H1N1-infected mice than the 
other infected groups.  The RANTES levels from the H1N1-infected group were significantly 
elevated compared to the RANTES levels from the H5N1-infected group.  Day 4 showed 
increased RANTES expression with levels from the p-H1N1-infected mice and H1N1-infected 
mice that were significantly higher than the levels from the H3N2 and H5N1-infected groups.  Day 
5 was similar to day 3 and 4 as the RANTES levels were higher in the p-H1N1-infected mice and 
H1N1-infected mice compared to the mice infected with the H3N2 and H5N1 viruses.  The levels  
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Figure 50 RANTES Levels in Influenza-Infected Mice.  On day 1, RANTES levels were higher 
in H3N2-infected mice than H1N1-infected mice (P<0.01).  On day 2, RANTES levels were higher 
in the p-H1N1-infected mice compared to all three other infected groups (P<0.001).  RANTES 
levels were higher in the H1N1-infected mice than in the H5N1-infected group (P<0.01). On day 
3, RANTES levels were higher in p-H1N1-infected mice than the other three infected groups 
(P<0.001).  Also on day 3, RANTES levels in H1N1-infected mice were higher than the levels in 
H5N1-infected mice (P<0.01).  On day 3, RANTES levels were higher in the p-H1N1-infected and 
H1N1-infected mice compared to mice infected with the H3N2 and H5N1 viruses (P<0.001).  On 
day 5, RANTES levels were higher in the p-H1N1-infected mice than the H3N2 and H5N1-
infected mice (P<0.001).  RANTES levels in H1N1-infected mice were also higher than the levels 
in H5N1-infected mice (P<0.01).  At day 6, RANTES levels in both H1N1-infected groups were 
higher than those in H5N1-infected mice (P<0.001).  Levels of RANTES were higher in the H3N2-
infected mice than in H5N1-infected mice at day 6 as well (P<0.05).   
 
of RANTES from H1N1-infected mice were significantly than the levels observed in the H5N1-
infected group.  Day 6 showed that RANTES levels were higher with all three virus-infected 
groups compared to those observed in the H5N1-infected group.  This cytokine may be the only 
one that supports the idea of increased cytokine expression depending on the virus strain, though 
it seems to support the idea that increased RANTES expression is beneficial to the host rather 
than the virus during an influenza infection.  RANTES levels from H5N1-infected mice never 
achieve the levels observed in H1N1 or p-H1N1-infected groups at any time point.  RANTES 
levels from H3N2-infected mice were elevated at day 1 and again at day 6, but never to the levels 
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observed in the other two H1N1-infected groups.  RANTES is a key cytokine in regulation of 
the inflammatory response and increased levels may be beneficial to controlling influenza 
infections.  Though this is an interesting feature, it is contrary to the notion of increased virulence 
due to a “cytokine storm.”  In this case a failure to induce RANTES expression would equate to 
increased lethality.   
Levels of RANTES were compared in infected and uninfected mice (Table 33).  Two-way 
ANOVA was used to determine the significance of the differences in levels of RANTES between 
infected and uninfected mice (Table A.78).  The levels of RANTES were higher in the p-H1N1-
infected mice than they were in the uninfected mice from day 2 until day 6.  RANTES levels were 
higher in H1N1-infected mice than in uninfected mice from day 2 until 6.  The levels of RANTES 
were higher in H3N2-infected mice than in control mice at days 1 through 5.  For the H5N1-
infected mice, RANTES levels were higher than those seen in uninfected mice but only on day 2.  
Though it is contrary to what was expected, levels of RANTES induced by both of the H1N1 
viruses were significantly different than the levels seen in both H5N1 and H3N2-infected groups.  
In this case, the levels of RANTES that were induced may provide a beneficial inflammatory 
response that helps to contain viral infection.  There is definitely a more pronounced response by 
the H1N1-infected groups than the other two infected groups. 
  
Table 33 RANTES Levels of Infected vs. Uninfected Mice.  Means, standard deviations and 
statistical significance compared to uninfected mice are shown.  RANTES levels were higher in 
the p-H1N1-infected mice than in uninfected mice from day 2 until 6 (P<0.001).  RANTES levels 
were higher in the H1N1-infected mice than uninfected mice from day 2 until day 6 (P<0.001).  
Levels of RANTES were higher in H3N2-infected mice than control mice at days 1 and 2 
(P<0.001) and days 3, 4 and 5 (P<0.05).  RANTES levels were higher in H5N1-infected mice than 
control mice, but only at day 2 (P<0.05).  Legend – ns = not significant, * = P<0.05, *** = P<0.001. 
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Conclusions 
 
 Despite many changes in levels of cytokines following influenza infection, there was not 
any evidence of a supposed “cytokine storm” that would explain the differences in oseltamivir 
sensitivity in mice infected with each influenza strain.  Of the sixteen cytokines that were tested, 
almost every one was increased following influenza infection. 
 Levels of IL-1α were significantly increased in mice infected with all four influenza strains.  
Levels of IL-1α increased most dramatically early in the infection in the mice infected with the 
H3N2 virus.  The levels of IL-1α seen at day 1 were higher than any of the IL-1α levels of the 
other three infected groups.  This suggests a more severe infection in the first 24 h with the H3N2 
virus. 
 Levels of IL-1β were elevated in all of the influenza-infected mice.  It is interesting to note 
that the IL-1β levels were highest on day 1 in the mice infected with the H3N2 and H5N1 viruses.  
This also indicates that both of these viruses are capable of inducing a more profound 
inflammatory event in the mouse lungs in the first day post-infection.   
 Levels of IL-2 were not significantly impacted by influenza infection and were not present 
at increased concentrations in the lungs of infected mice. 
 Following influenza infection, levels of IL-3 were only slightly elevated in the lungs of 
infected mice.  Differences in the levels of IL-3 were not significantly altered between groups 
infected with the different influenza strains. 
 Levels of IL-4 and levels of IL-5 were not significantly impacted by influenza infection in 
mice.  Neither of these cytokines showed consistent increases in cytokine concentrations after 
infection.  Any changes in the levels of these cytokines were approximately equal to the 
concentrations seen in uninfected mice. 
 IL-6 concentrations were significantly increased following influenza infection with each of 
the different strains of influenza.  Levels of IL-6 showed a similar trend that was seen with the 
cytokine IL-1.  The highest concentrations of IL-6 were seen in the mice infected with the H3N2 
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and H5N1 viruses.  This is the third cytokine that shows a more severe infection with the 
H3N2 and H5N1 viruses in mice on day 1.  Contrary to the cytokine storm theory, the levels of IL-
6 were dramatically increased in the p-H1N1-infected mice on day 2, 3 and 4.  Determining how 
susceptible infected mice are to oseltamivir, may help determine whether high levels of IL-6 are 
beneficial in influenza infections or not. 
 Levels of IL-10, IL-12p70, and IL-17 in mice are only slightly affected by influenza 
infection.  Levels of IL-10 in lung homogenates are elevated a small amount following infection, 
but the results are inconsistent depending on the day post-infection.  IL-12p70 levels increase 
slightly following infection, but are not consistently different from the levels of IL-12 seen in 
uninfected mice.  A relatively large increase in the levels of IL-12 was seen on day 2 in the H1N1-
infected and H3N2-infected mice but the difference was not visible at any other day post-
infection.  The only significant change in levels of IL-17 was seen in the mice infected with the p-
H1N1 and H1N1 viruses on day two.  This change is likely not significant since no other 
differences in the levels of IL-17 were seen at any of the other days. 
 Increases in the levels of MCP-1 were seen on day 1 in the H3N2-infected mice 
compared to the levels seen in all three other infected groups.  Concentrations of MCP-1 were 
significantly increased in all the infected groups compared to uninfected mice.  After the initial 
increase in MCP-1 levels seen on day 1, throughout the remainder of the experiment, the levels 
of MCP-1 were the highest in the p-H1N1 and H1N1-infected mice.  This suggests that the first 
day of infection is more severe in the H3N2-infected mice and likely indicates a more rapid 
infection in mice. 
 Levels of IFN-γ increased following infection in mice but took until day 5 to reach high 
levels of cytokine.  Levels of IFN-γ increased moderately through day 4 but approximately equally 
in all the infected groups.  The largest increases in levels of IFN-γ were seen on day 5.  On day 5, 
the levels of IFN-γ were highest in the H3N2-infected mice and the H5N1-infected mice.  This 
might indicate a more severe inflammatory response with those two groups of infected mice, 
however, the IFN-γ levels of H1N1-infected mice were even higher on day 6 than any level that 
 127 
was seen prior to that point.  Without that high level of IFN-γ seen at day 6, the IFN-γ data 
would support a more severe inflammatory response in the H3N2 and H5N1-infected mice. 
 Levels of TNF-α increased following infection but were only significantly elevated at day 2 
compared to uninfected mice.  Even at day 2, the levels of TNF-α were not significantly increased 
in the p-H1N1-infected mice compared to uninfected mice.  The production of TNF-α appears to 
be only slightly impacted by influenza infection in BALB/c mice. 
After infection, levels of MIP-1α increased significantly in all infected groups.  The most 
significant impact that might explain differences in oseltamivir sensitivity was seen on day 1 
where the levels of MIP-1α were the most elevated in mice infected with the H3N2 and H5N1 
viruses.  Since levels of MIP-1α increased after infection and increases were seen earlier in the 
H3N2 and H5N1-infected mice, this might indicate a more rapid infection with these two viruses.  
After day one, the increase in MIP-1α levels varied according to each individual infected group. 
 Levels of GM-CSF increased to a certain extent following infection, but showed too much 
variability to be of much use in measuring the severity of infection.  Levels of GM-CSF were only 
different on a few days when infected mice were compared to uninfected mice.  Despite the slight 
increase in levels, GM-CSF production did not seem to be significantly altered by influenza 
infection. 
 Levels of the cytokine RANTES increased dramatically in influenza-infected mice.  Levels 
of RANTES were highest in the H3N2-infected mice on day 1 possibly indicating a more severe 
reaction to infection with the H3N2 virus.  However, after day 1, the levels of RANTES were the 
most elevated in the mice infected with the p-H1N1 and H1N1 viruses.  Since these viruses did 
not show decreased susceptibility to oseltamivir treatment, this seems to show an effective 
immune response rather than an excessive inflammatory event.  This is contrary to what has 
been shown in the literature, at least with the highly pathogenic avian influenza virus.  In this 
case, the higher levels of cytokine seem to be beneficial to survival of the influenza infection. 
 While there were many differences in cytokine levels of influenza-infected mice, very few 
of the differences definitively showed an advantage for any one of the influenza viruses.  One 
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infected group could have the highest levels of cytokine at one day, but then be completely 
surpassed by a different infected group the next day.  The only differences that seem to favor the 
H3N2 and H5N1 viruses were seen very early in the infection with the exception of IFN-γ which 
showed an large increase on day 5.  The cytokine levels that are seen in the first two days of the 
infection may be the best indicator of the severity of the infection.   
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CHAPTER VII 
EFFECTS OF OSELTAMIVIR IN INFLUENZA-INFECTED MICE 
 
Effects of Oseltamivir on Survival for Influenza-Infected Mice 
 
Introduction 
 Infection of fifteen mice per treatment group allowed the generation of a separate survival 
curve for each virus and treatment group.  Survival curves were grouped according to treatment 
and viruses were compared to each other.  Differences in survival curves were compared to 
identical treatment groups. Placebo treated mice were included to ensure that all viruses were 
infected and achieved 100% mortality for each infection group.  Adjustments were made to the 
virus dilutions used from the first mouse study we performed.  The dilution of the p-H1N1 virus 
was altered so that the same number of viral particles were used but 90 µl were used for the 
infection so all infected mice were treated equally.  The dilution of the H1N1 virus was decreased 
from 1:150 to 1:120.  The dilution of the H3N2 virus was decreased from 1:45 to 1:30.  The 
changes in virus dilution were done to ensure that we achieved 100% mortality with each 
placebo-treated group.  The two treatment groups were a low dose of oseltamivir (5 mg/kg/day) 
or a high dose of oseltamivir (40 mg/kg/day). 
 
Survival for Mice Treated with Placebo 
 While not essential for comparison of oseltamivir treatment, a placebo treated group was 
included to verify differences in mean day of death that were seen in the initial study as well as 
ensure that 100% lethality was achieved with each virus strain (Figure 51).  Comparison of the 
survival curves from placebo treated mice was done by the Kaplan-Meier test followed by the 
Gehan-Brexlow Wilcoxon test (Table A.79).  As can be seen below, the adjustments to the 
amount of virus and dilution used for each strain were effective at achieving 100% lethality with 
each strain.  Influenza H5N1-infected mice were the only group that that generated a significantly 
different survival curve than any of the other placebo-treated mice.  The survival curve of the  
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Figure 51 Survival Curves for Influenza-Infected Mice Treated With Placebo.  Fifteen mice 
were infected with each strain and used to generate survival curves.  The survival curve of the 
H5N1-infected mice was significantly different from the survival curve of mice infected either of 
the H1N1 viruses (P<0.001) and the H3N2 virus (P<0.01).   
 
H5N1-infected mice was significantly different than survival curves of the H3N2-infected group 
and both of the H1N1-infected groups.  The different survival curve with the H5N1-infected mice 
that was observed in the first study that we performed was confirmed with infectious doses that  
were more balanced to obtain the same outcomes after infection.  When all virus doses were 
adjusted to achieve the same lethality in mice, the H5N1 virus was still significantly different from 
the other three viruses.  Something is different with the H5N1 virus that allows it to kill the mice 
more quickly.  Whether or not there is a significant difference with the H3N2 virus may be more 
apparent with oseltamivir treatment. 
 
Survival for Mice Treated with Oseltamivir (5 mg/kg/day) 
 The survival of mice treated with 5 mg/kg/day of oseltamivir was different than what was 
expected (Figure 52).  Comparison of survival curves following treatment with 5 mg/kg/day was 
done by the Kaplan-Meier test followed by a Gehan-Breslow-Wilcoxon test (Table A.80).  All mice  
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Figure 52 Survival Curves for Influenza-Infected Mice Treated Oseltamivir (5 mg/kg/day).  
Fifteen mice were infected with each strain and used to generate survival curves.  The survival 
curve in H3N2-infected mice was different than the survival curve from mice infected with either of 
the H1N1 viruses (P<0.001) and the H5N1 virus (P<0.05).  The survival curve from H5N1-
infected mice was significantly different compared to the survival curve from the H1N1-infected 
groups (P<0.001). 
 
infected with the p-H1N1 and H1N1 viruses survived the infection when treated with 5 mg/kg/day 
of oseltamivir.  Only one mouse infected with the H3N2 virus survived the infection.  Nine mice 
infected with the H5N1 virus survived the infection.  The survival curve of H3N2-infected mice 
was significantly different than the survival curve of p-H1N1 and H1N1-infected mice and was 
significantly different from the survival curve of the H5N1-infected group.  There was also a 
significant difference in survival curves between H5N1-infected mice and the mice infected with 
both p-H1N1 and H1N1 viruses. While we did not expect the influenza H3N2 virus to be more 
lethal than H5N1 with this treatment regimen, that is what appears to have happened.  Treatment 
with a higher dose of oseltamivir may help clarify the differences between each virus strain in 
infected mice.   
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Survival for Mice Treated with Oseltamivir (40 mg/kg/day) 
 Treatment with oseltamivir at 40 mg/kg/day confirmed the results of the study performed 
by Don Smee (69) (Figure 53).  Comparison of survival curves was done by the Kaplan-Meier test 
followed by a Gehan-Breslow-Wilcoxon secondary test (Table A.81).  Mice infected with the 
influenza H5N1 virus were the least susceptible to oseltamivir treatment followed by the mice 
infected with the H3N2 virus.  No mortality was seen in the mice infected with the p-H1N1 and 
H1N1 viruses following the high treatment dose of oseltamivir.  All mice infected with the p-H1N1 
virus and with the H1N1 virus survived the infection.  Thirteen mice infected with the H3N2 virus 
survived the infection.  Seven mice infected with the H5N1 virus survived the infection.  The 
survival curve in H5N1-infected mice was significantly different from the survival curve in H3N2-
infected mice and it was also different from the survival seen with the p-H1N1 and H1N1-infected 
groups.  The survival curves of mice infected with the p-H1N1, H1N1, and H3N2 viruses were not  
 
 
Figure 53 Survival Curves for Influenza-Infected Mice Treated With 40 mg/kg/day 
Oseltamivir.  Fifteen mice were infected with each strain and used to generate survival curves.  
The survival curve of the H5N1-infected mice was significantly different than the survival curve of 
the mice infected with either of the H1N1 viruses (P<0.01) as well as the H3N2 virus (P<0.05). 
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significantly different from each other.  The highest dose of oseltamivir clearly shows that the 
H5N1 virus is the most resistant to oseltamivir treatment in mice.  Despite oseltamivir  
treatment, 8 mice still died following infection with the H5N1 virus.  After comparing the survival 
curves at 5 mg/kg/day, the H3N2 virus appeared to be the most resistant to oseltamivir treatment.  
There seems to be a very thin line that defines whether or not the mice will survive the infection.  
We did not find any dramatic differences with these two viruses that explain the different 
responses to oseltamivir treatment.     
 
Effects of Oseltamivir on Mean Day of Death for Influenza-Infected Mice 
 
Mean Day of Death for Mice Treated with Placebo 
 Placebo treated mice were infected with each virus to confirm that the differences in 
mean days of death that was seen in the initial experiment held true when virus dilutions were 
adjusted to achieve 100% mortality with each virus strain.  In the initial experiment three mice 
survived the H3N2 infection and two survived the H1N1 infection.  Mean days of death were 
calculated when each virus was infected at a level producing 100% lethality in mice (Table 34).  
Comparison of the mean day of death for each group was done using the Mann-Whitney U test 
(Table A.82).  After adjusting the virus dilutions, the differences seen in the initial study were 
confirmed with these findings.  The mean day of death of mice infected with the H5N1 virus was 
significantly earlier than the mean day of death of H3N2-infected mice as well as the H1N1 and p-
H1N1-infected mice.  None of the other mean days of death were significantly different from each  
  
Table 34 Mean Day of Death for Influenza-Infected Mice Treated with Placebo.  Mice infected 
with the H5N1 virus had a significantly different mean day of death than mice infected with the 
H3N2 virus (P<0.01) as well as the H1N1 and p-H1N1 viruses (P<0.001). 
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other.  Comparison of mean days of death confirms differences seen with the survival curves 
that have been discussed previously.  While the exact cause is not clear, the H5N1 virus is able 
to kill mice significantly earlier following infection than the other viruses that were tested. 
 
Mean Day of Death for Mice Treated with Oseltamivir (5 mg/kg/day) 
 Following oseltamivir treatment at 5 mg/kg/day, a mean day of death was calculated for 
each infected group (Table 35).  Comparison was done using the Mann-Whitney U test (Table 
A.83).  All of the mice infected with H1N1 and p-H1N1 survived so the mean day of death is 
undefined for those two viruses.  Mean days of death for the mice infected with the H5N1 and the 
H3N2 virus were 9.6 and 9.4 respectively.  The difference between the two was not statistically 
significant.  It is interesting that treatment with the lower dose of oseltamivir removed the 
difference in mean days of death between the H5N1 group and the H3N2 group that was seen in 
the initial experiment.  It would be expected that differences would be seen with H1N1 and p-
H1N1 since they are both more sensitive to oseltamivir treatment than the H5N1 or H3N2 viruses.  
We did not expect the difference between the H5N1 and H3N2-infected mice to be altered by 
oseltamivir treatment.  It is also interesting that despite the higher mortality observed with the 
H3N2 virus, the mean days of death were not significantly different.  When treated with a low 
dose of oseltamivir, mortality is observed at nearly the same time, regardless of the virus used.   
 
Table 35 Mean Day of Death for Influenza-Infected Mice Treated with Oseltamivir (5 
mg/kg/day).  Mice infected with both of the H1N1 viruses did not have show any mortality so a 
mean day of death was undefined.  The mean days of death for the H3N2 and H5N1-infected 
mice were not significantly different. 
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Mean Day of Death for Mice Treated with Oseltamivir (40 mg/kg/day) 
 Mean days of death were calculated for each virus-infected group following oseltamivir 
treatment at 40 mg/kg/day (Table 36).  Comparison was done using the Mann-Whitney U test 
(Table A.84).  A mean day of death was not obtained for H1N1 or p-H1N1 since no mortality was 
observed with either infection.  The H5N1-infected group had a mean day of death of 9.3.  Two 
mice died following the H3N2 infection producing a mean day of death of 9.5.  A statistical 
comparison of the mean days of death was not possible between the two infected groups 
because the Mann-Whitney U test requires at least three subjects per group to be valid.  It is 
unlikely that the mean days of death were significantly different given the amount of deviation 
associated with each infected group.  When treated with oseltamivir at 40 mg/kg/day, it appears 
that the differences in mean day of death were reduced.  Both viruses are able to cause mortality 
following treatment, but neither is able to cause mortality more rapidly. 
 
Table 36 Mean Day of Death for Influenza-Infected Mice Treated with Oseltamivir (40 
mg/kg/day).  Mice infected with the p-H1N1 and the H1N1 virus did not show mortality following 
infection.  The mean day of death for H3N2 and H5N1-infected mice were not compared due to 
an insufficient number of mice to allow statistical analysis. 
 
 
Effects of Oseltamivir on Weight Loss in Influenza-Infected Mice 
 
Weight Loss in Mice Treated with Placebo  
 The percentage of initial body weights of placebo treated mice was similar for all four 
virus strains (Figure 54).  Comparison by one-way ANOVA did not show any significant 
differences between any of the infected groups (Table A.85).  The curves show the percentage of 
initial body weight for mice infected with each virus strain were nearly identical.   No statistical 
differences were seen between any of the viruses.  As seen in the first study, the impact of  
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Figure 54 Weight Loss in Influenza-Infected Mice Treated with Placebo.  No significant 
differences were seen in the percentages of initial body weights of influenza-infected mice when 
they were compared using a one-way ANOVA. 
 
infection on weight loss was approximately equal for all of the infected groups.  This is unique 
because mortality occurs with the H5N1 virus more quickly, as shown by the mean day of  
death, but do not show a more rapid decrease in body weight.  Loss of body weight is a good 
indicator of disease but it takes a fairly severe difference in infections to produce a marked 
change in weight loss after infection.  While the infection may be more severe in the H5N1 and 
H3N2-infected mice, weight loss alone is not sensitive enough to reflect the differences in the 
infection between virus strains.  Comparison of weight loss following oseltamivir treatment may 
be more beneficial in showing the differences between virus strains. 
 
Weight Loss in Mice Treated with Oseltamivir (5 mg/kg/day) 
 Mice treated with 5 mg/kg/day of oseltamivir had intriguing effects on mean body weights 
of influenza-infected mice (Figure 55).  Two of the infected groups had different weight loss 
curves when comparison was done by one-way ANOVA (Table A.86).  Infection with the H5N1 
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virus initially showed weight loss that very closely mirrored to that of the mice infected with the 
H3N2 virus.  The weight loss shown by influenza H5N1-infected mice was significantly different 
from the H1N1-infected mice.  Influenza H3N2-infected mice actually displayed more significant 
weight loss until day 13 post-infection.  The 14th mouse succumbed to infection on the 15th day 
post-infection leaving only one mouse infected by the H3N2 virus in this treatment group.  That 
last remaining mouse increased in body weight dramatically throughout the remainder of infection 
until it weighed as much as the control mice on day 21.  This one mouse impacted the statistical 
significant of the group infected with the H3N2 virus so the difference compared to the H1N1-
infected mice was masked.  The weight loss shown by the p-H1N1-infected mice resulted in a 
curve that was not significantly different from any other group.  Mice infected with the H1N1 virus 
lost a very small amount of weight after treatment with 5 mg/kg/day and remained very close to 
the uninfected mice.  The visible differences in the percentages of initial body weights mirrors the 
  
 
Figure 55 Weight Loss in Influenza-Infected Mice Treated with Oseltamivir (5 mg/kg/day).  
Mice infected with the H3N2 virus had a significantly different weight loss curve than the H1N1-
infected mice (P<0.05).  H5N1-infected mice had a different weight loss curve than the H1N1-
infected mice as well (P<0.01). 
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severity of infection with each virus strain.  Even a low treatment dose of oseltamivir is able to 
negate the weight loss due to infection from the influenza H1N1 virus.  The mice infected with the 
p-H1N1 virus show an increased impact on weight loss but all of the mice survive the infection 
even at the lower treatment dose.  The mice infected with the H5N1 and H3N2 viruses both show 
the most significant weight loss and display mortality despite oseltamivir treatment.   
 
Weight Loss in Mice Treated with Oseltamivir (40 mg/kg/day) 
 Weight loss in the infected mice was compared following treatment with the high dose of 
oseltamivir (Figure 56).  Comparison of weight curves was done by one-way ANOVA (Table 
A.87).  The mice infected with the p-H1N1 virus showed a 20% decrease in body weight but that 
difference was not significant compared to any of the other infected groups.  The H1N1-infected 
mice showed almost no change in percentage of initial body weight compared to control mice. 
   
 
Figure 56 Weight Loss in Influenza-Infected Mice Treated with Oseltamivir (40 mg/kg/day).  
H3N2-infected mice had a significantly different weight loss curve compared to the p-H1N1-
infected (P<0.05) and H1N1-infected (P<0.001) groups.  H5N1-infected mice had a different 
weight loss curve than the mice infected with the p-H1N1 (P<0.01) and the H1N1 (P<0.001) 
viruses. 
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They are almost identical to uninfected mice and are not largely affected by infection with the 
H1N1 virus.  Change in body weight was largely eliminated for the H1N1-infected mice when 
treated with 40 mg/kg/day of oseltamivir.  Infected mice were nearly identical to uninfected mice 
throughout the entire experiment.  H1N1 infected mice continued to gain weight and the weight 
loss was nearly zero.  The influenza H3N2 virus produced the second largest impact on body  
weight throughout infection and was significantly different from the mice infected with the p-H1N1 
and H1N1 viruses.  Mice infected with the H5N1 virus showed the most average body weight loss 
at every time from day three until day twenty-one.  The difference in body weights was 
significantly different when compared to the mice infected with the p-H1N1 virus and the mice 
infected with the H1N1 virus. 
 
Effects of Oseltamivir on Mean Lung Virus Titers in Influenza-Infected Mice 
 
Explanation of Statistical Significance 
 Lung virus titers from each mouse were compared throughout the infection.  Statistical 
comparisons were completed until there were not enough survivors to allow significant 
comparisons to be made.  Placebo treated mice died early in the infection and were only 
evaluated until day six.  Treatment with 5 mg/kg/day of oseltamivir had enough survivors to 
perform statistical evaluation until day eight post-infection.  While mice infected with the H1N1 
and the p-H1N1 viruses survived throughout the experiment, even at 5 mg/kg/day of oseltamivir, 
statistical comparisons are not included because they could not be compared to all other viruses.  
With oseltamivir treatment at 40 mg/kg/day enough mice survived until day ten to allow a 
statistical comparison to be performed at all time points.  Comparisons were made between 
treatment groups by comparing only two virus-infected groups at a time to make the many 
differences between infected groups easier to understand and visualize.  With all of the lung virus 
titers on one graph, the figure became too cluttered to be useful. 
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Mean Lung Virus Titers in Mice Treated with Placebo 
 Without oseltamivir treatment there were visible differences between the mean lung virus 
titers of influenza-infected mice (Figure 57).  Comparison of mean lung virus titers was done by 
two-way ANOVA (Table A.88).  There were many significant differences between groups of mice 
infected with the four different virus strains.  Infected groups were compared two at a time to 
make comparisons easier to understand. 
Comparison of mice infected with the p-H1N1 and the H1N1 virus without oseltamivir 
treatment revealed very similar lung virus titers at nearly every day post-infection (Figure 57.A).  
No significant differences were seen at any time point.  This may partially explain why survival 
curves remained very similar following oseltamivir treatment.  The main differences between 
these two viruses were seen with changes in body weight following infection and treatment.  This 
lends support to the theory that the H1N1 virus is uniquely sensitive to oseltamivir treatment.  It is 
interesting to see that lung virus titers to not vary significantly in viruses that were isolated from 
different flu seasons that are so chronologically distant from one another.  Despite the time span 
separating them, the newer flu strain is not markedly more adept at producing higher viral titers in 
the lungs of mice.  It appears to remain markedly sensitive to oseltamivir treatment, though the 
mice do show changes in body weight that was not seen with the H1N1 virus. 
Apart from one significant difference at day one, comparison of mean lung virus titers of 
the mice infected with the p-H1N1 and H3N2 viruses showed very similar replication curves 
(Figure 57.B).  The lung virus titers of the H3N2-infected mice were significantly higher than the 
lung virus titers from the p-H1N1-infected mice at day 1.  Days 2, 4 and 6 were nearly identical 
between the two infected groups.  The lung titers from the p-H1N1-infected mice were slightly 
lower compared to the titers from the H3N2-infected mice at day eight but the difference was not 
significant after statistical analysis.  The very similar growth curves make sense seeing that the 
mean days of death are nearly equal for both of these viruses.  That small difference at day one 
may be part of the reason that H3N2 virus shows an increased ability to overcome oseltamivir 
treatment, especially at the lower dose.  
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Figure 57 Mean Lung Virus Titers in Influenza-Infected Mice Treated with Placebo.  A. Lung 
virus titers were not significantly different when p-H1N1-infected mice and H1N1-infected mice 
were compared.  B. Lung virus titers from H3N2-infected mice were significantly higher than lung 
virus titers from p-H1N1-infected mice at day 1 (P<0.01).  C. Lung virus titers from p-H1N1-
infected mice and H5N1-infected mice were not significantly different at any time point.  D. Lung 
virus titers from H3N2-infected mice were higher than mean lung virus titers from H1N1-infected 
mice at day 1 (P<0.01).  E. Mean lung titers from H5N1-infected mice were higher than lung virus 
titers from H1N1-infected mice at day 1 (P<0.05).  F. Lung virus titers from H3N2-infected mice 
were not significantly different from those in H5N1-infected mice. 
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Without oseltamivir treatment, lung virus titers from the mice infected with the p-H1N1 
and H5N1 viruses displayed replication curves that were very closely related (Figure 57.C).  None 
of the differences that were seen were statistically significant.  The lung virus titers from the 
H5N1-infected mice were higher than the lung virus titers from the p-H1N1-infected mice at day 1 
and day 6 but the differences were not significant after statistical analysis.  Lung virus titers were 
higher in the p-H1N1-infected mice than the H5N1-infected mice at day 2 and 4, but not 
significantly different.  The interesting thing revealed by placebo treatment is that despite similar 
lung virus titers, the H5N1 virus kills the mice significantly more quickly than the p-H1N1 virus.  
This difference separates the H5N1 virus from the two viruses compared so far.  It does not 
explain the exact reason why oseltamivir does not protect H5N1-infected mice but is probably at 
least part of the reason for the lack of efficacy.  The fact that mortality is observed earlier with the 
H5N1 virus means that the infection is more difficult to treat because the drug has less time to 
contain the infection.  Mean day of death and survival curves from placebo-treated mice both 
support the idea that the H5N1 virus induces mortality more quickly in mice. 
Differences in lung virus titers without oseltamivir treatment were visible throughout the 
infection when the mice infected with the H1N1 and H3N2 viruses were compared (Figure 57.D).  
The only day that was significantly different was day one where the lung virus titers of the H3N2-
infected mice were higher than the lung virus titers of H1N1-infected mice.  The lung virus titers 
were higher in the H3N2-infected at days 2, 4 and 6 but not significantly higher.  Mean virus titers 
were nearly identical at day 8.  When compared without oseltamivir treatment, the H3N2-infected 
mice were capable of producing higher lung virus titers than the H1N1-infected group.  The 
differences in susceptibility to oseltamivir observed in mice are at least partially attributable to a 
difference in lung virus titers seen with each virus strain. 
When lung virus titers from the mice infected with the H1N1 and H5N1 viruses were 
compared only one difference between the two infected groups was statistically significant (Figure 
57.E).  At day 1, the lung virus titers from H5N1-infected mice were significantly higher than titers 
from the H1N1-infected group.  The lung titers from H1N1-infected mice were higher at day 2 and 
4 but those points were not statistically significant.  Lung virus titers from H5N1-infected mice 
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were higher at day 6 but the difference was not significant.  Besides the small difference at 
day one, the lack of a difference in lung titers throughout the remaining days confirms what has 
been seen with the other infected groups.  Despite similar lung titers, mortality is seen earlier with 
the H5N1-infected mice. 
There was an interesting phenomenon that was seen with the lung virus titers of the mice 
infected with the H3N2 and H5N1 viruses.  The mice infected with the H3N2 virus had higher lung 
titers than the H5N1-infected group at nearly every time point but the differences were not 
significant (Figure 57.F).  The lung virus titers from H3N2-infected mice were higher than titers 
from the H5N1-infected mice at day 1, 2 and 4.  Lung virus titers were nearly equal at day 6.  No 
comparison was possible at day eight because the five mice that were infected with the H5N1 
virus were all dead by day 8.  Based upon these results, it still appears that there is something 
unique about the influenza H5N1 virus.  It is interesting to note that mortality is observed earlier 
with the H5N1 virus despite having lower overall lung virus titers throughout the infection.  The 
H3N2 virus is able to produce higher titers on days 1 and 2 that may give it a beneficial 
advantage and help to overcome oseltamivir treatment.   
 
Mean Lung Virus Titers in Mice Treated with Oseltamivir (5 mg/kg/day) 
 Treatment with 5 mg/kg/day of oseltamivir revealed many significant differences in the 
mean lung virus titers that were not visible in the placebo-treated mice (Figure 58).  Comparison 
of all mean lung virus titers was done by two-way ANOVA (Table A.89).   
The lung virus titers from the two H1N1 virus-infected groups were significantly different 
after day 1 (Figure 58.A).  The lung virus titers from p-H1N1-infected mice were higher than lung 
virus titers from H1N1-infected mice on day 1, but the difference was not significant.  The mean 
lung titers from p-H1N1-infected mice were significantly higher than the H1N1-infected group on 
day 2.  They titers from p-H1N1-infected group were still significantly higher on day 4 and day 6.  
In this case, no lung titer was detectable in the p-H1N1-infected mice, however, the titers from the 
H1N1-infected mice were still measurable.  It is clear from the comparison of the mean body 
weights that the p-H1N1 infection is more severe due to the visible difference in weight loss.  The 
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surprising result is that the H1N1 virus is markedly more inhibited by oseltamivir treatment 
than any of the other viruses.  It might be possible that part of the difference between these 
viruses may be a unique characteristic of the H1N1 virus.  Influenza H1N1 is unique among the 
four viruses tested in that lung virus titers are significantly lowered by oseltamivir treatment even 
at the lower dose.  The possibility that the H1N1 virus is uniquely sensitive to oseltamivir is one 
that had not been considered previously.  From the differences in lung virus titers shown at 5 
mg/kg/day that appears that may be the case.  With the four viruses that we tested, three of the 
four do not show large reductions in virus titer from oseltamivir treatment.  The H1N1-infected 
mice are the only ones that show these large changes in titer even at low treatment doses.  
Analyzing the lung titers of mice infected with the H1N1 virus and treated with oseltamivir at 40 
mg/kg/day may clarify some of the results seen here.  
Two differences in mean lung virus titers were visible between the p-H1N1 and H3N2-infected 
mice and they were statistically significant (Figure 58.B).  The lung titers of the H3N2-infected 
mice were higher than lung virus titers of the p-H1N1-infected group at day 1 and at day 8 as 
well.  Lung titers from the H3N2-infected mice were also higher at day two although the 
differences were not significant.  On day 4, lung virus titers in p-H1N1-infected mice were higher 
than those in H3N2-infected mice, but not significantly higher.  Mean lung virus titers were nearly 
identical at day 6.  On day 8, the statistical difference was noticeable since the p-H1N1-infected 
mice did not have detectable titers while H3N2-infected mice still had detectable lung titers.  The 
small lung virus titer differences do not likely explain the fact that fourteen mice died with the 
H3N2 virus infection and none died from the p-H1N1 infection. At 5 mg/kg/day, it is clear that 
there is a unique aspect of the H3N2 virus as well that makes it more lethal than the p-H1N1 or 
H1N1 viruses.  So far, none of the characteristics that we have analyzed fully explains the 
differences that make the H3N2 and H5N1 viruses different than the two H1N1 viruses. 
 Comparison of the lung virus titers of the p-H1N1 and H5N1-infected mice 
following oseltamivir treatment at 5 mg/kg/day revealed very few differences between the two 
infected groups (Figure 58.C).  The titers were very close throughout the infection and the only 
day that was significant was day 8.  On that day, virus titers from the H5N1-infected mice were  
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Figure 58 Mean Lung Virus Titers for Influenza-Infected Mice Treated with Oseltamivir (5 
mg/kg/day).  A. Lung titers from p-H1N1-infected mice were higher than the lung titers from 
H1N1-infected mice at day 2 (P<0.01), 4 (P<0.001) and 6 (P<0.01).  Lung titers from H1N1-
infected mice were higher than lung titers from p-H1N1-infected mice at day 8 (P<0.001).  B. 
Lung titers from H3N2-infected mice were higher than the virus titers from p-H1N1-infected mice 
at day 1 (P<0.05) and day 8 (P<0.001).  C. Lung virus titers from H5N1-infected mice were higher 
than those from p-H1N1-infected mice at day 8 (P<0.001).  D. Lung titers from H3N2-infected 
mice were significantly higher than lung virus titers from H1N1-infected mice at day 1 and 2 
(P<0.001) as well as day 6 (P<0.01) and 8 (P<0.001).  E. Lung virus titers from H5N1-infected 
mice were significantly higher than those from H1N1-infected mice at day 1 (P<0.001), 4 
(P<0.05), 6 (P<0.01) and 8 (P<0.001).  F. Lung titers from H3N2-infected mice were higher than 
those from H5N1-infected mice at day 2 (P<0.01). 
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significantly higher than titers in p-H1N1-infected mice, since those were not detectable by 
day 8.  Lung virus titers were higher in the H5N1-infected mice than the p-H1N1-infected mice at 
day 1.  The difference was not large enough to be statistically significant.  It is hard to believe that 
the small difference in lung titers at day 1 would impact the difference in survival seen with these 
two viruses.  All of the p-H1N1-infected mice survived and while only six survived infection with 
the H5N1 virus.  It is not likely that lung virus titers could influence lethality so dramatically without 
some other factor that is significantly different between the p-H1N1 and H5N1 viruses.  
Oseltamivir treatment at 5 mg/kg/day does not dramatically impact the lung virus titers of mice 
infected with the p-H1N1 and the H5N1 virus so there must be other factors that also help in 
determining lethality in mice. 
 Mean lung virus titers of mice infected with the H1N1 and H3N2 viruses were compared 
following oseltamivir treatment at 5 mg/kg/day (Figure 58.D).  All of the differences in lung virus 
titers were significant with the exception of day 4.  The differences at day 1 and 2 were equal.  
The lung titers from H3N2-infected mice were about one half-log higher at day 4, but that 
difference was not statistically significant.  Lung titers from H3N2-infected mice were higher at 
day 6 as well as at day 8.  These differences explain, at least in part, why only one mouse 
survived when infected with H3N2 virus, but all the mice survived the H1N1 infection.  The large 
decreases in lung titers at days 1 and 2 are probably a large contributing factor to the survival 
differences.  The differences in mean body weight loss can likely be attributed to the difference in 
lung virus titers as well.   The ability of oseltamivir to reduce lung virus titers of H1N1-infected 
mice significantly more than the mice infected with the H3N2 virus was clearly visible here. 
 Treatment at 5 mg/kg/day produced differences between mean lung virus titers of H1N1 
and H5N1-infected mice that were significant at nearly every day post-infection (Figure 58.E).  
Lung virus titers from H5N1-infected mice were significantly higher than the titers from the H1N1-
infected mice at day 1, 4, 6, and 8.  The large statistical differences seen in lung virus titers also 
correlates to noticeable differences in survival and weight loss.  No mice died following infection 
with the H1N1 virus and weight loss was minimal even when treated with a lower dose of 
oseltamivir.  Nearly the same amount of mice died from the H5N1 infection regardless of the 
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oseltamivir treatment regimen.  The differences between these two viruses are at least 
partially explained by the lung virus titers.  It is not clear why oseltamivir does not reduce lung 
virus titers of the H5N1-infected mice as well as it does for the mice infected with the H1N1 virus. 
 Mean lung virus titers from mice infected with the H5N1 and H3N2 virus were notably 
similar following oseltamivir treatment at 5 mg/kg/day (Figure 58.F).  Titers were nearly identical 
at days 1, 4, 6 and 8.  The only difference that was significantly different was day 2.  The titers 
from the H3N2-infected mice were significantly higher than the titers from the H5N1-infected mice 
on day 2.  The mice infected with the H5N1 virus did not have detectable titers at day 10 and no 
mice survived the H3N2 infection until day 10.  There was a significant difference between the 
survival curves of these two viruses.  9 mice died from the H5N1 infection while 14 died from the 
H3N2 infection.  Apparently the differences in virus titer that most impact survival are in the first 
two days post-infection.  While lung virus titer certainly contributes to lethality of the viruses, there 
must be other factors that are impacting whether or not the mice survive infection.  
 
Mean Lung Virus Titers in Mice Treated with Oseltamivir (40 mg/kg/day) 
 Treatment with 40 mg/kg/day of oseltamivir revealed other differences between infected 
groups that were not seen in the prior treatments (Figure 59).  Comparison of lung virus titers was 
done by two-way ANOVA (Table A.90).   
 Comparison of the mean lung virus titers from the two H1N1-infected groups showed 
large differences following treatment with 40 mg/kg/day of oseltamivir (Figure 59.A).  The lung 
titers from p-H1N1-infected mice were higher than mean lung virus titers from H1N1-infected 
mice at days 1, 2, 4 and 6.  Neither group of infected mice had detectable titers of virus at days 8 
or 10.  Differences in the amount of virus varied from about one-half log at day 1 to nearly three 
logs at day 6.  Despite the large differences in virus titer, survival was not affected by the 
dramatic differences that were seen.  There was however a difference in body weight that could 
be attributed to the higher virus titers associated with the mice infected with the p-H1N1 virus.  
For the viruses that were tested it would appear that approximately a one log reduction in virus 
titers is sufficient to protect the mice from death but a more significant reduction is necessary to 
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prevent weight loss.  Both viruses seem to be readily cleared from the lungs since neither of 
them is detectable even at day 8 after infection. 
Lung virus titers in mice infected with the p-H1N1 and H3N2 viruses were compared 
following oseltamivir treatment at 40 mg/kg/day (Figure 59.B).  Lung titers from H3N2-infected 
mice were higher than the lung virus titers from p-H1N1-infected mice at day 1 and 8.  The early 
difference may help explain part of the difference between these two viruses.  The difference at 
day 1 is approximately one log lower for the p-H1N1-infected mice.  As seen previously, a large 
reduction is not necessary to alter survival.  Only three of the mice infected with the H3N2 virus 
succumbed to infection so the one log difference would seem appropriate given the outcomes 
from each infection.  There was also a difference seen at day 8 where lung titers were not 
detectable with the p-H1N1-infected mice but titers are still high in the mice infected with the 
H3N2 virus.  When compared to the H3N2 virus, the p-H1N1 virus is more easily cleared from the 
lungs of mice.  The difference between day 6 and day 8 were especially noticeable.  At day 6, p-
H1N1-infected mice actually had higher lung titers than those in H3N2-infected mice but they are 
completely eliminated in just two days.  These two differences in lung titers likely explain a 
substantial part of the differences seen between these two viruses. 
Lung virus titers from mice infected with the influenza p-H1N1 and H5N1 viruses were 
compared following treatment with oseltamivir at 40 mg/kg/day (Figure 59.C).  The lung virus 
titers from H5N1-infected mice were significantly higher than lung virus titers from p-H1N1-
infected mice at day 1 and also at day 8 and day 10.  In fact, the lung titers from H5N1-infected 
mice were higher at all points except day 6.  While the titers from H5N1-infected mice were higher 
at all of the days except one, the differences in lung titers were not extremely large.  This may be 
significant because the outcomes following treatment were extremely different.  All of the mice 
survived the p-H1N1 infection despite differences in lung titers that are only around one-half log 
higher in the H5N1-infected mice.  The most noticeable difference is that the p-H1N1-infected 
mice had a titer below detectable levels at day 8 post-infection.  As seen before, H5N1-infected 
mice have lung titers that remain visible even at day 10.  There is a noticeable difference in 
infection with the H5N1 virus that cannot be completely attributed to difference in lung titers.   
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Figure 59 Mean Lung Virus Titers in Influenza-Infected Mice Treated with Oseltamivir (40 
mg/kg/day).  A. Lung titers were higher in p-H1N1-infected mice compared to H1N1-infected 
mice at day 1 (P<0.05), 2 (P<0.01), 4 and 6 (P<0.001).  B. Lung titers in H3N2-infected mice 
were higher than titers in p-H1N1-infected mice at day 1 and day 8 (P<0.001).  C. Lung titers 
were higher in H5N1-infected mice than p-H1N1-infected mice at day 1 (P<0.01) and day 8 and 
10 (P<0.001).  D. Lung titers in H3N2-infected mice were higher than in H1N1-infected mice at 
day 1, 4, 6 and 8 (P<0.001).  E. Lung titers were higher in the H5N1-infected mice compared to 
the H1N1-infected mice at day 1, 2, 4, 6, 8 and 10 (P<0.001).  F. Lung titers in H5N1-infected 
mice were higher than in H3N2-infected mice at day 2 and 10 (P<0.01). 
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There is a fatal outcome with the mice infected with the H5N1 virus while the lung titers are 
not very different.  A similar amount of H5N1 virus has a significantly different outcome following 
treatment.  Mice also die more quickly when infected with the H5N1 virus without oseltamivir 
treatment.  The H5N1 virus is also more difficult to clear following infection.  The fact that lung 
virus titers from p-H1N1-infected mice are not largely altered by oseltamivir treatment helps to 
explain why the mouse body weights still decrease following infection.  It was surprising that 
similar lung virus titers from these two viruses resulted in markedly different survival curves.   
 Mean lung titers from mice infected with the H1N1 and H3N2 viruses were compared 
following oseltamivir treatment at 40 mg/kg/day (Figure 59.D).  Lung titers from H3N2-infected 
mice were significantly higher than lung virus titers from H1N1-infected group at day 1, 4, 6 and 8.  
The lung titers from mice infected with the H3N2 virus were higher at day 2 as well, but the 
difference was not statistically significant.  Neither infected group had detectable virus titers at 
day 10.  The average titer was roughly one and a half logs higher for the H3N2-infected mice 
compared to the H1N1-infected mice.  There was not a dramatic difference in survival between 
the two viruses but weight loss was significantly different.  Mice infected with the H3N2 virus lost 
weight following infection while the H1N1-infected mice gained weight comparable to uninfected 
mice.  In this case, the combination of survival and body weights is a good indicator of the effect 
of virus titer on disease severity.  Overall, the lung virus titer curves are very similar except that 
oseltamivir treatment considerably impacted the lung titers from H1N1-infected mice much more 
than the H3N2-infected mice.  Lung virus titers correlate fairly well with the severity of disease 
except that with increased severity is marked by relatively small changes in viral lung titers. 
 Mean lung virus titers were compared in mice infected with the H1N1 and H5N1 virus 
following oseltamivir treatment at 40 mg/kg/day (Figure 59.E).  As seen from both survival and 
changes in body weights, the outcomes after treatment were very different for the mice infected 
with these two viruses.  Differences in lung virus titers confirmed dramatic differences in each 
infected group’s response to oseltamivir.  The mean lung virus titers from H5N1-infected mice 
were significantly higher than the lung virus titers from H1N1-infected mice at all time points post-
infection.  This large decrease in lung virus titers with the influenza H1N1 virus makes sense 
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since all of the mice survived and body weight change was nearly identical to uninfected 
mice.  The most interesting point is that oseltamivir treatment, even at 40 mg/kg/day, did not 
completely eliminate viral production in the lungs. Most of the differences in lung titers between 
these viruses were approximately two logs lower for H1N1-infected mice.  It shows that a 
decrease of only two logs in virus titer will produce drastically different results in an influenza 
infection.  Virus is below detectable levels by 8 days after infection.  These viruses are an 
excellent example that complete reduction in virus titers is not needed to increase survival and 
minimize the impacts of infection.  The other question that remains unanswered is why 
oseltamivir is unable to lower lung virus titers of the H5N1-infected mice.  In cell culture and in the 
neuraminidase assay the H5N1 virus and the H1N1 virus appear equally susceptible to 
oseltamivir.  When used in vivo, the two viruses could not be more different. 
High-dose oseltamivir treatment did not create large differences in lung virus titers 
between the H5N1 and H3N2-infected mice (Figure 59.F).  Only two differences were statistically 
significant.  Higher lung titers were seen in the H5N1-infected mice than with the H3N2-infected 
mice on day 2 and day 10.  The highest dose of oseltamivir used did not significantly reduce titers 
with either of these viruses.  The differences are difficult to see when comparing the two viruses 
that show decreased susceptibility to oseltamivir but become more apparent when compared 
against the two H1N1 viruses.  The slight advantages in titer observed with the H5N1-infected 
mice are apparently important because eight mice died at this treatment dose.  The day 2 time 
point is probably significant since the higher titers make containment of the infection more difficult 
for oseltamivir.  Day 10 becomes significant because another difference between the two viruses 
becomes apparent.  Mice infected with the H3N2 virus do not have detectable titers of virus in the 
lungs by day 10 while mice infected with the H5N1 virus still have measurable titers at day ten.  
The H5N1 virus is more difficult to clear from the mouse lungs with oseltamivir treatment.   
When compared to the mice treated at 40 mg/kg/day oseltamivir, eleven more mice died 
from the H3N2 virus infection at 5 mg/kg/day.  The only titer that is markedly different is day two.  
Another interesting point from this comparison is that the H5N1 virus did not have detectable lung 
titers at day ten after treatment with 5 mg/kg/day.  When treated with 40 mg/kg/day, virus was still 
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obtained from lung samples at day ten.  Clearly for both of these viruses, a dose response to 
oseltamivir is not readily apparent.  Small differences in titers produce large changes in survival 
outcomes.  The fact that oseltamivir treatment does not reduce lung titers is noticeable with both 
of these viruses.  Other differences between the viruses must help account for the differences in 
survival seen with each virus. 
  Without testing more viruses, it is difficult to say which one is the “typical” influenza virus.  
Up to this point, the assumption was that the H1N1 virus was the standard influenza virus and 
that H5N1 and H3N2 viruses were uniquely different from H1N1 virus.  This hypothesis was 
based upon the differences in survival shown with each virus.  From the differences in lung virus 
titers and changes in body weight following infection, a new theory is plausible.  The p-H1N1 virus 
might be the typical influenza virus and that the H5N1 and H3N2 viruses are slightly less 
susceptible to oseltamivir than the typical flu virus while the H1N1 virus is uniquely sensitive to 
oseltamivir treatment in mice. 
 
Effects of Oseltamivir on Gross Lung Scores in Influenza-Infected Mice 
 
Gross Lung Scores in Mice Treated With Placebo 
 There were various differences observed in lung scores from placebo-treated mice 
infected with the four influenza virus strains (Figure 60).  Comparison of the lung scores was 
done by the Kruskal-Wallis test (Table A.91).  Since lung scores are nonparametric data, they 
must be evaluated using nonparametric tests.  Since the data from the initial study was not 
analyzed immediately following collection, the numbers of mice were not increased sufficiently for 
each group to make differences between infected groups visible using the Kruskal-Wallis test.  
None of the lung scores were significantly different from each other at any day.  We will still 
compare the differences in lung scores but acknowledge that none of the differences are 
significant.  The first treatment group that will be analyzed is the placebo-treated group.  This will 
establish a baseline that can then be compared with the addition of oseltamivir treatment.  On day 
1, no lung scores were visible in any infected mice.  On day 2, the only measurable lung scores  
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Figure 60 Gross Lung Scores in Influenza-Infected Mice Treated with Placebo.  None of the 
differences in gross lung scores were statistically significant. 
 
were observed in the H3N2-infected mice.  By day 4, the lung scores were highest in the H5N1-
infected group.  The second highest lung scores were seen in the H3N2-infected mice.  
Surprisingly, the lung scores from H1N1-infected mice were only slightly behind the H3N2-
infected mice.  The lung scores from p-H1N1-infected mice were the lowest of the infected groups 
on day 4.  On day 6, the lung scores from H5N1-infected mice were still the highest.  The second 
highest lung scores were seen in the H3N2-infected mice.  The lung scores from mice infected 
with the p-H1N1 and H1N1 were nearly equal to each other on day 6 and they were lower than 
both of the other infected groups.  Day 8 lung scores were approximately equal for the three 
remaining viruses since all the H5N1-infected mice had all succumbed to the infection.  On day 
10, only one mouse infected with p-H1N1 virus was still alive.  Without oseltamivir treatment we 
were able to observe differences between the H5N1 and H3N2-infected mice.  Despite the fact 
that the lung scores of the H3N2-infected mice were elevated more quickly than the H5N1-
infected mice, lung scores that did not seem to correlate with previously reported data was the 
increase in lung scores shown by H1N1-infected mice on day 4 compared to the mice infected 
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with the p-H1N1 virus.  It would be worthwhile to repeat this part to confirm its veracity, but 
the low dose of oseltamivir showed a similar trend.  If this were true, it would point towards the 
H1N1 virus being uniquely sensitive to oseltamivir.  Without oseltamivir, the H1N1 virus causes 
pathology more quickly than the p-H1N1 virus.  With oseltamivir, the H1N1 virus causes almost 
no pathology and does not cause weight loss in infected mice.  While identifying these differences 
is encouraging, lung scores are based upon one technician’s observations and are thus very 
subjective. 
 
Gross Lung Scores in Mice Treated With Oseltamivir (5 mg/kg/day) 
 Treatment with oseltamivir at 5 mg/kg/day greatly impacted survival but did not create 
large differences in the trends seen with the viruses from the higher treatment dose (61).  
Comparison was again done by utilizing the Kruskal-Wallis test (Table A.92).  None of the 
differences were statistically significant.  Mice infected with the H5N1 and H3N2 viruses showed 
gross pathological signs sooner than the p-H1N1 or H1N1-infected mice.  H3N2-infected mice 
were the only ones that showed a visible lung score on day 2.  On day 4, the H3N2-infected mice 
had the highest lung scores but were very close to the H5N1-infected mice.  The H1N1-infected 
mice had the third highest lung scores on day 4.  The p-H1N1-infected mice did not have 
measurable lung scores on day 4.  By day 6, the lung scores were highest in the H5N1-infected 
mice followed by the H3N2-infected mice.  These two groups clearly had elevated lung scores 
compared to the both of the groups infected with the H1N1 strains.  On day 6, the p-H1N1-
infected mice had detectable lung scores but the H1N1-infected group no longer had any lung 
scores.  On day 8, the differences are still clearly visible.  The H5N1 and H3N2-infected mice 
have the highest lung scores of the four infected groups.  The p-H1N1-infected mice have lung 
scores that are roughly half that of the other two groups.  The mice infected with the H1N1 virus 
had only minimal gross lung pathology.  On day 10, the H5N1-infected mice had the highest lung 
scores.  The H3N2-infected mice had all died by this time point.  The mice infected with the p-
H1N1 virus had lung scores that were slightly worse than those seen on day 8.  Very little gross 
lung pathology was observed in the H1N1-infected mice at day 10.  Treatment with a lower dose   
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Figure 61 Gross Lung Scores in Influenza-Infected Mice Treated with Oseltamivir (5 
mg/kg/day).  None of the differences in lung scores were statistically significant. 
 
of oseltamivir showed differences between the viruses that are indicative of the pathogenicity 
seen with each virus.  Differences in lung scores confirmed that the H5N1 and the H3N2 viruses 
are less impacted by treatment with oseltamivir and continue to damage lung tissue.  A difference 
between the two H1N1 strains was also observed with the lower treatment dose of oseltamivir.  
The p-H1N1 strain was able to cause more severe lung scores with oseltamivir treatment than the 
H1N1 virus.   
 
Gross Lung Scores in Mice Treated With Oseltamivir (40 mg/kg/day) 
 Treatment with oseltamivir at 40 mg/kg/day dramatically impacted gross lung scores of 
influenza infected mice (Figure 62).  The Kruskal-Wallis test was used for comparison of lung 
scores but no significant differences were seen (Table A.93).  Lung scores were not apparent 
until day 4.  On day 4, the lung scores were highest in the H5N1-infected mice followed by the 
lung scores from mice infected with the H3N2 virus.  No lung scores were observed in the mice 
infected with the p-H1N1 or the H1N1 virus.  On day 6, the lung scores in H5N1-infected mice  
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Figure 62 Gross Lung Scores of Influenza-Infected Mice Treated with Oseltamivir (40 
mg/kg/day).  None of the differences were statistically significant. 
 
were the highest of the infected groups.  For the first time, the lung scores in p-H1N1-infected 
mice were higher than the lung scores seen in H3N2-infected mice.  No lung scores were 
detectable in the mice infected with the H1N1 virus.  On day 8, the lung scores were the highest 
in the H5N1-infected mice but they were nearly equal to the lung scores observed in H3N2-
infected mice. The lung scores in p-H1N1-infected mice were the third highest of the four groups.  
The lung scores in H1N1-infected mice were very low and likely negligible.  At day 10, the lung 
scores of the H5N1 and H3N2-infected mice were equally severe.  The lung scores of the mice 
infected with the p-H1N1 virus were still the third highest.  The lung scores of the H1N1-infected 
mice were not measurable at day ten.  Differences in lung scores following treatment with 
oseltamivir confirmed findings from the lung virus titers.  Despite high dose oseltamivir treatment, 
the H5N1 and H3N2 viruses continue to produce pathological damage in the lungs.  There is a 
difference between the H5N1 and H3N2 viruses when compared to both of the H1N1 strains.  
With the H5N1 and H3N2-infected groups, oseltamivir treatment is unable to significantly alter 
mortality, weight loss, lung virus titers, or damage to the lung tissue.  Despite a dose of 
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oseltamivir that should be very effective, the mice continue to show signs of severe infection 
with those two strains of influenza. 
 
Effects of Oseltamivir Treatment on Lung Weights in Influenza-Infected Mice 
 
Lung Weights in Mice Treated With Placebo 
 As was seen with gross lung scores, treatment with placebo eliminated some of the 
differences that were seen with oseltamivir treatment (Figure 63).  Comparison was again done 
using the two-way ANOVA (Table A.94).   
When the lung weights from mice infected with the p-H1N1 and the H1N1 virus were 
compared, no significant differences were seen (Figure 63.A).  The lung weights from the mice 
infected with the H1N1 virus were slightly elevated compared to the lung weights from p-H1N1-
infected mice, but none of the differences were statistically significant.   
 Comparison of the lung weights from the mice infected with the p-H1N1 virus and the 
H3N2 virus only showed one significant difference (Figure 63.B).  The lungs from mice infected 
with the H3N2 virus were heavier than the lungs from mice infected with the p-H1N1 virus at day 
4.  This does indicate a slightly more severe infection with the H3N2 virus than the p-H1N1 virus 
and confirms the difference in lung weights that was observed in the initial study. 
When the lung weights from p-H1N1 and H5N1-infected groups were compared, only one 
significant difference was apparent (Figure 63.C).  On day 4, the lung weights from mice infected 
with the H5N1 virus were significantly higher than the lung weights from p-H1N1-infected mice.  
This shows that the infection produced by the H5N1 virus is more severe compared to the p-
H1N1 virus.   
 Comparison of the lung weights from the mice infected with the H1N1 and H3N2 viruses 
showed one significant difference between the two groups (Figure 63.D).  On day 4 again, the 
lung weights in H3N2-infected mice were significantly higher than the lung weights in H1N1-
infected mice.  This illustrates the increased severity of infection with the H3N2 virus that is  
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Figure 63 Lung Weights in Influenza-Infected Mice Treated with Placebo.  A. Lung weights in 
p-H1N1-infected mice were not significantly different than in H1N1-infected mice.  B. Lung 
weights in H3N2-infected mice were significantly higher than in p-H1N1-infected mice at day 4 
(P<0.05).  C. The lung weights were higher in H5N1-infected mice than in p-H1N1-infected mice 
at day 4 (P<0.001).  D. Lung weights were higher in H3N2-infected mice than in H1N1-infected 
mice at day 4 (P<0.05).  E. Lung weights were higher in H5N1-infected mice than in H1N1-
infected mice at day 4 (P<0.001).  F. Lung weights were higher in H5N1-infected mice than in 
H3N2-infected mice at day 6 (P<0.01).   
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present without oseltamivir treatment.  From this data, the H3N2 virus seems to be more 
pathogenic than the H1N1 virus. 
 The lung weights in mice infected with the H1N1 virus as well as the H5N1 virus only 
showed one significant difference between groups (Figure 63.E).  At day 4, lung weights in H5N1-
infected mice were significantly higher than lung weights in H1N1-infected mice.  This is a clear 
indicator that the H5N1 virus is more pathogenic than the H1N1 virus.  The severity of the 
infection is also demonstrated by the fact that the mice infected with the H5N1 virus all died by 
day 10. 
 The lung weights in H3N2 and H5N1-infected mice were compared following placebo 
treatment (Figure 63.F).  The lung weights in the H5N1-infected mice were higher than the lung 
weights in the H3N2-infected mice at day 6.  The differences in lung weights show some of the 
differences between these two viruses that were not visible with the lung scores or lung virus 
titers.  This might explain why the H5N1 virus appears to be less susceptible to oseltamivir 
treatment in mice than the H3N2 virus. 
 
Lung Weights in Mice Treated With Oseltamivir (5 mg/kg/day) 
When mice were treated with a 5 mg/kg/day oseltamivir regimen, the lung weights of the 
infected groups were altered depending on the virus strain used for infection (Figure 64).  
Comparison of the lung weights of infected groups was done by two-way ANOVA (Table A.95).  
No statistical comparison was done at day ten because all of the mice infected with the H3N2 
virus had already succumbed to infection.   
The lung weights in the p-H1N1-infected mice were higher than the lung weights seen in 
the H1N1-infected mice (Figure 64.A).  Differences were observed starting at day 4, but only day 
6 was statistically significant.  This is slightly different than the comparison of the same two 
infected groups with the placebo.  Lung weights in both infected groups were comparable when 
treated with placebo.  When treated with oseltamivir at 5 mg/kg/day, the lung weights were 
reduced more dramatically in the H1N1-infected mice than in the p-H1N1-infected mice.  
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Figure 64 Lung Weights in Influenza-Infected Mice Treated with Oseltamivir (5 mg/kg/day).  
A. Lung weights were higher in p-H1N1-infected mice than in H1N1-infected mice at day 6 
(P<0.05).  B. Lung weights were higher in H3N2-infected mice than in p-H1N1-infected mice at 
day 4, 6 and 8 (P<0.001).  C. Lung weights were higher in H5N1-infected mice than in p-H1N1-
infected mice at day 4, 6 and 8 (P<0.001).  D. Lung weights were higher in H3N2-infected mice 
than in H1N1-infected mice at day 4, 6 and 8 (P<0.001).  E. Lung weights were higher in H5N1-
infected mice than in H1N1-infected mice at day 4, 6 and 8 (P<0.001).  F. Lung weights in H3N2-
infected mice were not significantly different from those in H5N1-infected mice at any time point. 
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Lung weights in H3N2-infected mice were heavier when compared to the p-H1N1-
infected mice at all time points (Figure 64.B).  The only significant increases in lung weights in the 
H3N2-infected mice were observed on day 4, 6, and 8.  This is indicative of a more severe 
infection with the H3N2-infected mice compared to the mice infected with the p-H1N1 virus.  Day 
10 would likely have continued the same trend, however, none of the H3N2-infected mice 
survived that late in the infection. 
The lung weights in H5N1-infected mice were heavier than the lung weights in p-H1N1-
infected mice at all 6 days (Figure 64.C).  The lung weights in H5N1-infected mice were 
significantly higher than the lung weights in p-H1N1-infected mice at day 4, 6, and 8.  This is 
evidence of a more severe infection caused by the H5N1 virus.  Oseltamivir treatment revealed 
more differences between the infected groups than were seen with the placebo treatment. 
Lung weights in H1N1 and H3N2-infected mice were compared following oseltamivir 
treatment at 5 mg/kg/day (Figure 64.D).  The lung weights in H3N2-infected mice were 
significantly higher than the H1N1-infected mice at day 4, 6, and 8.  The H3N2 virus is capable of 
producing a more severe infection in mice than the H1N1 virus.  The lung weights make sense 
when considered along with the lung virus titer data as well as the survival curves.  Mortality is 
observed earlier with the H3N2 virus compared to the H1N1 virus and this is reflected with the 
low dose oseltamivir treatment.  
 The lung weights in mice infected with the H1N1 and H5N1 virus were compared after 
treatment with oseltamivir at 5 mg/kg/day (Figure 64.E).  Lung weights in H5N1-infected mice 
were significantly higher than the lung weights in mice infected with the H1N1 virus at day 4, 6, 
and 8.  This is very similar to the trend that was seen with the H3N2-infected mice.  Clearly, the 
H5N1 virus is less affected by oseltamivir treatment than the H1N1 virus.  Lung weights in the 
H1N1-infected mice stay very close to those observed in uninfected controls.  No large increases 
in lung weights due to consolidation and inflammation are observed in the H1N1-infected mice.  
In stark contrast to what was seen with the H1N1-infected mice, the lung weights in the H5N1-
infected mice more than double following infection. 
 162 
 Lung weights in H3N2 and H5N1-infected mice were not significantly different at any 
time point (Figure 64.F).  When treated with 5 mg/kg/day of oseltamivir, the lung weights in the 
mice infected with the H3N2 and H5N1 viruses were similar.  This makes sense when correlated 
with the survival data.  The survival was similar for each group of mice so it would make sense 
that the lung weights would increase in approximately the same manner.  
  
Lung Weights of Mice Treated With Oseltamivir (40 mg/kg/day) 
 Lung weights of influenza-infected mice were compared following oseltamivir treatment at 
40 mg/kg/day (Figure 65).  Comparison by two-way ANOVA revealed many differences between 
the infected groups (Table A.96).  Lung weights at day 1 were not significantly altered which is 
not surprising that early in the infection.  All 10 days were compared because enough mice 
survived from each group to allow a valid comparison at all time points. 
 The lung weights increased more in the p-H1N1-infected mice than in the H1N1-infected 
mice (Figure 65.A).  The increase in lung weights was significant at day 6, 8, and 10.  This is 
significant because it shows a difference between the mice infected with the p-H1N1 virus and 
the mice infected with the H1N1 virus.  The p-H1N1 virus produces a more severe infection and 
lung weights increase despite the higher dose of oseltamivir that was used to treat the mice.  All 
the mice survived the infection so the oseltamivir was able to protect the mice from mortality.  The 
lung weights in the H1N1-infected mice remained constant throughout the infection and did not 
increased above the lung weights seen in uninfected mice. 
 Lung weights of the H3N2-infected mice increased following infection more than the lung 
weights of p-H1N1-infected mice (Figure 65.B).  The only significant difference in lung weights 
was observed on day six where the lung weights in H3N2-infected mice were significantly higher 
than those from p-H1N1-infected mice.  Treatment with the highest dose of oseltamivir showed 
more similarity between the two infected groups than was expected.  This may be somewhat 
explained by the fact that the survival between these two infected groups was fairly similar. 
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Figure 65 Lung Weights in Influenza-Infected Mice Treated with Oseltamivir (40 
mg/kg/day).  A. Lung weights were higher in p-H1N1-infected mice than in H1N1-infected mice 
at day 6 (P<0.01), 8 and 10 (P<0.001).  B. The lung weights were higher in H3N2-infected mice 
than in p-H1N1-infected mice at day 6 (P<0.001).  C. Lung weights were higher in H5N1-infected 
mice than in p-H1N1-infected mice at day 2 (P<0.05), 6 (P<0.001), 8 (P<0.001) and 10 (P<0.01).  
D. Lung weights were higher in H3N2-infected mice than in H1N1-infected mice at day 4, 6, 8 and 
10 (P<0.001).  E. Lung weights were higher in H5N1-infected mice than in H1N1-infected mice at 
day 4, 6, 8 and 10 (P<0.001).  F. The lung weights were higher in H5N1-infected mice than in 
H3N2-infected mice at day 8 (P<0.01). 
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The lung weights in H5N1-infected mice were compared to the lung weights in the p-
H1N1-infected mice after oseltamivir treatment at 40 mg/kg/day (Figure 65.C).  The lung weights 
in H5N1-infected mice were significantly higher than the lung weights in the mice infected  
with the p-H1N1 virus at day 2, 6, 8, and day 10.  This is not surprising given the dramatically 
different outcomes following infection with each virus.  All the mice survived the p-H1N1 infection 
while eight died from the H5N1 infection.  It is actually surprising that the lung weights of the p-
H1N1-infected mice increased as much as they did since no mortality was observed at this 
treatment dose. 
 Lung weights were compared in the mice infected with the H1N1 and H3N2 virus 
following oseltamivir treatment at 40 mg/kg/day (Figure 65.D).  The lung weights in H3N2-infected 
mice were significantly higher than the lung weights in H1N1-infected mice at day 4, 6, 8 and 10.  
The H3N2 virus is less affected by oseltamivir treatment than the H1N1 virus.  It does seem 
surprising that the lung weights are so different between these two infected groups when there is 
such a small difference in survival.   
 Lung weight in mice infected with the H5N1 and H1N1 virus were evaluated after 
oseltamivir treatment at 40 mg/kg/day (Figure 65.E).  The lung weights in H5N1-infected mice 
were significantly higher than the lung weights in mice infected with the H1N1 virus at day 4, 6, 8 
and 10.  This indicates that the H5N1 infection is more severe than the H1N1 infection.  The 
greater increase in lung weights was expected following the H5N1 infection since the survival 
curves and weight loss were so different between the two infected groups.   
 Lung weights in mice infected with the H3N2 virus were very similar to the lung weights in 
the H5N1-infected mice throughout the infection (Figure 65.F).  The only significant difference 
between the two infected groups was seen on day 8.  The lung weights in H5N1-infected mice 
were significantly higher than the lung weights in H3N2-infected mice.  No other differences in 
lung weights were significant.  This shows that the H5N1 infection is slightly more severe than the 
H3N2 infection when treated with 40 mg/kg/day of oseltamivir.  This is also not surprising since 
more mice died following the H5N1 infection than the H3N2 infection.   
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Conclusions 
 
Survival 
All four sets of infected mice died with the placebo treatment.  This confirmed that 
adjustment of the virus dilutions ensured that all viruses achieved 100% lethality.  In placebo-
treated mice, only the survival curve for the H5N1-infected mice was significantly different.  One 
of the first initial questions that we had when starting this study was about the amount of virus 
used to create 100% lethality with all four of the virus strains.  We narrowed the focus of the 
research down to two options.  The first was to compare differences between the virus strains 
when infecting with equal amounts of virus.  The second option was to compare differences 
between the viruses when infecting with different infectious doses of each virus that were 
necessary to achieve the same outcome.  We decided to pursue the second option.  We decided 
to ignore the difference in the amounts of virus initially used for infection and compare differences 
based upon a 100% lethal infection for each virus.  While some mice survived the initial study, we 
adjusted the dilutions enough to get the same outcome from each infection in the second study.  
We also used identical infecting volumes in the second study to remove the amount of volume 
used to infect the mice as a possible cause for differences between the infected groups.  All of 
this data supports the idea that stimulated the research that we completed.  Mice infected with the 
H3N2 and the H5N1 viruses often suffer mortality following oseltamivir treatment when compared 
with either of the H1N1 virus.  As far as survival curves were concerned, both of the H1N1-
infected groups were the same although other differences were seen with the parameters that 
were measured following infection. 
When oseltamivir treatment was added at 5 mg/kg/day, all H1N1 infected mice survived.  
Nine of fifteen H5N1-infected mice died from infection.  The H3N2 virus appeared to be the least 
affected by treatment since fourteen of fifteen mice died.  With the lower dose of oseltamivir 
treatment, the survival curves of the mice infected with the H5N1 virus and the H3N2 virus were 
significantly different.  That makes sense given that all the mice infected with the two H1N1 
strains survived the infection. 
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Survival curves for the four viruses were significantly altered by oseltamivir treatment.  
With the 40 mg/kg/day treatment, all mice infected with p-H1N1 and H1N1 viruses survived the 
infection.  Two of fifteen mice infected with H3N2 died following treatment.  Eight of fifteen mice 
infected with H5N1 died with this treatment regimen.  Only the H5N1 survival curve was 
significantly different from the others.   
 
Mean Day of Death 
 Placebo treated mice confirmed findings observed in the first study we performed.  This 
was valuable since the first study had survivors that were not counted towards mean day of death 
but did not allow comparison with equal outcomes following infection.  Mice infected with the 
influenza H5N1 virus had a significantly earlier mean day of death in the placebo treated mice.  
This confirmed the hypothesis that the H5N1 virus has a unique advantage over the other 
viruses.  It is able to kill mice more quickly and thus treatment with oseltamivir has less time to 
help the mice overcome the infection. 
Following treatment with oseltamivir at 5 mg/kg/day, none of the mice infected with the p-
H1N1 and H1N1 viruses suffered mortality.  Without mortality, a mean day of death was not 
determinable.  Despite nine mice suffering mortality from the H5N1 infection and fourteen from 
the H3N2 infection, the mean days of death were not significantly different.   
When treated with oseltamivir at 40 mg/kg/day, none of the mice infected with the p-
H1N1 and H1N1 viruses suffered mortality.  Due to this fact, a mean day of death was undefined 
for these two groups.  The differences in mean day of death between the mice infected with the 
H5N1 and H3N2 viruses were not evaluated since only two mice died from the H3N2 infection.   
 
Mean Body Weight Loss 
Placebo treated mice all lost weight in a nearly identical manner.  None of the viruses 
were visibly different from the others.  It is interesting that when treated with placebo, the 
percentage of body weight loss is very similar for every infected group.  Treatment with 
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oseltamivir reveals differences between the viruses that were not observed with the placebo 
treatment. 
When treated with 5 mg/kg/day of oseltamivir, the highest percentage of weight loss was 
seen with the H3N2-infected mice.  The second largest amount of weight loss was seen with the 
H5N1-infected mice.  One mouse survived the H3N2 infection and rapidly gained weight the last 
six days of infection.  This weight gain by one mouse largely altered the statistical significance of 
that infected group.  The H5N1-infected mice lost weight at a rate very similar to the higher 
treatment dose.  The weight loss was very similar with the p-H1N1-infected mice in a manner that 
was nearly identical to the 40 mg/kg/day treatment.  The H1N1-infected mice lost very little weight 
compared to uninfected mice.  Again, weight loss was only significant when the H5N1 and H3N2-
infected groups were compared to the H1N1-infected group.   
At 40 mg/kg/day of oseltamivir, differences in mouse body weight for each virus were 
clearly seen.  The greatest change in body weight loss was seen in the H5N1-infected mice.  The 
second biggest change in percentage of initial body weight was observed in the H3N2-infected 
mice.  The third largest change in percentage of initial body weight was seen in the mice infected 
with the p-H1N1 virus.  When treated with oseltamivir at 40 mg/kg/day, the weight loss seen in 
H1N1-infected mice was nearly identical to uninfected mice.  The only changes in percentage of 
initial body weight that were significantly different after comparison by one-way ANOVA were the 
mice infected with the H5N1 and H3N2 virus.  Both of those groups showed a significantly 
different change in body weight following infection compared to the H1N1-infected group. 
 
Lung Virus Titers 
Treatment with placebo showed similar lung virus titers in all infected groups.  
Differences were limited to one or two days and lung titers were not dramatically different from 
the other infected mice.  Lung virus titers from the placebo-treated mice did not sufficiently 
explain the differences in survival outcomes.   
When treated with oseltamivir at 5 mg/kg/day, the H1N1 virus appeared uniquely 
sensitive to oseltamivir treatment.  Even at the lower treatment dose, lung titers were significantly 
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reduced throughout infection.  The lung virus titers from mice infected with the p-H1N1 virus 
were only slightly decreased by oseltamivir treatment.  The lung virus titers from mice infected 
with the H5N1 and H3N2 virus showed virtually no reduction in titer following treatment. 
 Comparison of lung virus titers following oseltamivir treatment at 40 mg/kg/day showed 
differences especially early and late in the infection.  Lung virus titers were not dramatically 
decreased following oseltamivir treatment in any of the infected groups except one.  The lung 
virus titers of H1N1-infected mice were severely reduced following the 40 mg/kg/day treatment of 
oseltamivir.  This shows an impact on lung virus titers that is only seen with the H1N1-infected 
group.  Differences in lung virus titers also showed that H3N2 and H5N1 infections persisted for a 
longer duration in the mice as well.  Lung virus titers were still detectable at day ten for both of 
those infected groups.  Lung virus titers were not detected in either of the H1N1-infected groups 
by day 10.  It appears that oseltamivir allows the H1N1 viruses to be cleared from the lungs more 
rapidly than the other two viruses. 
 
Lung Scores 
In placebo-treated mice, the H5N1 and H3N2 were capable of inducing more lung tissue 
damage in mice than either of the H1N1 viruses.  Placebo treated mice also showed that higher 
lung scores were observed the H1N1-infected mice at day 6 compared to the lung scores 
observed in p-H1N1-infected mice.  This is significant because it shows that the H1N1 virus 
causes more lung damage in mice without oseltamivir treatment.  This supports the idea that the 
H1N1 virus is uniquely sensitive to oseltamivir.  When treated with oseltamivir, the H1N1 virus 
seems to be uniquely affected as seen by reductions in lung virus titers, lung scores, and lung 
weights. 
When treated with oseltamivir at 5 mg/kg/day, a pattern emerged.  The lung scores 
observed in the H5N1 and H3N2-infected mice were clearly higher than the lung scores seen with 
the H1N1-infected and p-H1N1-infected mice.  The lung scores in the p-H1N1-infected mice were 
lower than the lung scores from the H5N1 and H3N2-infected mice but the lung scores from the 
H1N1-infected mice were still the lowest of all the infected groups. 
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 Analysis of gross lung scores after 40 mg/kg/day oseltamivir treatment showed that 
lung scores observed in the H5N1 and H3N2-infected mice and were different than the lung 
scores from the H1N1-infected mice.  Lung scores from the oseltamivir-treated mice remained 
very close to the lung scores seen with the placebo-treated mice and were able to cause lung 
tissue damage despite treatment, but only in the mice infected with the H5N1 and H3N2 viruses.  
Both of those infected groups also showed gross lung scores that increased earlier in the 
infection.  
 Differences in lung scores showed differences between each of the viruses but none of 
the differences were statistically significant because of the nonparametric data.  Lung scores 
indicated that oseltamivir has a greater impact on the lung scores in the H1N1-infected mice 
compared to the other infected groups.  The lung scores in p-H1N1-infected mice were the 
second most affected by oseltamivir treatment.  Lung scores from the H5N1 and H3N2-infected 
mice were not dramatically affected by oseltamivir treatment. 
 
Lung Weights 
For the most part, placebo treatment masked many of the differences that were apparent 
following oseltamivir treatment.  Lung weights were similar for all of the infected groups when 
they were treated with the placebo. 
 Treatment with oseltamivir at 5 mg/kg/day reinforced the observations noted from the 
lung scores where the highest lung scores were seen in the H3N2 and H5N1-infected mice.  The 
lung weights increased in the groups infected with the H5N1 and H3N2 viruses when treated with 
oseltamivir.  The lung weights from the p-H1N1-infected mice decreased slightly following 
oseltamivir treatment at 5 mg/kg/day.  The lung weights decreased in H1N1-infected mice when 
treated with the lower dose of oseltamivir. 
Treatment with oseltamivir at 40 mg/kg/day illuminated some of the differences between 
the viruses.  Higher lung scores were observed in the H3N2 and H5N1-infected mice.  Higher 
lung scores mean there will be more inflammation and consolidation of lung sample, thus 
increasing lung weights.  The lung weights of mice infected with the H5N1 and H3N2 viruses 
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were the highest out of all the infected groups.  The lung weights in p-H1N1-infected mice 
showed very slight reductions after treatment with the high dose of oseltamivir.  The lung weights 
in H1N1-infected mice were similar to uninfected mice when treated with oseltamivir at 40 
mg/kg/day. 
Lung weights correlated well to the severity of the infection as indicated from the survival 
curves.  The highest lung weights were seen in the H5N1-infected mice that also suffered the 
most mortality.  The lung weights in H5N1-infected mice were the highest even following 
treatment.  The lung weights in H3N2-infected mice were the second highest among the infected 
groups and also suffered the second most mortality among treated groups.  The lung weights in 
p-H1N1-infected mice were slightly reduced following treatment.  Lung weights in H1N1-infected 
mice were similar to lung weights in uninfected mice.  This shows a trend that oseltamivir is able 
to prevent the increase in lung weights from consolidation and inflammation in the H1N1-infected 
mice.  Even though changes in lung weights were observed later in the infection, changes in lung 
weights were important because the differences were statistically significant.  Lung titers from the 
infected mice showed that oseltamivir was only able to significantly reduce titers in the H1N1-
infected mice.  Lung scores showed a more severe infection with the H3N2 and H5N1-infected 
mice, but none of the differences were statistically significant.  Lung weights were valuable 
because the theory of a more severe infection with the H3N2 and H5N1 viruses was confirmed 
with statistically significant values.  Lung scores could become significant if the number of mice 
were increased to a level to observe significant differences.  The lung weights of infected mice 
increased a full day earlier in mice infected with the H3N2 and H5N1 virus.  This supports the 
idea that a more rapid influenza infection is more severe and more difficult to treat with 
oseltamivir. 
 Treatment with oseltamivir significantly increased differences in survival, lung titers, lung 
scores, and lung weights that were previously quite small.  Large differences with survival could 
not be directly correlated with any other large differences from any of the measured parameters.  
What did become apparent is that only the H1N1 virus displays a dose-response to oseltamivir 
treatment.  The other three viruses are altered by treatment with oseltamivir but not in a way that 
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can be directly linked to the dose.  We began this work under the assumption that the H5N1 
and the H3N2 viruses were more resistant to oseltamivir treatment in mice.  While this may be 
partially true, we now also hypothesize that the H1N1 virus may be uniquely sensitive to 
oseltamivir treatment.  This means that p-H1N1 is a more “typical” influenza virus with the H1N1 
being slightly more susceptible to oseltamivir treatment and the H3N2 and H5N1 viruses being 
susceptible to oseltamivir treatment.  The H1N1 virus was isolated in 1933 and has been used 
extensively in research laboratories since then.  Even though it is still commonly used today, it 
may not be the best virus to use as a model for the viruses that are currently circulating in the 
population.  Influenza viruses continually evolve to continue to infect new individuals.  Whether or 
not an isolate from nearly 80 years ago is a good model should be a standard question for any 
animal model.  While viruses such as the H1N1 are still valuable for a proof of concept, any 
current antiviral therapy should be tested fully against more recent strains of viruses to determine 
give the best possible understanding of the efficacy of the treatment.  Oseltamivir may work very 
well against a virus isolated 80 years ago, but may be less effective at treating the seasonal virus 
to which we will likely be exposed.     
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CHAPTER VIII 
EFFECTS OF OSELTAMIVIR ON LUNG HISTOPATHOLOGY 
 
Histological Lesion Scoring 
 
 The initial experiment determined that the histological lesion score would be a valuable 
tool to measure the efficacy of oseltamivir.  Since the histopathology results were difficult to 
compare directly, a rough conversion of the lesion scores was made to convert the descriptive 
value to a numerical value.  This conversion was not done by the pathologist and thus may have 
possible errors.  One possible error is that it was created after the fact and thus was based upon 
my own interpretation of a certified pathologist’s findings.  Another possible error was that the 
findings weighted based solely upon severity of the finding.  Thus severe luminal cellular debris, 
which might be considered a less serious symptom, was equally weighted with severe necrosis of 
bronchiolar epithelial cells, a more severe sign of disease.  To correct this problem in the second 
study, we asked Dr. Ramona Skirpstunas of the Utah Veterinary Diagnostic Lab to score each 
sample using a numerical value based upon severity of disease.  She created a scoring table on 
a scale of 0 to 6 displaying increasing disease severity.  All samples were categorized into the 
numerical value associated with the signs that were observed.  This system had several 
advantages.  The first was that it was employed at the beginning of the second experiment so all 
infected mice were compared on the same scale.  Second, it was created by a pathologist and 
thus did not suffer from a lack of knowledge of histopathological signs may have introduced error 
into the initial study.  The following scoring values are taken directly from the report sent by Dr. 
Skirpstunas. 
 A score of zero indicated that no significant histologic lesions were visible.   
A score of one was called “mild inflammation” and was linked to small numbers of 
neutrophils in scattered airways.  Moderate aggregates of neutrophils were seen adjacent to 
scattered small airways.   
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A score of two was termed “moderate inflammation” and showed moderate numbers 
of neutrophils and fewer lymphocytes surround peribronchiolar vessels.  Scattered airways 
contain neutrophils.   
A numerical value of three was called “moderate inflammation with epithelial necrosis” 
and had widely scattered individual necrotic bronchiolar epithelial cells lining the smaller airways.  
Mild to moderate numbers of nuetrophils and lymphocytes surrounded scattered bronchioles and 
peribronchiolar vessels. 
“Moderate inflammation with increased epithelial necrosis” was given a value of four.  
This meant that many smaller bronchioles have segmental groups of necrotic lining epithelial 
cells.  Some also contained luminal plugs of necrotic cellular debris.  Moderate numbers of 
neutrophils and lymphocytes surrounded affected bronchioles and associated vessels. 
A value of 4A, converted to a numerical value of 4.25, was labeled as “moderate 
inflammation with bronchiolar lining cell attenuation and mild necrosis”.  These samples showed 
marked attenuation of bronchiolar lining epithelium and scattered necrosis of individual epithelial 
cells in many smaller airways.  Small amounts of luminal cellular debris were seen.  Moderate 
numbers of neutrophils and lymphocytes surrounded affected bronchioles and associated 
vessels.   
A value of 4.5 was also labeled 4B and was identified as “severe inflammation with 
bronchiolar lining cell attenuation and mild necrosis”.  Marked attenuation of bronchiolar lining 
epithelium and scattered necrosis of individual remaining epithelial cells in many of the smaller 
airways were visible.  Small amounts of luminal cellular debris were found.  Moderate numbers of 
neutrophils and lymphocytes surrounded affected bronchioles and associated vessels.  Large 
groups of associated alveoli contained sheets of neutrophils or evenly scattered macrophages 
and neutrophils. 
 A score of 4C was converted to 4.75 and was indicative of “moderate inflammation with 
severe bronchiolar epithelial necrosis”.  These findings showed many smaller bronchioles that 
contained luminal plugs of necrotic cellular debris and have segmental groups of necrotic lining 
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epithelial cells.  Moderate to heavy peribronchiolar and perivascular neutrophilic and 
lymphocytic infiltrates with mild edema were seen as well. 
 A histologic score of 5 was named “moderate alveolitis with scattered smaller bronchioles 
lined by attenuated cells and bands of luminal fibrin”.  Markedly attenuated epithelial cells lined 
many smaller bronchioles and bands of fibrin covered bronchiolar walls.  Mild to moderate 
numbers of neutrophils were evenly scattered in airspaces (alveoli).  Other bronchioles were lined 
by normal epithelium as well as those lined by attenuated cells contained small amounts of 
luminal neutrophils.  Moderate numbers of lymphocytes and fewer neutrophils surrounded small 
vessels associated with necrotic bronchioles.   
 The highest value was a 6 and was identified as “Moderate alveolar inflammation, 
marked alveolar fibrin accumulation and small bronchioles lined by attenuated cells and bands of 
luminal fibrin”.  Markedly attenuated epithelial cells lined many smaller bronchioles and bands of 
fibrin covered bronchiolar walls.  Mild to moderate numbers of neutrophils and macrophages were 
evenly scattered in airspaces (alveoli).  In addition, there were marked lamellar accumulations of 
alveolar fibrin (hyaline membranes).  Other bronchioles lined by normal epithelium as well as 
those lined by attenuated cells contained small amounts of luminal neutrophils.  Moderate 
numbers of lymphocytes and fewer neutrophils surrounded small vessels associated with necrotic 
bronchioles. 
 Each sample was given a score according to this standard and was then compared for 
statistical differences.  Again, the Kruskal-Wallis test with Dunn’s multiple comparisons was used 
to determine if there were any significant differences in histological lesion scores between 
infected groups.  As with the prior study, because of the difficulty with analysis of nonparametric 
data that was not anticipated, there were not any significant differences in the histological lesions 
scores in influenza-infected mice. 
 
Lesion Scores in Mice Treated with Placebo 
 When treated with placebo, differences between virus strains are still apparent from the 
lesion scores that were seen (Figure 66).  Analysis of lesion scores by the Kruskal-Wallis test did  
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Figure 66 Histological Lesion Scores in Influenza-Infected Mice Treated with Placebo.  
Despite differences in lesion scores among the infected groups, none of the differences in 
histological lesion scores were statistically significant. 
 
not show any significant differences (Table A.97).  With placebo-treated mice, the histological 
lesion scores were the highest in the H3N2-infected mice on the day 1.  This is surprising since 
the H3N2 virus seems to be more susceptible to oseltamivir treatment yet the histological lesion 
scores are more severe in the H3N2-infected mice than in the H5N1-infected mice.   
On day 2, the histological lesion scores in the mice infected with the H3N2 and H5N1 
viruses were higher than the lesion scores from the mice infected with the p-H1N1 and H1N1 
viruses.   
By day 4, the histological lesion scores were similar for all the infected groups with the 
exception of lesion scores in the p-H1N1-infected mice.  The lesion scores from that particular 
group of mice were lower at day 4 than the other infected groups.   
At day 6, the histological lesion scores were roughly the same for all infected groups.  
Technically, the lesion scores were the highest in the H5N1-infected mice, followed by the H1N1-
infected mice with the lesion scores from the H3N2-infected mice and p-H1N1-infected mice 
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slightly lower than the other two groups.  It is interesting that when treated with placebo, the 
lesions scores are approximately equal this late in the infection. 
At day 8, the highest histological lesion scores were seen in the H1N1-infected mice 
while the lesions scores from the p-H1N1 and H3N2-infected mice were much lower.  All of the 
mice infected with the H5N1 virus had already died from the infection, so there weren’t any 
samples available for analysis from the H5N1-infected group.   
Only one infected group had any mice that survived until day 10.  Of the five mice 
infected with the p-H1N1 virus, one survived until day 10 and the histological lesion score of that 
mouse was very low.  This likely indicates that the virus was never able to effectively infect that 
particular mouse.  By day 10, the lesion score should have been much higher if the mouse was 
still alive this late in the infection. 
 
Lesion Scores in Mice Treated with Oseltamivir (5 mg/kg/day) 
 Following oseltamivir treatment at 5 mg/kg/day, differences in the histological lesion 
scores were more apparent (Figure 67).  However, none of the differences were statistically 
significant after analysis using the Kruskal-Wallis test (Table A.98).  The same difference in lesion 
scores that was noted with the placebo-treated mice was seen here as well.  Lesion scores were 
higher in the H3N2-infected mice than all three other infected groups.  This is somewhat 
surprising, but maybe not entirely unexpected.  The survival from the groups treated with 5 
mg/kg/day of oseltamivir was the lowest in H3N2-infected mice.  This shows that despite drug 
treatment, the infection progresses more rapidly in the mice infected with the H3N2 virus. 
 On day 2, the lesion scores were identical in the mice infected with the H3N2 and H5N1 
viruses.  Lesion scores seen in the mice infected with the p-H1N1 and H1N1 viruses were less 
than half as severe as those seen from the other two infected groups.  This seems to fit perfectly 
with the results that were seen in both the survival and weight loss data from the same groups of 
mice.  Even the lower treatment dose of oseltamivir is able to lower the lesion scores in mice 
infected with either of the H1N1 strains, but does not seem to be able to affect the lesion scores 
in mice that were infected with the H3N2 and H5N1 viruses. 
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Figure 67 Histological Lesion Scores in Influenza-Infected Mice Treated with Oseltamivir (5 
mg/kg/day).  Even with the visually dramatic differences in lesion scores of infected mice, none 
of the differences in lesion scores were statistically significant.   
 
On day 4, the lesion scores stayed approximately the same as the lesion scores seen on 
day 2 with the exception of the scores from the p-H1N1-infected mice that increased moderately 
between day 2 and 4.  This also correlates well with the weight loss data that showed a more 
severe infection in the mice infected with the p-H1N1 virus compared to the mice that were  
infected with the H1N1 virus.  Day four was important because it shows where the p-H1N1 virus 
starts to distinguish itself from the H1N1 virus. 
On day 6, the lesion scores were approximately equal for the mice infected with the p-
H1N1, H3N2, and H5N1 viruses.  The group that stands out as different from the others is the 
H1N1-infected group.  The lesion scores in mice infected with the H1N1 virus were much lower 
than the histological lesion scores from the other infected groups.  Even oseltamivir treatment at 5 
mg/kg/day is sufficient to contain the infection in H1N1-infected mice.  This supports the theory 
that the H1N1 virus is different from the other three strains and may be uniquely sensitive to 
oseltamivir treatment in mice. 
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 At first glance, the lesion scores on day 8 appear similar to those from day 6.  
However, this seems to be a turning point for the infected groups.  The lesion scores in mice 
infected with the H3N2 and H5N1 viruses actually get slightly worse on day 8 while the lesion 
scores in the p-H1N1-infected mice start to improve.  This shows that the oseltamivir has been 
effective in the p-H1N1-infected mice as they have survived the worst part of the infection and 
start to heal and will all eventually survive the infection.  The lesion scores in the H3N2 and 
H5N1-infected mice are already fairly severe and the increase shown at day 8 pushes them that 
much closer to a fatal outcome.  Lesion scores from the H1N1-infected mice remain very close to 
those that were seen at days 2, 4 and 6.   
 On day 10, the histological lesion scores give a good approximation of the survival 
outcomes previously observed.  No lesion scores were available from the H3N2-infected groups 
since all the mice had succumbed to the infection.  The histological lesion scores were the most 
severe in the H5N1-infected mice since any that survived until day 10 would likely die within a 
very short time period.  Between day 8 and 10, the lesion scores of the p-H1N1-infected mice 
drop significantly and were very similar to the lesion scores seen in the mice infected with the 
H1N1 virus.  The lesion scores at day 10 showed the differences between the virus strains.  
Lesion scores were either extremely high in the H3N2 and H5N1-infected mice or were extremely 
low in the p-H1N1 and H1N1-infected mice 
 
Lesion Scores in Mice Treated with Oseltamivir (40 mg/kg/day) 
 Comparison of histological lesion scores following oseltamivir treatment at 40 mg/kg/day 
helped elucidate the differences between the four groups of infected mice (Figure 68).  However, 
none of the differences were significant after comparison with the Kruskal-Wallis test (Table 
A.99).  Treatment with oseltamivir at 40 mg/kg/day reduced some of the differences in histological 
lesion scores that were seen at day 1.  In all the infected groups, the lesion scores were lower at 
day 1.  The lesion scores were roughly the same for all the infected groups except the lesion 
scores in the H1N1-infected mice were slightly lower than the lesion scores from the other 
infected groups. 
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Figure 68 Histological Lesion Scores of Influenza-Infected Mice Treated with Oseltamivir 
(40 mg/kg/day).  Though there were some large differences in the lesion scores of the infected 
groups, none of the differences were statistically significant. 
 
The largest difference in lesion scores was seen at day 2.  The lesion scores in the H3N2 
and H5N1-infected mice were markedly higher than the lesion scores from mice infected with the 
p-H1N1 and H1N1 virus.  It is interesting that even with the higher dose of oseltamivir, the lesion 
scores from the mice infected with the H3N2 and H5N1 viruses still increase to nearly the same 
levels observed when treated with placebo.  Clearly, those two viruses are significantly more  
virulent and are still able to cause destruction of lung tissue when treated with oseltamivir.  Day 2 
showed the biggest separation of lesion scores among all infected groups. 
 On day 4, the lesion scores remained nearly the same in mice infected with the H3N2 
and H5N1 viruses while they increased moderately in the mice infected with the p-H1N1 and 
H1N1 viruses.  The lesion scores in the H1N1-infected mice reached a peak at day 4 and then 
started to decrease. 
 The lesion scores in the p-H1N1-infected mice were at their highest at day 6.  The scores 
from the p-H1N1-infected mice were nearly as high as the lesion scores from the mice infected 
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with the H3N2 and H5N1 viruses.  The lesion scores in the H1N1-infected group had already 
started to decline by day 6.  This shows that the H1N1-infected mice are beginning to overcome 
the infection while lesion scores are still increasing in the other three infected groups.   
 Day 8 was when the lesion scores from the p-H1N1-infected mice began to decrease 
while the lesion scores from the H3N2 and H5N1-infected mice increased slightly.  As with the 
treatment at 5 mg/kg/day, the separation between survival and a fatal outcome occurred on day 
8.  This time point seems to be significant.  If the mice are able to survive the infection, the lesion 
scores should be decreasing by this time.  If the histological lesion scores remain high or increase 
on day 8, the mice will likely not survive the infection. 
 The lesion scores of infected mice at day 10 reflected the severity of the infections with 
each virus strain.  Lesion scores were highest in the H5N1-infected mice followed closely by the 
lesion scores of the H3N2-infected mice.  The lesion scores were much lower in the mice infected 
with the p-H1N1 and H1N1 viruses.  This makes sense when considering that all of the mice 
infected with either strain of the H1N1 virus survived the infection.  It is interesting that the lesion 
scores in the H5N1-infected mice increased again on day 10 while the lesions scores in the 
H3N2-infected mice decreased slightly.   
 
Conclusions 
 
Following treatment with placebo, there are still differences between the viruses.  
Surprisingly, the highest lesion scores were seen in the H3N2-infected mice but the lesion scores 
of the H5N1-infected mice were nearly equal by the day 2.  Day 2 showed that the lesion scores 
were highest in the mice infected with the H3N2 and H5N1 viruses when compared with the 
lesion scores from mice infected with the p-H1N1 and H1N1 viruses.  This fact likely explains a 
large portion of the decreased susceptibility to oseltamivir observed with these two viruses.  The 
ability of these two viruses to cause increased tissue destruction early in the infection allows them 
to cause enough lung tissue damage to remain lethal despite oseltamivir treatment.  The exact 
mechanism that allows these two viruses to cause increased pathological damage is unclear.  As 
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discussed previously with the 1918 pandemic influenza virus, it is probably a collection of 
traits rather than one specific gene or feature of the viruses.  Regardless of the exact reason for 
the differences, the H3N2 and H5N1 viruses are especially lethal due to the increased tissue 
destruction that they are able to cause within the first 48 h of infection. 
Oseltamivir treatment at 5 mg/kg/day helped illuminate some of the differences between 
these four viruses. The lesion scores in mice infected with the p-H1N1 virus increased from day 1 
until day 6 and then started to decrease as the mice were able to overcome the infection.  Lesion 
scores in H1N1-infected mice increased until day 4 but were always below a value of two.  
Treatment with even 5 mg/kg/day of oseltamivir seemed to minimize the amount of tissue 
destruction associated with the H1N1 infection.  The histological lesion scores in mice infected 
with the H3N2 virus were high even starting at day 1 but then increased at every day post-
infection until no mice survived at day 10.  The lesion scores in H5N1-infected mice were very low 
at day 1 but increased dramatically at day 2 and increased steadily until day 10.  The low dose 
treatment with oseltamivir helped separate the differences in tissue damage caused by each virus 
strain. 
 Treatment with oseltamivir at 40 mg/kg/day further highlighted the differences between 
these four virus strains.  Starting at day 2, it is clear that oseltamivir cannot prevent tissue 
damage in the mice infected with the H3N2 and H5N1 viruses.  The lesion scores from the mice 
infected with the p-H1N1 virus showed a similar trend to that seen at the lower treatment dose.  
The lesion scores increased from day 1 until 6 and then began to decrease throughout the 
remainder of the infection.  The same trend was seen with the H1N1-infected mice only on a 
smaller scale.  Lesion scores in H1N1-infected mice increased from day 1 to day 4 but decreased 
on days 6 through 10.  With the higher treatment dose of oseltamivir, the lesion scores in the 
H3N2-infected mice seemed to be impacted at day 1.  Lesion scores in H3N2-infected mice 
increased significantly at day 2 and remained high until day 10.  The histological lesion scores in 
H5N1-infected mice increased at a steady rate throughout the infection.  It was interesting that 
the lesion scores from the H5N1-infected group increased even up until the last day that was 
measured.  
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A difference that seems to be confirmed in this study is that the H1N1 virus is unique 
in its susceptibility to oseltamivir treatment.  The lesion scores from the H1N1-infected mice are 
very low when treated with oseltamivir, however when placebo treated, the lesion scores are 
higher in the H1N1-infected mice than in the p-H1N1-infected mice at days 4 and 6.  The lesion 
scores from the p-H1N1-infected mice do show a dose response to oseltamivir but are still much 
higher than the lesion scores in the H1N1-infected mice.  This data seems to support the idea, 
that the p-H1N1 virus is the more typical influenza virus and H1N1 is remarkably sensitive to 
oseltamivir treatment.  This would need to be confirmed with testing of the same parameters with 
additional virus strains to completely verify these findings.  Testing multiple strains of influenza in 
the same format could determine whether the viruses show a susceptibility to oseltamivir 
treatment that is more similar to the H1N1 virus or the p-H1N1 virus. 
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CHAPTER X 
FINAL CONCLUSIONS AND FUTURE RESEARCH 
 
In Vitro Studies 
 
Replication Kinetics 
 While there were significant differences from the in vitro replication kinetics, they were not 
extremely large and were mostly differences observed very early post-infection.  A lack of 
differences between the two viruses that seem to be susceptible to oseltamivir and those that 
seem less susceptible kept the replication kinetics from being very useful.  None of the viruses 
were capable of producing significantly higher titers in MDCK cells when compared to each other.  
The true impact of the slight differences in virus titers in the first 24 h is difficult to ascertain.  The 
fact that the H3N2 and H5N1 virus produce higher titers in the first day post-infection may help 
them produce a more lethal infection in mice. 
 
Neuraminidase Inhibition Assay 
 The neuraminidase inhibition assay confirmed that all four viruses neuraminidase 
enzymes are in fact inhibited by oseltamivir.  There is not a significant resistance inherent in any 
of the viruses that were tested.  The neuraminidase EC50 of the H5N1 virus was significantly 
different from the EC50 of the other three viruses.  Even that difference was relatively small and 
the H5N1 virus would not be considered resistant to oseltamivir by the neuraminidase assay.  
That slight difference might give the H5N1 virus a potential advantage when treated with 
oseltamivir, as the virus would be less affected by treatment and thus better able to cause tissue 
destruction in mice. 
 
Antiviral Assay 
 While it does not always correlate well with effectiveness in mice, oseltamivir was 
capable of providing protection against viral cytopathic effects in cell culture antiviral studies.  
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Though it is not always conclusive, in conjunction with the neuraminidase inhibition assay it 
shows that the viruses are all susceptible to oseltamivir.  The data obtained from this study was 
somewhat contradictory since it showed that the p-H1N1 virus was the least affected by 
oseltamivir.   
 
In Vivo Studies 
 
Typical Mouse Parameters 
 An initial mouse experiment was run to assess possible differences between the viruses 
and to refine parameters that could be used when oseltamivir treatment was added as a factor.  
Survival curves were significantly different for the mice infected with the H5N1 virus.  This 
experiment was somewhat flawed since different volumes were used to infect with the p-H1N1 
virus and a few mice survived both the H1N1 and H3N2 infections.   For the second experiment, 
virus dilutions were equilibrated to achieve 100% mortality in all the placebo-treated mice.   
The mean day of death of H5N1-infected mice was also significantly different from the 
mean day of death of the other three infected groups.  While the cause is for this is not clear, the 
H5N1 virus is capable of killing mice more quickly than the other three viruses.   
The weight loss curves demonstrated by each of the infected groups were not 
significantly different.   
Lung virus titers for each of the viruses varied slightly but did not seem to explain any 
large differences between viruses.  The mean lung titers were higher early in the infection in the 
mice infected with the H3N2 and H5N1 virus but other groups were capable of producing higher 
titers throughout the infection.   
Lung scores were higher in the mice infected with the H5N1 and H3N2 viruses compared 
to the scores from mice infected with p-H1N1 and H1N1 viruses.  While these differences are 
encouraging, lung scores are very subjective and based on gross examination of the lungs.  The 
other problem with lung scores is that they are nonparametric data and none of the differences 
were statistically significant.   
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Lung weights mirrored the differences seen with lung scores but were beneficial 
because the lung weights were comparable by two-way ANOVA.  Lung weights increased more 
dramatically in the mice infected with the H3N2 and H5N1 viruses indicating a more severe 
infection.   
 
Complete Blood Count 
 A complete blood count was done for each virus on days one through six post-infection to 
determine if there are any characteristics visible in the CBC that might be useful in tracking 
disease severity with influenza viruses or that might explain the differences in oseltamivir 
sensitivity.  A few parameters were identified that might be interesting to monitor in future studies 
such as lymphocyte count or the granulocyte, but none of the data was deemed useful to track in 
conjunction with oseltamivir treatment.  Some of the parameters were altered by infection but the 
effects were approximately equal for all of the infected groups and did not seem to be more or 
less severe in any particular infected group.     
 
Cytokines 
 Influenza infections stimulate a profound inflammatory response in the lungs of infected 
mice.  A number of pro-inflammatory and anti-inflammatory cytokines were higher following 
infection.  Cytokines were measured to determine if there was a significant difference in the host 
response to each virus.  Specifically, we looked for a pronounced “cytokine storm” where the 
more lethal viruses would produce significantly higher levels of pro-inflammatory cytokines that 
supposedly lead to excessive tissue damage.  No evidence of a cytokine storm was seen in mice 
with any of the viruses that were used for infection.  However, IL-1α was found in significantly 
higher levels in H3N2-infected mice at day 1 compared to all other groups.  This suggests a more 
rapid and severe infection associated with the H3N2 virus.  Levels of IL-1β were significantly 
higher in mice infected with the H3N2 and H5N1 virus compared to the mice infected with the p-
H1N1 virus and the H1N1 virus, but that difference was limited to day 1.  Those large increases at 
day 1 suggest that the H3N2 and H5N1 viruses are inducing a more profound response in the 
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mice compared to the other virus strains.  Levels of IL-6 showed a similar trend and were 
significantly higher in mice infected with the H3N2 and H5N1 viruses at day 1.  The levels of IL-6 
in the p-H1N1-infected and H1N1-infected mice were much lower at day 1, perhaps showing a 
less severe initial response to infection.  After day 1 however, the IL-6 levels were the highest in 
the p-H1N1-infected mice at day 2, 3 and 4.  This might suggest a beneficial inflammatory 
response for the host that aids in survival and clearance of the virus.  Levels of MIP-1α were 
higher at day 1 in the mice infected with the H3N2 and H5N1 viruses than in the mice infected 
with the p-H1N1 and H1N1 viruses.  Levels of RANTES were significantly higher in mice infected 
with the p-H1N1 and H1N1 viruses from day 2 until day 6.  This appears to be beneficial to the 
host because all of the mice survive following treatment with oseltamivir. 
 
Histopathology 
 Histopathological lesion scores of infected mice appear to be important because they 
showed increased lung tissue damage by the two viruses that were less susceptible to 
oseltamivir.  The results had to be converted to a numerical value to be analyzed statistically.  
Because this was done after the fact, the scores likely did not reflect actual disease severity but 
did give ideas on how to refine the study for use with oseltamivir treatment.  This part of the 
experiment proved invaluable for development of the rest of the study.  The possible errors in the 
first histopathology study allowed the development of a standardized scoring table of samples 
created by an expert that was more accurate than the initial attempt. 
 
In Vivo Studies with Oseltamivir Treatment 
 
Survival 
 Survival curves varied greatly depending on oseltamivir treatment for each virus.  All 
placebo treated mice died following infection achieving 100% lethality with all four virus strains.  
The survival curve for the H5N1-infected mice was significantly different from the other three 
survival curves.   
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With 5 mg/kg/day of oseltamivir, all mice survived the p-H1N1 and H1N1 infections.  
Nine mice died from the H5N1-infection but fourteen died from the H3N2 infection with the lower 
treatment dose of oseltamivir.  This was surprising since we assumed the H5N1-infected mice 
would have a lower survival compared to the H3N2-infected mice.  The survival curves of the 
H3N2-infected and H5N1-infected mice were significantly different from the survival curves of the 
mice infected with the p-H1N1 and H1N1 viruses. 
With oseltamivir treatment at 40 mg/kg/day, eight mice died from H5N1 infection with the 
high dose of oseltamivir while only two died from H3N2 infection.  Again, all the mice infected with 
the p-H1N1 and H1N1 viruses survived the infection.  The only survival curve that was 
significantly different from the others was from the H5N1-infected mice.  Despite oseltamivir 
treatment, mice infected with the H5N1 virus still succumb to the infection.  This may be due to 
the ability of the H5N1 virus to cause disease before oseltamivir has a chance to protect the mice.   
 
Mean Day of Death 
 Placebo treatment mice confirmed that the mean day of death of the H5N1-infected mice 
was significantly earlier than the mean day of death than the other infected groups.   The other 
infected groups were not significantly different from each other.   
Comparison of the mean day of death with the 5 mg/kg/day oseltamivir treatment was 
valid for the mice infected with the H5N1 and the H3N2 viruses, but the mean days of death were 
not significantly different.   
With the 40 mg/kg/day treatment of oseltamivir, an insufficient number of mice suffered 
mortality to allow comparison of the mean days of death.   
 
Weight Loss 
 Mouse body weight was slightly impacted by oseltamivir treatment.  Without oseltamivir, 
the weight-loss curves were nearly identical for all four infected groups.  Mice lost weight at a very 
similar rate according to the day post infection.  No significant differences were seen in the 
amount of weight lost in infected mice.   
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Oseltamivir treatment at 5 mg/kg/day initially showed the most severe weight loss in 
the mice infected with the H5N1 virus as well as the mice infected with the H3N2 virus.  The 
weight loss seen in the H3N2 mice would have likely been more severe except the mouse that 
survived returned to near normal weight over the final 6 days of the experiment.  This is one of 
the limitations of the one-way ANOVA measurement that was utilized for analysis of this 
parameter.  Mice infected with the p-H1N1 virus also lost weight following infection but at a rate 
between the one seen with the H5N1-infected mice and the H1N1-infected mice.   
At 40 mg/kg/day all of the infected mice lost weight with the exception of those infected 
with the H1N1 virus.  The most significant weight loss was seen in the H5N1-infected mice 
followed by the H3N2-infected mice.  The mice infected with the p-H1N1 virus lost weight at a 
rate roughly in the middle of the H1N1-infected group and the H5N1-infected group.  The loss in 
body weight seemed to characterize the severity of disease fairly well at the highest dose of 
oseltamivir.  
 
Lung Virus Titers 
Without treatment the lung virus titers were all fairly similar which was seen previously.  
None of these viruses seem to have an advantage in mice when they are not treated with 
oseltamivir.  Similar virus titers were seen at each time point with each virus strain that was used. 
At 5 mg/kg/day of oseltamivir, a similar trend was seen with each infected group.  The 
only lung titers that were noticeable impacted by oseltamivir treatment were seen in the mice 
infected with the H1N1 virus.  Again small differences were visible early and late in the infection, 
but nothing that seemed conclusive.   
Oseltamivir treatment at 40 mg/kg/day only greatly affected the titers of the H1N1-
infected mice.  Lung virus titers of the mice infected with the H5N1 and H3N2 viruses remained 
largely unaffected by oseltamivir.  Lung titers from the p-H1N1-infected mice were reduced 
slightly throughout the ten days that were measured.  The lung titers of the H1N1-infected mice 
were greatly reduced when compared to the titers of placebo-treated mice.  There were small 
differences within the first two days or the last days of infection, but nothing seemed to explain 
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the differences in oseltamivir sensitivity, especially since the titers of the p-H1N1-infected 
mice were very close to the titers seen in mice infected with the H5N1 and H3N2 viruses.   
 
Gross Lung Score 
When treated with placebo, the differences in the lung scores of infected mice were 
minimized and compressed into a short time frame.  The lung scores from mice infected with the 
H3N2 virus were visible on day 2 when lung scores were not seen in any other infected group.  
The gross lung scores were the highest in the H5N1-infected mice followed by the H3N2-infected 
mice.  That same pattern was seen on day 6 as well.  Despite lack of statistical significance from 
the lung scores, a trend was observed that indicates a more severe infection in the H5N1-infected 
mice as well as the H3N2-infected mice. 
With the addition of oseltamivir treatment at 5 mg/kg/day, the trend was still visible.  The 
lung scores were highest in the mice infected with the H5N1 and H3N2 viruses.   This was 
especially noticeable at day 4, 6 and 10.   
Even at 40 mg/kg/day of oseltamivir, the lung scores in mice infected with the H5N1 and 
H3N2 viruses were consistently higher than the lung scores in mice infected with the p-H1N1 
virus as well as the H1N1 virus.  Though they are subjective and did not show any statistical 
differences between infected groups, the gross lung scores are a good indicator of the severity of 
infection associated with each virus.   
 
Lung Weights 
In placebo treated mice, the lung weights increased more in the H3N2 and H5N1-infected 
mice.  The most notable effect was seen at day 4 where the lungs from the mice infected with the 
H3N2 and H5N1 viruses were significantly heavier than the lungs from mice infected with the p-
H1N1 and H1N1 viruses. 
Treatment with 5 mg/kg/day of oseltamivir helped to identify the differences between 
each virus strain.  The lung weights from H3N2 and H5N1-infected mice continued to increase 
according to the day post-infection while the lung weights from p-H1N1 and H1N1-infected mice 
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did not increase at the same rate that was seen with the placebo treatment.  Oseltamivir is 
able to lessen the amount of consolidation and inflammation in the lungs of mice infected with 
either of the H1N1 strains but is not as beneficial to the mice infected with the H3N2 and H5N1 
viruses.   
A similar trend was observed following treatment with oseltamivir at 40 mg/kg/day.  The 
lung weights from mice infected with the p-H1N1 virus and the H1N1 virus did not increase as 
dramatically after infection as did the lung weights from mice infected with the H3N2 and H5N1 
viruses.  Lung weights correlated well with the severity of the infection but take longer to show 
differences. 
 
Histopathology 
The first study led to a more accurate system of measuring lung pathology that could still 
be visualized and analyzed statistically.  Use of a standard scoring system shed light on the 
differences between these four viruses. 
Placebo-treated mice showed that higher histological lesion scores are seen in the H3N2-
infected mice earlier on in the infection.  Histological lesion scores are consistently higher in the 
mice infected with the H3N2 and H5N1 viruses.  This was observed early in the infection since 
histological lesions scores are roughly equal in all infected groups at the later parts of the 
infection. 
When H1N1-infected mice were treated with oseltamivir at 5 mg/kg/day, the ability of 
oseltamivir to prevent tissue destruction was observed.  The histological lesion scores in H1N1-
infected mice are the lowest of the infected groups at each day that was measured.  Again, the 
highest histological lesion scores were seen in the H3N2-infected mice but the lesion scores 
observed in the H5N1-infected mice are nearly equal by day 2.  From this data the difference 
between p-H1N1 and H1N1 virus is even more apparent since histological lesion scores from the 
p-H1N1-infected mice are higher at every day post-infection when compared to the H1N1-
infected mice.  
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When treated with oseltamivir at 40 mg/kg/day, the early tissue damage caused by 
the H3N2 virus was not visible.  However, the histological lesion scores from the H3N2 and 
H5N1-infected mice are higher at every time point than the lesion scores from the mice infected 
with the p-H1N1 and H1N1 viruses.  This remained true throughout the infection.  The differences 
in histological lesion score are a direct indicator of disease severity and it became clear that a 
more rapid and severe infection is seen with the H3N2 and H5N1 viruses.  These results also 
made the differences between the p-H1N1 and H1N1 viruses more visible.  While the mice do 
survive the p-H1N1 infection, histological lesion scores increase more than those seen in the 
H1N1-infected mice.  This lends credibility to the theory that the H1N1 virus is more susceptible 
to oseltamivir treatment in mice than any of the other viruses.   
 
Final Results 
 
Despite large differences in survival outcomes when treating with oseltamivir, comparison 
of four different virus strain yielded results that were remarkably similar for most of the 
parameters that were measured with the four viruses.  Small differences were seen at individual 
times for many of the parameters that were tested.  Overall, one virus was not dramatically 
different than any of the others.  It appears that survival of an influenza infection is a very fine line 
and it does not take a large difference to push the mice to one side or the other.  A relatively 
small change in a few factors can create a much more lethal outcome in an influenza infection.   
There were not large differences in the amount of weight loss seen in infected mice.  With 
placebo-treated mice, weight loss was approximately equal.  The only differences in the 
percentage of weight loss were seen after treatment with oseltamivir. 
Lung virus titers were similar both in vitro and in vivo with the exception of the lung titers 
seen in the H1N1-infected mice treated with 40 mg/kg/day of oseltamivir.  Oseltamivir was only 
able to greatly impact the lung virus titers of mice infected with the H1N1 virus and that was only 
at the higher dose of oseltamivir.   
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The most conclusive evidence was seen in the lung scores and lung weights of the 
infected mice.  Lung scores increase more quickly in the mice infected with the H5N1 and H3N2 
viruses.  Both of these viruses seem to have a distinct advantage to create more pathology early 
on in the infection and thus become more lethal viruses.  The exact difference that makes these 
two viruses more lethal is unknown and likely a summation of all of the characteristics of each 
virus.  Lung weights showed a similar trend in the infected mice.  Lung weights were significantly 
higher in the mice infected with the H3N2 and H5N1 viruses, indicative of more consolidation and 
inflammation with both of these viruses.  The histopathology report reinforced the trends that 
were seen with gross lung scores and lung weights.  The H3N2 and H5N1 viruses are capable of 
causing more severe lung tissue damage early in the infection that leads to a more lethal infection 
with these two viruses. 
While not proven definitively, it appears that the H1N1 virus is uniquely sensitive to 
oseltamivir treatment.  To prove whether this is the case or not, the experiments would need to be 
repeated with additional viruses to see whether those viruses would be more or less sensitive to 
oseltamivir.  It would be interesting to use a few different strains that are genetically different from 
each other to determine whether most influenza viruses are more similar to the H1N1 virus or to 
the p-H1N1 virus.  It would make sense that the H1N1 virus is the most sensitive to oseltamivir 
since it is the oldest isolate that was used.   
 
Discussion 
 
As one of the few FDA approved antiviral drugs available for the treatment of influenza, 
oseltamivir remains an important subject of research in labs throughout the world.  Oseltamivir 
remains the primary antiviral therapy that is stockpiled and conserved in the event of a pandemic 
influenza outbreak.  While there have been many studies that focus on the effectiveness of 
oseltamivir in treating influenza infections in mice and ferrets, most of these studies focus on the 
ability of viruses to become resistant to oseltamivir.  Very few studies have been done showing 
that viruses that are supposedly sensitive to oseltamivir remain lethal in animal models at the 
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standard treatment regimen.  I was only able to find two such studies in the literature.  The 
first study was performed at St. Jude’s Children’s Research Hospital and focused on five different 
clades of H5N1 viruses and the differences in mortality following a standard oseltamivir treatment 
(29).  The second was done at Utah State University and was the basis for this research (69).   
The first study, performed by Elena Govorkova and others, compared the five H5N1 
viruses in the neuraminidase assay but did not do any other in vitro assays to determine potential 
differences between the viruses.  In vivo, they compared survival, as well as lung and brain titers 
from infected mice following oseltamivir treatment.  They also analyzed six cytokines to determine 
differences in host response to the virus as well as genetic sequencing of the viruses that were 
used for infection of the mice.  Though the concepts are similar, there were some significant 
differences between our studies and those performed by Elena Govorkova.  We compared four 
different virus strains rather than using five different clades of one strain.  We also compared 
virus replication in MDCK cells and an antiviral assay in addition to the neuraminidase assay.  
While in vitro results cannot always be correlated to in vivo efficacy, we did show that none of the 
viruses had an inherent advantage to replicate more quickly or the ability to generate much higher 
titers than the other viruses.  Rather than testing the six cytokines that are commonly impacted by 
influenza infections, we used a cytokine array that allowed us to profile sixteen different cytokines 
throughout the infection.  We were able to conclude that for the viruses that we used, a “cytokine 
storm” does not play a critical role in the infection in the mouse model.  Govorkova also identified 
that one of the factors that may affect pathogenicity could be the ability of the virus to infect the 
brain.  This has been seen to a limited extent in mice and may be unique to the high 
pathogenicity avian influenza viruses.  Some of the strains that were used in Govorkova’s studies 
were unable to produce a lethal infection in ferrets, even when infected with very high titers of 
virus.  We were able to show that, even when all viruses were capable of producing a lethal 
infection, there are still significant differences in the pathogenicity of certain viruses that make 
them more difficult to treat with oseltamivir.  Another factor that may play a part in the 
pathogenicity of influenza viruses is the tropism for either the sialic acid α2,6 galactose receptors 
or the sialic acid α2,3 galactose receptors.  Ferrets express a higher amount of α2,6 receptors 
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that more closely mimic the lower respiratory tract in humans.  Mice have not been shown to 
express α2,6 receptors and this may impact the pathogenicity of certain influenza strains in mice 
(35).  The importance of either α2,3 or α2,6 receptors in relationship to the pathogenicity of 
influenza viruses was not done in our study or Govorkova’s and could be beneficial to 
understanding the mechanisms surrounding influenza infections.  We also noted differences each 
virus’ ability to cause lung tissue damage in mice.  Results from the histopathology, while not 
conclusive, suggest that the H5N1 and H3N2 viruses share an ability to cause a severe infection 
a full 24 h before the H1N1 and p-H1N1 viruses.  Lung scores, lung weights, and histological 
lesion scores all confirmed a more rapid and severe infection in the mice infected with the H3N2 
and H5N1 viruses.  Besides the lung virus titers, the impact of influenza infection on the lung 
tissue of ferrets was not noted in Govorkova’s study. 
The study performed by Don Smee and others, noted the lack of effectiveness of 
oseltamivir in a study that primarily focused on the combination of oseltamivir with T-705 to treat 
influenza infections.  Differences in survival noted in that study prompted the majority of the 
questions that we tried to answer in our studies.  We were able to confirm a difference in the 
mean day of death in the H5N1-infected mice relative to the infected groups.  We also saw similar 
results regarding the ability of oseltamivir to prevent a lethal infection in mice infected with the 
H3N2 and H5N1 viruses.  We were able to discover more of the differences between virus strains 
than just the initial difference in survival with oseltamivir treatment. 
The neuraminidase assay is the standard that is employed to determine the resistance to 
oseltamivir shown by the new seasonal influenza isolates.  It was not known if the neuraminidase 
assay would be effective in predicting the efficacy of oseltamivir in vivo.  Many host factors can 
affect the outcome of the infection that cannot be determined by an in vitro assay.  The results of 
this research show that the neuraminidase assay accurately predicts the sensitivity of each virus 
to neuraminidase inhibitors, but sensitivity to oseltamivir does not guarantee effectiveness in vivo.  
The impact of influenza infections on the CBCs of mice has not been previously reported.  
While we were looking for different host reactions to the viruses that we were unable to find, we 
did find a few measurements from the CBC that may be useful in tracking the severity of influenza 
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infection in mice.  Measuring the CBC at many more time points for a longer infection could 
give more insight into the factors that help determine whether or not an infection is lethal in mice.   
 
Directions for Future Research 
  
As with nearly all research, the data that we found seemed to uncover more questions instead of 
answering the questions that we already had.  Many of the findings would provide an adequate 
starting point for future research and could be beneficial to our understanding of influenza viruses 
and infections.   
 The first potential area of research is the link between the neuraminidase assay and the 
ability to protect mice from a lethal influenza infection.  While we did see significant difference in 
the EC50s of each virus in the neuraminidase assay, how much does that difference in EC50 
values ultimately impact the ability of oseltamivir to contain the viral infection?  Does a three-fold 
difference in EC50s from the neuraminidase assay significantly alter the ability of oseltamivir to 
prevent a lethal outcome?   
 Another direction for future research would be to discover the actual mechanism that 
allows the H5N1 and H3N2 viruses to cause more lung tissue damage earlier than the other 
viruses.  What makes these viruses different from the H1N1 and p-H1N1 viruses?  Is there a 
unique feature common to the H3N2 and H5N1 virus that allow them to infect the lung tissue 
more quickly or more effectively that would give them an advantage in the mouse model?  In fact, 
it may be appropriate to ask if the differences between these viruses are really valid.  Are the 
results that were seen with the lung score and histological lesion scores real?  If so, can statistical 
significance be seen in the lung scores and histological lesion scores?  If we increased the 
number of samples in a future study, would those differences in lung scores and histological 
lesion scores become statistically significant with a sufficient number of mice?   
One avenue that we did not address in our study was the affinity of each virus for a 
specific surface receptor.  Does each virus have a preference for either the α2,3 or α2,6 
galactose receptor that might alter the area of the lungs that is infected with each virus?  Though 
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the α2,6 is not seen in the respiratory epithelium of mice, does a preference for that receptor 
alter the ability of each virus to infect the lung tissue of mice?   
One idea that was talked about but was not realized in this study was the development of 
an assay to measure the spread of influenza virus in the lungs of mice.  Does one of the viruses 
have an ability to spread more quickly or perhaps deeper into the respiratory tract, causing a 
more severe infection?  Can the spread of influenza virus in the lungs be adequately measured 
and characterized? 
The last direction of future research relates to the role of cytokines in influenza infection.  
Though we did not see evidence of a “cytokine storm”, we did note that infection with different 
strains of influenza virus generates a different cytokine profile in mice.  What is the role of 
cytokines in influenza infection?  What level of each cytokine represents a beneficial reaction to 
the influenza virus?  Is there a point when the cytokines do reach levels that cause an excessive 
inflammatory event?  Is a strong induction of cytokines evidence of a “cytokine storm” or just a 
normal healthy response to a severe infection?  Does weak induction of cytokines show that the 
infection is being contained or is the virus simply evading immune detection and causing 
additional damage without being recognized?  What is the impact of oseltamivir on the levels of 
cytokines produced following an influenza infection?  Does oseltamivir reduce the levels of 
cytokines because it reduces the viral loads, or is there another mechanism of oseltamivir that 
perhaps affects the immune response in some way? 
All of these questions, along with others, provide new directions for research on influenza 
infections and the ability to use antiviral drugs to prevent the next pandemic.  Since oseltamivir is 
the antiviral drug of choice for preventing a possible influenza pandemic, research should 
continue regarding its effectiveness in animal models. 
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